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Abstract 
Alzheimer’s disease (AD) is the most common form of dementia. AD has been linked 
to the aggregation of amyloid beta (Aβ) peptides into extracellular deposits, Aβ 
plaques. These are also found in cognitively unimpaired amyloid-positive (CU-AP) 
individuals, but these Aβ plaques are primarily diffuse in structure. In AD brains, Aβ 
plaques often have a dense core and a more diffuse periphery. Aβ exists in various 
lengths, where the 42 amino acid-long Aβ form (Aβ1-42) is considered most 
neurotoxic. Aβ1-42 is currently used as an AD biomarker when measured in 
cerebrospinal fluid or plasma. Measurements of the relative amount of different 
biomolecules within Aβ plaques are generally performed using antibodies. Usually, up 
to three molecules, can be visualized using this technique. Recently it has been shown 
that Aβ aggregates can have distinct 3D structures. These differences in structures can 
be the result of which particular Aβ peptides the aggregates are made of. Aβ aggregates 
may also differ between AD patients, which makes it difficult to visualize and compare 
Aβ plaque pathology, and poses challenges in the development of new drugs targeting 
Aβ aggregates. It is likely that the composition of different Aβ plaques, making them 
more or less diffuse, could vary depending on different Aβ peptides. 
This thesis presents the development of methods to study chemical factors underlying 
the variation between different types of Aβ plaques. These are mainly based on three 
advanced technologies. The first is imaging mass spectrometry, which enables the 
accurate separation and visualization of molecules based on their mass in brain tissue. 
The second is hyperspectral light microscopy, which utilizes different light 
wavelengths to characterize the structural properties of Aβ aggregates in different 
plaque types. The third is high resolution electron microscopy, which enables the 
visualization of individual aggregates. Furthermore, stable-isotope labelling is used to 
study the dynamics of Aβ plaque formation. These methods were applied to 
characterize the biomolecules (different Aβ peptides and lipids) between diffuse and 
dense structures within and between Aβ plaques in mice, AD patients and CU-AP 
individuals. It was demonstrated that the shorter Aβ1-40 peptide localized to the dense 
core, and, at least in mice, this localization appeared to be a result of Aβ plaque 
maturation. CU-AP-associated diffuse plaques were not the same as the AD-associated 
diffuse or cored plaques, when it came to the aggregation state. The chemical 
modification of the N-terminal part could be responsible for such structural 
heterogeneity, and possibly for the neurotoxicity associated with AD. Further, an 
altered lipid composition was identified between diffuse and dense Aβ aggregate 
structures. Finally, with the help of stable-isotope labelling, it was verified that Aβ 
plaque spread starts in the cortex and continues towards the hippocampus. This was 
initiated through the deposition of Aβ1-42. Shorter C-terminally truncated peptides 
were deposited only at a later stage. These peptides were newly produced, and did not 
stem from already accumulated Aβ1-42.   
In summary, Aβ plaque pathology is much more complex than what it is currently 
considered during ordinary post-mortem neuropathological assessments. It needs to be 
researched with the help of advanced methods, to provide us with important 
information about how, where and why Aβ and other biomolecular factors contribute 
to the development of AD.  
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Sammanfattning på svenska 
Alzheimers sjukdom (AD) är den vanligaste demenssjukdomen. AD har kopplats till 
aggregation och ackumulering av amyloid beta (Aβ) peptiden i intra- och extracellulära 
ansamlingar eller Aβ plack. Aβ plack kan också ses hos kognitivt opåverkade amyloid-
positiva (CU-AP) individer. Aβ plack som finns i CU-AP-hjärnor är mestadels diffusa 
i naturen. I AD-hjärnan har placken ofta en tät kärna och ett mer diffust ytterområde. 
Aβ förekommer i flera olika längder (antal aminosyror), där den 42 aminosyror långa 
Aβ-peptiden (Aβ1-42) anses vara den huvudsakliga neurotoxiska formen. Dess 
koncentration kan mätas i ryggvätska och blodprover och fungerar då som en AD-
biomarkör. Mätning av de relativa mängderna av biomolekyler inom Aβ plack utförs 
generellt med antikroppar. Vanligtvis kan upp till tre olika biomolekyler, t.ex. Aβ 
peptider av olika längder, visualiseras. Det har nyligen visats att Aβ aggregat 
(ansamlingar av Aβ peptider) kan ha olika tredimensionella (3D) strukturer. Detta kan 
bero på vilka Aβ peptider (deras längder), som aggregaten är uppbyggda av. Aβ 
aggregat skiljer sig också mellan AD patienter. Detta gör det svårt att visualisera och 
jämföra Aβ plack patologin, samt utveckla läkemedel mot Aβ aggregat. Vidare väcker 
det tanken att de olika Aβ placken, som är mer eller mindre diffusa, kan bestå av olika 
Aβ peptider.  
I denna avhandling presenteras utveckling av metoder som kan användas för att 
undersöka vilka kemiska faktorer som bidrar till variationen mellan Aβ plack. Dessa 
bygger huvudsakligen på tre avancerade tekniker. Masspektrometri-baserad 
avbildning, som gör det möjligt att extremt noggrant separera molekyler från varandra 
utifrån deras förhållande mellan massa och laddning, och visualisera deras fördelning 
direkt i hjärnvävnad, hyperspektral ljusmikroskopi, som utnyttjar ljusets olika 
våglängder för att karakterisera hur aggregerade Aβ ansamlingar är, samt 
högupplösande elektronmikroskopi, som möjliggör visualisering av individuella Aβ 
aggregat. Vidare används icke-radioaktiva tunga isotop inmärkning för att studera Aβ 
plack formations dynamik. 
Dessa metoder applicerades för att karakterisera biomolekyler (Aβ peptider av olika 
längder, samt lipider) mellan de diffusa och täta strukturerna inom/mellan Aβ placken 
i möss, samt AD patienter och CU-AP individer. Resultaten visade att en kortare Aβ 
peptid (Aβ1-40) lokaliserades till den täta kärnan av plack.  I alla fall i möss, kan detta 
vara ett resultat av plack åldrande. CU-AP-associerade diffusa plack skiljde sig vad 
gäller aggregationsgrad och struktur jämfört med både diffusa och täta plack i AD. 
Kemiska förändringar av den N-terminala delen (början på peptiden) verkade ligga 
bakom denna strukturella heterogenitet och skulle möjligen även kunna vara 
associerad med den neurotoxicitet som finns i AD. Vidare identifierades förändrad 
lipidsammansättning mellan de diffusa och täta Aβ aggregat. Slutligen, med hjälp av 
tunga isotopinmärkning, verifierades det faktum att plackspridning börjar i cortex och 
fortsätter mot hippocampus. Plackspridningen initierades via deponering av Aβ1-42, 
medan kortare C-terminala trunkerade peptider kom först vid ett senare skede. Dessa 
var nyproducerade och uppkom inte från redan ansamlat Aβ1-42.  
Sammanfattningsvis är det tydligt att Aβ plackpatologin är mycket mer komplex än 
vad man tidigare har visat vid ordinär neuropatologisk undersökning efter obduktion. 
Plackuppkomst och utveckling behöver utforskas med hjälp av nya avancerade 
metoder, för att förse oss med viktig information om hur, var och varför Aβ och andra 
biokemiska faktorer bidrar till AD utveckling. 
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1 INTRODUCTION 
1.1 Dementia, neurodegenerative disorders and protein 
misfolding 
Dementia is a syndrome term that describes a chronic and persistent (lasting more than 
6 months) cognitive symptoms severe enough to interfere with a person’s daily 
functioning. These typically include memory loss, reduction of intellectual 
capabilities, changes in behaviour, decline in social abilities and social withdrawal 1,2. 
Advanced age appears to be the greatest contributing factor for dementia. The 
prevalence increases nearly exponentially after the age of 65 (around 2%), nearly 
doubling every fifth years, with almost every other person exhibiting dementia 
symptoms above 90 years of age 3. Gender appears also to influence the frequency rate 
of dementia, with elderly females exhibiting higher prevalence 3,4.   
Neurodegeneration defines a pathological process of progressive neuronal dysfunction 
with loss of neurons ultimately leading to gross atrophy. It is manifested in a variety 
of clinical symptoms such as amnesia, aphasia, apraxia and agnosia, depending on the 
brain region that is affected 5. Progressive neurodegeneration is the main cause of many 
commonly known neurological diseases, including Parkinson’s disease (PD), 
amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and Alzheimer’s 
disease (AD). It often leads to dementia, as in the case of AD (the most common cause), 
or dementia with Lewy bodies (DLB), frontotemporal dementia (FTD) or Creutzfeldt-
Jakob disease (CJD).  
A common pathological occurrence in many neurological diseases is the progressive 
accumulation and aggregation of misfolded proteins as extra- and/or intracellular 
deposits. Native protein folding, a process guided by protein primary amino acid 
sequence, results in a three-dimensional structure that is necessary for proper protein 
interaction. The native folding is believed to be the most energetically favourable state, 
achieved through continuous rearrangement and influenced by the local environment. 
When misfolded, the protein is recognized by the cellular machinery and rapidly 
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degraded. Sustained balance between correctly folded proteins and degradation of 
misfolded ones is necessary for maintenance of cell function6. If failure to degrade a 
misfolded protein occurs, multiple copies of the proteins might stick together and begin 
to aggregate 7,8. This leads to the formation of larger intracellular and extracellular 
insoluble fibrillary deposits, referred to as amyloid9. Indeed, amyloid formation and 
deposition is characteristic for many neurodegenerative that share similar 
morphological features, even though the aggregates themselves comprise a variety of 
different proteins 7,10. This is also the case for the earlier mentioned dementias, 
including AD, DLB, FTD and CJD. The presence of amyloid appears however not to 
be necessary for development of dementia, as for instance in the case of Vascular 
dementia, or dementias as result of infections, e.g. herpes simplex virus. 
1.2 Alzheimer’s disease 
1.2.1 History and epidemiology 
Alzheimer’s disease is the most common type of dementia. It was first described in 
1901 by a German physician at the Frankfurt Psychiatry Hospital, Dr. Alois Alzheimer, 
in a 50-years-old woman Auguste Deter who suffered early clinical symptoms of the 
disease11. Dr. Alzheimer followed symptomatology and progression of Auguste 
Deter’s condition and after her death in 1906 he also investigated the morphology and 
histopathology of her brain. Post-mortem examination revealed severe atrophy, 
neuronal tangles, extracellular aggregates, lipid droplets, and signs of inflammation. 
He reported these findings later that year at a meeting in Tübingen, and published them 
in 190712. Few years later, the condition was reported as a separate disease, a subtype 
of senile dementia, by Dr. Emil Kraepelin in Leipzig13.   
Over the years the medical nomenclature has changed and became refined based on 
better understanding, classification of the disease, and differential symptoms and 
diagnosis. Currently, the disease is typically divided into early-onset AD (EOAD) and 
late-onset AD (LOAD). EOAD comprises primarily cases with inherited, rare genetic 
form of AD, referred to as familial AD (fAD), that affects people younger than 65 
years 2. While some non-genetic cases of EOAD occur, the majority of the non-genetic 
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cases are considered Late-onset AD (LOAD), also known as sporadic AD (sAD)2. 
These affect people above the age of 65 years. The sAD is considered the most 
common type of dementia, even though the actual causes of the disease remain 
unknown 2,14.   
Today 1 in 3 elderly die from AD or other dementias, with AD accounting for almost 
80% of all dementia cases 3,15. The disease kills more than breast cancer and prostate 
cancer combined, and is the 6th leading cause of death in the world3. While the rate of, 
for instance, heart diseases has decreased by almost 15% since 2000, the rate of AD 
has increased by almost 90%3. One of the main causes of this rise in AD is the growing 
geriatric population (particularly in developed countries), which remains the main risk 
factor for sAD. In the US, this factor is estimated to contribute to a rise in the number 
of people with AD from a current 5.2 million to almost 16 million cases by 2050 3. 
This puts immense costs and strains on society, with the estimate of an increase in 
annual cost from the current $250 billion, to over $1 trillion by 2050 3. This makes the 
current cost of treating AD and other forms of dementia more expensive than the 
treatment of cancer and equal to that of heart diseases3.  
1.2.2 Clinical symptoms and diagnosis  
Initially patients who suffer from AD experience mild memory impairments, 
especially in episodic memory, which may be accompanied by other symptoms such 
as depression. These symptoms are often “unnoticed”, develop slowly and worsen over 
time. At later stages, cognitive symptoms such as confusion, general behavioural 
changes, impaired judgement, and finally problems with motor functions and speech 
develop 2,16,17.  
Until today there is no single test to diagnose AD or other forms of dementia. Rather, 
the diagnosis is made based on the history of the patient, mental status and mood 
testing, physical and neurological examination, and variety a of medical tests of blood 
and cerebrospinal fluid (CSF) in order to rule out alternative causes of dementia.  
The cognitive functions are typically judged based on CERAD (Consortium to 
Establish a Registry for Alzheimer's Disease)18,19, however other methods of 
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assessment such as MMSE (Mini-Mental State Examination)20, CDR (Clinical 
Dementia Rating Scale Sum of Boxes)21, and BDRS (Blessed Dementia Rating 
Scale)22 are also used. In combination with other assessments, the disease is then 
diagnosed following the revised criteria of NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease 
and Related Disorders Association) 23 and/or DSM-IV-TR (Diagnostic and Statistical 
Manual of Mental Disorder) 24. Progression of AD is typically categorized into 
preclinical stages, followed by mild cognitive impairment (MCI) and finally full blown 
AD dementia, however the progression spectrum is very diversified 2.  
Given that brains of AD patients display characteristic neuropathological features 
including Aβ and tau aggregates (discussed in detail in section 1.2.3), as well as brain 
atrophy, the clinical assessment is now complemented with imaging techniques and 
neurochemical techniques to examine, biological-, molecular- and metabolic-, as well 
as structural-changes associated with the disease.  
Analyses of AD-related biomarkers in CSF are becoming increasingly common in 
guiding clinical diagnosis, assessment of disease risk or progression, and monitoring 
of eventual treatments. Here CSF concentration of total tau (T-tau) and phosphorylated 
tau (P-tau181) and Aβ42 are commonly used 25-27.  While increased levels of both T-tau 
and P-tau181 reflect general neuronal and axonal damage associated with the 
neurodegeneration 26-29, P-tau181 provides additional information about altered 
phosphorylation and is a good predictor of increased deterioration rate of AD patients 
30. On the other hand decreased CSF levels of Aβ42 reflect the brain Aβ aggregation 
and accumulation 26,27,31.  
In addition to these classical biomarkers, other proteins, lipids and metabolites, 
including synaptic proteins, signalling molecules, markers of inflammation and many 
others, alone or in combination, are being evaluated for their diagnostic value in CSF 
25. Given the limited applicability of CSF biomarkers due to the need of a lumbar 
puncture for collection, evaluation of biomarkers in blood is under development, for 
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detailed review see Hampel et al32. While certain lipids and metabolites have shown 
promising results, the reliability of these techniques has not been proven so far.  
Alongside fluid biomarkers, static imaging techniques, such as non-enhanced 
computed tomography (CT), and magnetic resonance imaging (MRI), as well as 
dynamic, temporally resolved imaging techniques, including functional MRI (fMRI), 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT), have been shown to be useful for in vivo evaluation of 
structural, respective functional and metabolic changes in variety of brain regions.  
Here MRI (CT is often no longer used) has been shown useful for high resolution 
evaluation of brain atrophy and shrinkage 33-35. Measurement of brain activity caused 
by changes in oxygen levels during blood flow using MRI 36, measurement of 
metabolic processes through positron emission in PET 37 and gamma emission in 
SPECT 38,39, all provide functional and/or metabolic information about any alterations 
in physiological processes associated with AD. They are extensively used for research 
and, in some cases, for diagnosis 40. Each technique offers its own advantages but all 
are nowadays combined in order to improve their diagnostic properties.  
In AD, PET has become commonly adapted technique, with the possibility to directly 
and indirectly monitor AD associated changes. Direct monitoring of metabolic activity 
of neurons is typically performed using radioactive fluorine-18-labelled 
fluorodeoxyglucose (FDG-PET) 37,41. Indirect visualization of, for instance, Aβ 
plaques, is accomplished thanks to the development of ligands, and also antibodies, 
conjugated to the radioactive tracers (11C or 18F, the latter of which exhibits longer 
half-life), such as Pittsburgh compound B (PiB) based 11C-PiB 42 or the close structural 
analogue, 18F-flutemetamol 37,43,44. While the imaging techniques proved robust, and 
provide the most information about brain related changes, they are expensive, involve 
radiation exposure, and are yet not readily accessible.     
Both the fluid biomarkers and the imaging techniques provide us with general trends 
related to biological, molecular/metabolic and structural changes over the course of 
aging. These methods are constantly refined and are gradually incorporated into 
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revised diagnosis criteria. The definite diagnosis of a suspected AD patient is however 
performed first post-mortem after a careful neuropathological examination and 
assessment of AD staging based on cerebral profile of Aβ aggregates as plaques and 
tau aggregates in form of neurofibrillary tangles (NFT) is performed. 
1.2.3 Neuropathology  
Macroscopic pathological features of AD comprise a general reduction in cortical brain 
volume, referred to as atrophy, most prominent in parietal and temporal lobes, as well 
as widened sulci and enlarged ventricles. On a microscopic scale, neurofibrillary 
tangles (NFTs) and plaques are the main lesions present in AD45. 
NFTs are intracellular deposits composed mainly of truncated and 
hyperphosphorylated microtubule-associated protein tau. In AD, tau becomes 
truncated and excessively phosphorylated. It then loses its ability to bind to and 
stabilize microtubules, misfolds and begins to aggregate 2,45,46. This loss of function 
may be induced by plaque pathology, and has been suggested to underlie the axonal 
and dendritic breakdown, and eventually neuronal loss, that occurs in AD.  
Extracellular plaques are composed mainly of Aβ peptide, produced from sequential 
cleavage of amyloid precursor protein (APP) (discussed below), and are hence 
commonly referred to as Aβ plaques 45,47-49. These deposits are typically divided into 
dense cored plaques, often referred to as “congophilic” based on their detection with 
Congo Red (CR) stain, and diffuse plaques, which cannot be visualized with CR 50. 
The former, dense cored plaques, are the dominating type of Aβ plaque pathology in 
AD patients 51. They are associated with dystrophic neurites, signs of inflammation, 
activated microglia and astrocytes, as well as a general loss of synapses and neurons 
52,53. Diffuse plaques are, on the other hand, more common in non-demented, 
cognitively normal elderly individuals, a pathological condition previously referred to 
as pathological aging, and nowadays as cognitively unaffected amyloid positive (CU-
AP) 54. Most AD patients (and some CU-AP individuals) also display aggregation of 
Aβ peptides on the walls of arteries, a condition referred to as cerebral amyloid 
angiopathy (CAA) 45.  
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In line with the high hydrophobicity and consequently increased aggregation 
propensity of the Aβ1-42 peptide (42 amino acid-long peptide)55, Aβ plaque formation 
has been shown to involve N-terminal truncated Aβx-42 peptides 45,56-58. The shorter, 
less hydrophobic Aβ1-40 peptide has been suggested to be present particularly in cored 
plaques as observed in AD 56,57,59,60, and to be a necessary constituent of the CAA 
(nature of Aβ peptides discussed below) 56,61. The exact differences in the peptide 
composition of individual plaque morphotypes remains unknown.  
Further, Aβ plaque pathology has long been believed to result from extracellular 
aggregation of the Aβ peptide. Recent studies have however suggested a potential, 
intracellular origin of the Aβ peptide aggregation, as highlighted by in vitro studies 
and histological assessment of brain tissue 62,63. Therefore, potential mechanisms and 
factors that influence such proposed plaque “aging”, or the alternative independent 
aggregation pathway, as well as the origin for primary plaque deposition remain 
controversial.  
Stereotypical spatiotemporal distribution of NFT and Aβ plaque pathology differs in 
AD and have been described extensively by Braak & Braak and Thal et al respectively. 
The NFTs spread “outwards” in 6 stages starting from locus coeruleus, transenthorinal 
and enthorinal regions (stages I, II), progressing to the limbic system, with the 
innermost neocortical areas and hippocampal formation (III, IV), and finally spreading 
to the isocortical areas, including primary and secondary sensory and motor areas of 
the neocortex (V, VI). This pathological spread correlates well with the cognitive 
decline in AD patients 64-66.  
The spread of the Aβ plaque pathology on the other hand can be considered an 
“inward” progression that occurs in 5 stages, with the isocortial areas being affected 
first (stage I), followed by the limbic system and allocortical structures, including the 
rest of the neocortex, hippocampal formation, basal nuclei, diencephalon and 
amygdala (II, III), and lastly spreading to subcortical structures, including 
mesencephalon, pons, and cerebellar cortex (IV, V). The progression of the disease 
does not correlate with either the spread or size of the Aβ plaques 64,66,67. 
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1.3 Amyloid pathology  
1.3.1 Aβ peptide generation 
Amyloid β (Aβ) has been identified to be critical in initiating and driving AD pathology 
leading to downstream processes including Tau pathology, synaptic changes and 
neurodegeneration. Aβ is a product of sequential cleavage of amyloid precursor protein 
(APP) by the β- and γ-secretase 2,68,69. 
1.3.1.1 APP processing pathways 
Amyloid precursor protein (APP) is a receptor-like transmembrane protein that 
comprises a large extracellular N-terminal domain, and a smaller, intracellular C-
terminal domain70. The most commonly expressed isoforms are APP695, APP751 and 
APP770 (these are 695, 751 and 770 amino acid-long proteins) with APP695 being the 
predominant variant expressed in neurons71,72. In addition, paralogues of APP, known 
as amyloid precursor-like proteins, characterized by their lack of Aβ domain, exist in 
mammals73.   
APP has been suggested to be involved in a variety of neuronal functions, including 
neurogenesis and neuronal differentiation, neurite outgrowth and branching, as well as 
synaptogenesis74. While some of the APP localizes to the cell surface, the majority of 
it localizes to the Golgi complex or is internalized into endosomes, either to be recycled 
back to neuronal surface or to be targeted for lysosomal degradation74-77.       
APP is sequentially cleaved by several proteases along two major pathways, 
commonly referred to as the non-amyloidogenic and the amyloidogenic pathways 
(Figure 1)76,78. Three major classes of enzymes have been shown to be involved in 
these two pathways, the α- and β-secretases (non-amyloidogenic pathway), and β- and 
γ-secretases respectively (amyloidogenic pathway)78,79.  
The members of a disintegrin and metalloproteinase (ADAM) enzyme family, are cell-
membrane expressed proteases that are responsible for the α-secretase cleavage within 
the brain80. Their processing of APP is protein kinase C (PKC)-regulated. ADAM-
mediated processing of APP occurs mainly at the neuronal surface, and only to some 
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extent in the trans-Golgi network (TGN)81,82. In addition to APP, α-secretases are also 
involved in processing of several other substrates, including interleukin 6 (IL-6) and 
tumour necrosis factor (TNF), both implicated in AD77.  
The beta-site APP-cleaving enzymes 1 and 2 (BACE1/BACE2), also known as Asp-2 
and memapsin-2, are ubiquitous transmembrane enzymes, members of the pepsin 
family of aspartyl proteases responsible for β-secretase activity83-85. While the brain 
enriched BACE1 is involved in cleavage of APP to produce Aβ, the expression of 
BACE2 is much lower and its activity results in cleavage within the Aβ sequence 86,87. 
BACE1 is active mainly in TGN and the endosome, where its activity is favoured by 
the acidic environment84,88. Some of the activity also occurs at the neuronal surface84,85. 
Recently, the lysosomal cysteine protease cathepsin B has also been suggested to have 
β-secretase activity89,90. This protease may be involved in the production of 
pyroglutamylated (pE) forms of Aβ, formed when N-terminal glutamate is cyclized by 
glutaminyl cyclase91,92.   
The γ-secretase is a multi-subunit protease complex that consists of four individual 
proteins: presenilin 1 or 2 (PSEN1/PSEN2), nicastrin (NCSTN), anterior pharynx 
defective 1 (APH1), and presenilin enhancer 2 (PEN2)93,94. When activated, γ-
secretase cleaves off the C-terminal fragment of APP to generate Aβ83,95,96. As this 
cleavage can occur at multiple positions, several Aβ species of different lengths can be 
generated83,96. The activity of γ-secretase has been shown to occur within various sub-
cellular units, and the cleavage sites have been suggested to depend on the subcellular 
localization and conditions68,78,83,97,98.    
Processing of APP695 (predominant in neurons) along the non-amyloidogenic 
pathway is characterized by α-secretase-mediated cleavage within the Aβ domain, 
which results in a short intracellular and a long extracellular fragment78,79. The short 
intracellular fragment is an 83 amino acid-long C-terminal fragment (known as CTFα 
and C83), which spans the APP intracellular domain (AICD), including its YENPTY 
interaction motif, as well as p3 peptide (Aβ17-42) region that is sequentially cleaved 
off by γ-secretase70,77. The longer, soluble extracellular N-terminal fragment (sAPPα) 
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consists of the heparin-ELQGLQJGRPDLQ+%'DQGthe copper-binding domain, shown 
to bind both copper and zinc (CuBD), together referred to as a cysteine-rich globular 
(GRPDLQDQ acid domain (AcD), a second heparLQELQGLQJGRPDLQ+3'DQGD
UDQGRP FRLO UHJLRQ WRJHWKHU UHIHUUHG WR DV D KHOL[ ULFK ( GRPDLQ DV ZHOO DV WKH
UHPDLQLQJ $ȕ SHSWLGH UHJLRQ $ȕ-16)70,99-102. The APP751 and APP770 contain, 
respectively, an additional Kunitz-type protease inhibitor (KPI) domain, or both KPI 
DQGDQ2[UHJLRQORFDWHGEHWZHHQthe E2 and Ac domain70,72.  
)LJXUH 6FKHPDWLFRI WKH $33SURFHVVLQJE\HLWKHUĮ- DQGȖ-VHFUHWDVHWKURXJKQRQ-
DP\ORLGRJHQLF SDWKZD\ OHIW DQG ȕ- DQG Ȗ-VHFUHWDVH LQ DP\ORLGRJHQLF SDWKZD\
ULJKW%RWKSDWKZD\UHVXOWLQJHQHUDWLRQVRIVROXEOH1-WHUPLQDOIUDJPHQWVV$33ĮRU
V$33ȕDQGHLWKHUSIUDJPHQWRUWKHDP\ORLG-IRUPLQJ$ȕSHSWLGH 
If instead APP is processed along the amyloidogenic SDWKZD\ȕ-secretase cleaves APP 
into a shorter 99 amino acid long C-WHUPLQDO IUDJPHQW NQRZQDV&7)ȕDQG&
ZKLFK LVVHTXHQWLDOO\SURFHVVHGE\Ȗ-VHFUHWDVH LQWR$,&'DQG LQWDFW$ȕSHSWLGHDV
well as a longer soluble N-WHUPLQDO IUDJPHQW V$33ȕ 70,78,79.  As a result of the 
SUHGRPLQDQW DFWLYLW\ RI ȕ- DQG Ȗ-secretase within the cell, the majority of APP 
SURFHVVLQJWRJHQHUDWH$ȕSHSWLGHVDORQJWKHDP\ORLGRJHQLFSDWKZD\RFFXUVZLWKLQ
the intracellular compartments77. Cell surface-processing of APP on the other hand, 
proceeds through the non-amyloidogenic pathway 77,88. 
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In addition to these three secretases, novel δ-secretase, η-secretases, and meprin β have 
been recently discovered as additional APP proteases103. Here, asparagine 
endopeptidase (AEP) and matrix metalloproteinase MT5-MMP, a δ-secretase 
respective η-secretase, have been suggested to result in production of proteolytic 
fragments that contribute to the AD pathology104,105. Likewise, meprin β, which is a 
zinc metalloprotease, has been also been linked to AD, through its generation of Aβ2-
X peptides and potential β-secretase activity106. 
1.3.1.2 Amyloid β truncations and homeostasis  
Aβ exists in over 15 different isoforms and truncations with varying length of the 
amino acid sequence 107. Depending on the site of γ-secretase cleavage, the C-terminal 
can vary in length, ending anywhere from amino acid 37 to 43 68,69. The most common 
isoforms are, however, the Aβx-38, Aβx-40, and Aβx-42 68,96. The N-terminal part of 
the Aβ peptide also varies, with Aβ1-x, Aβ3-x, Aβ4-x, Aβ5-x, and Aβ11-x as common 
truncations 68,69. The Aβ3-x and Aβ11-x truncated peptides have been shown to result 
from β-secretase activity 68. In addition, these N-terminal glutamate residues (Aβ3-x 
and Aβ11-x), get cyclized to form pyro-glutamylated forms of Aβ, the AβpE3-x and 
AβpE11-x, both of which have been frequently detected in brains of AD patients 108,109.  
As most of other naturally synthesized peptides, Aβ production is normally balanced 
by its enzymatic degradation and/or clearance110, but its concentration has been shown 
to naturally become elevated in an age-dependent manner 111.  In the non-pathological 
state, Aβ has been shown to have a short half-life of a few hours 112,113. Therefore, it 
has been hypothesized that non-genetic sporadic AD (sAD) is caused by the 
misbalance in the Aβ production and clearance 114,115. This, in turn would lead to its 
aggregation and exertion of a wide variety of neurotoxic effects, eventually resulting 
in Aβ plaque formation. Recent studies of Aβ turnover rate in CSF has indeed shown 
such a misbalance in sAD patients 116. The cause of impairment and precise 
components of the clearance mechanism that underlie this misbalance remain 
unknown.  
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Aβ is normally degraded by a wide variety of enzymes 110. This depends on protease 
related factors, such as their subcellular localization, optimal working pH, and many 
other Aβ related factors, such as its source and location 110,117. Further, the dynamic 
equilibrium of the Aβ peptide, between various interconnected compartments, and 
between its passive and active transport, will affect the relative Aβ levels at various 
sites 110. An example of this is the decreased CSF levels of Aβ, believed to correspond 
to aggregation of the peptide in the brain 26,31. Finally, proteases responsible for Aβ 
degradation also have their specific substrates, including non-aggregated and/or 
aggregated Aβ 110. Combined, all these factors will affect the overall concentration of 
the peptide (and possibly its isoforms), at different sites.   
Two of the major Aβ degrading enzymes, both degrading non-aggregated Aβ, are the 
metalloproteases neprilysin (NEP) and the insulin degrading enzyme (IDE) 110,118. NEP 
degrades Aβ in Golgi, the endoplasmic reticulum and the extracellular space 110,118,119. 
IDE, on the other hand, plays a major role in cytosolic, endosomal, lysosomal, 
extracellular and, in particular interstitial Aβ degradation 110,117,120. Other proteases 
able to degrade fibrillary (and oligomeric) Aβ include matrix metallopeptidase 2 and 
9 (MMP2 and MMP9), active in the extracellular space, Golgi and endoplasmic 
reticulum; the cysteine protease - cathepsin B (mentioned earlier in relation to its β-
secretase activity), active in the extracellular space, lysosome and endosome; and the 
aspartyl protease - cathepsin D, active in endosomes and lysosomes 110,118.  
Under physiological conditions, Aβ is believed to be present at picomolar (pM) 
concentration 121. While the precise physiological role of Aβ remains unclear, it is 
believed to be involved in several cellular processes. Low Aβ concentration has been 
suggested to possess trophic properties, exhibiting anti-oxidant activity, including 
metal ion sequestration, playing a role in neurogenesis and in calcium homeostasis, 
and maintaining the structural integrity of the blood-brain barrier (BBB) 122. Further, 
studies have shown a low concentration of Aβ to be important in modulation of 
synaptic activity and plasticity, thereby having an effect on the memory and learning 
121,123. Clear alterations of these processes are related to higher than physiological 
levels of Aβ, and represent physiological changes observed in AD patients 2,122,124.  
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1.3.2 Aβ aggregation  
A common feature of all amyloidogenic proteins is the presence of a hydrophobic 
component (that consists of hydrophobic amino acids).  In the case of Aβ, the 
aggregation propensity has been attributed to two highly hydrophobic components, the 
C-terminal end of the peptide, and the so-called KLVFF motif that is present in the 
mid-region of the peptide 125-128.  
The initial stage of Aβ aggregation is the formation of a β-hairpin, as result of the C-
terminal region folding onto the mid-region of the peptide 125,126,128. Here, the longer 
peptides are more prone to aggregate than the shorter ones 125,129. This folding process 
itself is believed to depend on the aromatic-stacking interaction of the two 
phenylalanine residues present in the KLVFF17-21 (lysine-leucine-valine-
phenylalanine-phenylalanine) amino acid motif. These aromatic moieties stabilize 
both intramolecular (within a single β-hairpin) and intermolecular interactions in a 
larger assembly 127,130,131. Further, the salt bridge (hydrogen bond and electrostatic 
interaction) between the anionic carboxylate (RCOO−) of D23 (aspartic acid) and 
cationic ammonium (RNH3+) of K28 (lysine) further stabilizes the loop region 132,133.   
Subsequent aggregation of multiple β-hairpins, along with conformational 
rearrangements and formation of hydrogen bonds between adjacent strands, results in 
the formation of first dimers, and later different oligomers (Figure 2) 126,128,134,135. The 
pattern present in this assembly can be parallel, with the same directions of C-terminus 
and N-terminus on the adjacent strands, anti-parallel, with opposite directions, or with 
both parallel and anti-parallel patterns being present in larger assemblies 135,136. If the 
formation of oligomerization stops, the process is referred to as off-pathway 
aggregation 137-139. Otherwise, aggregation continues along the fibrillogenic pathway 
126,128,135 and eventually leads to the formation of β-sheet structures, stacked in either 
parallel or anti-parallel way, that build up protofibrils 128,136,140,141. Finally, two or more 
protofibrils can twist around one-another, leading to formation of fibrils. This is 
considered the end state of fibrillogenic aggregation 127,128,141.  
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,QWHUHVWLQJO\WKHȕ-sheets organization (parallel/anti-parallel) has been suggested to be 
subject to structural rearrangement between aggregation states 135,136. Further, it has 
been proposed that this structural rearrangement may depend on which $ȕSHSWLGHs 
are LQYROYHG:KLOHWKHFROODSVHGVWDFNHGȕ-VKHHWVFRQIRUPDWLRQRI$ȕ-42, and the 
H[WHQGHG VWDWH DQWL-SDUDOOHO ȕ-VKHHWV RI $ȕ -40 140 result in the assembly of 
protofibrils with a similar structure 135, the continuation of this self-aggregation process 
results in the IRUPDWLRQRIPDWXUH$ȕILEULOVZLWKGLIIHUHQWȕ-sheet organization within 
each fibrillary layer 142+HUHWKHPRVWWKHUPRG\QDPLFDOO\VWDEOHFRQIRUPDWLRQIRU$ȕ
1-40 fibrils has been shown to be a three-fold conformation FRPSULVLQJWKUHHȕ-sheets 
in each layer of the fibril 142. This imposes a major challenge to any form of 
FRQIRUPDWLRQVSHFLILFDQWLERG\GHWHFWLRQRIDJJUHJDWHG$ȕ 
)LJXUH 6LPSOLILHGRYHUYLHZRIDJJUHJDWLRQSURFHVVRI$ȕ7KHPRQRPHUVEHFRPH
PLVIROGHG DQGDJJUHJDWHLQWRORZRUGHUDJJUHJDWHVVXFKDVGLPHUVDQGWULPHUWKHn 
KLJKHU RUGHU ROLJRPHUV DQG HYHQWXDOO\ SURWRILEULOV 0XOWLSOH SURWRILEULOV FDQ
DJJUHJDWHDQGIRUPORQJLQVROXEOHPDWXUHILEULOV 
%DVHGRQZKHWKHUH[WUDFWHGDJJUHJDWHVRI$ȕUHPDLQLQWKHDTXHRXVSKDVHIROORZLQJ
KLJK VSHHG FHQWULIXJDWLRQ WKH\ DUH UHIHUUHG WR DV ³VROXEOH´ RU ³LQVROXEOH´ $ȕ
aggregates 143$OOIRUPVRI$ȕDJJUHJDWHVSULRUWRILEULOVDUHFRQVLGHUHGVROXEOH)RU
H[WUDFWLRQRILQVROXEOHDJJUHJDWHV, detergents and acids, such as 70% formic acid, are 
used. This concept has become widely applied since the identification of cognitively 
unaffected amyloid positive (CU-$3SDWLHQWVZKRGLVSOD\ERWK$ȕSODTXHSDWKRORJ\
54.  
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Whole brain extracts (combined “insoluble” and “soluble” Aβ extracts) of CU-AP 
(previously referred to as pathological aging) and AD patients have suggested an 
overlapping Aβ peptide profile between two groups 144,145, but higher levels of Aβ1-40 
were found to be present in CU-AP 144. Interestingly, in a study where soluble and 
insoluble fractions were separated, 10-fold higher levels of insoluble Aβ1-40 (and only 
2-fold higher insoluble Aβ1-42) were found present in brains of AD patients as 
compared to CU-AP 146. On the other hand, the soluble Aβ1-40 and Aβ1-42, as a 
fraction of total Aβ, were higher in CU-AP 146. Given that Aβ plaques are considered 
to be mostly made up of insoluble fibrils, this suggests that Aβ plaques, in particular 
the cored pathology in AD, comprise the majority of insoluble Aβ1-40 in AD brain.  
1.3.3 The amyloid cascade hypothesis 
Since its discovery 1984, and later its cloning, Aβ has played a central role in AD 
research 72,147,148. The focus on Aβ aggregation, and its interplay with downstream 
event as the driving force or trigger in AD was only first put forward in 1991 with the 
amyloid cascade hypothesis 48,49,149-151. The originally postulated hypothesis placed 
deposition of Aβ in parenchymal space as the trigger for AD. This was supported by 
the missense mutations in APP itself, or two presenilin genes (PSEN1 and PSEN2, 
encoding the active region of γ-secretase), both leading to either an increased Aβ 
production or an increased propensity for aggregation152-155. The observation that 
trisomy 21 in Down’s syndrome, associated with an extra copy of APP, leads to early-
onset dementia with Aβ plaque pathology strengthened this view156. Interestingly, 
mentally disabled adults who do not have Down’s syndrome, and have no additional 
copy of APP have been shown to have just as many Aβ plaques and NFT as individuals 
with Down’s syndrome157,158. Since its initial postulation, the amyloid hypothesis has 
been challenged and refined; it does still however place Aβ and its dyshomeostasis at 
the centre of AD114,159,160. 
In its current form, the amyloid cascade hypothesis proposes either failure in Aβ 
clearance or an increase in Aβ production as initial steps driving AD160. On the one 
hand any mechanism contributing to faulty Aβ degradation, including genetic risk 
factors (e.g. APOE ε4), are the initial triggers in sporadic AD (sAD)161,162. On the other 
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hand, the earlier mentioned missense mutations lead to an increase in the relative Aβ 
production throughout life in familial AD (fAD). Both of these characteristics 
eventually lead to the accumulation and oligomerization of Aβ (particularly Aβ1-42) 
in the limbic system and association areas of the cerebral cortex. Besides gradual 
deposition into diffuse plaques, the Aβ oligomers can affect synaptic activity, lead to 
activation of inflammatory responses (comprising both microglial and astrocytic 
involvement), induce oxidative stress, and alter neuronal ionic homeostasis. At the 
same time, Aβ oligomers can also directly affect kinase and phosphatase activities, 
leading to tau hyperphosphorylation and formation of neurofibrillary tangles (NFT). 
Together these processes cause direct injury to synapses and, later, to neurons, inhibit 
long-term potentiation (LTP), lead to neuronal loss, neurodegeneration, and eventually 
end in dementia.  
The amyloid cascade hypothesis has been challenged in multiple ways159,163,164.  For 
instance, Aβ pathology has been found in cognitively unaffected-amyloid positive 
(CU-AP) subjects54,165. Further, there is no correlation of Aβ plaque pathology with 
cognitive symptoms64,66,67. Most importantly, the majority of clinical trials where anti-
Aβ therapies have been used have failed166,167. While clearly undercutting the initial 
version of the hypothesis, these can be explained in the light of the redefined 
postulates, in which general Aβ, including soluble oligomers, lies in focus. 
With regard to CU-AP subjects, these display predominantly diffuse, rather than cored 
plaque pathology, which dominates in sAD. Diffuse pathology in CU-AP does not 
appear to be associated with gliosis or neurodegeneration, and therefore might not be 
neurotoxic. In support of this, a limited presence of soluble oligomers in CU-AP 
patients as compared to sAD has been reported168. Further, also with regard to limited 
correlation between cognitive symptoms and Aβ plaque pathology, soluble Aβ 
oligomer species, rather than full-blown Aβ plaques, have indeed been found to 
correlate with disease severity169.  
Along the line of the revised amyloid hypothesis, Aβ itself might not cause the 
cognitive impairment (and hence not correlate as well as, for instance, tau), but rather 
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causes initial cellular and molecular changes that in turn lead to observed dysfunctions. 
In support of this, a similar duration has been observed for both fAD and sAD 
(regardless of APOE ε4 carrier status), in spite of different age-at onset of the 
disease166.  
Further, this causative, but not necessarily symptom-driving role of Aβ might also 
explain the negative results in most anti-Aβ-based clinical trials that often target 
patients with mild cognitive impairment (MCI) or mild to moderate AD. The trial 
failures may further highlight that Aβ pathology occurs much earlier in life than we 
previously thought; most data suggests that it might appear already in mid-life. Early 
intervention would thus mean intervention at a preclinical disease stage, which 
highlights the need for biomarkers for screening.  
The amyloid cascade hypothesis does not explain the heterogeneity in Aβ aggregation 
states, or Aβ pathology polymorphism (described below); neither does it address the 
physiological function of Aβ, the mechanism of Aβ pathology spread, or for that matter 
how long it takes for Aβ to transition from a soluble to an insoluble state. Still, given 
the finding of APOE ε4-impaired Aβ clearance being a risk factor for AD, as well as 
low CSF Aβ42 levels and amyloid-PET positivity preceding other clinical and 
molecular manifestations in AD (e.g. tau), the amyloid cascade hypothesis continues 
to provide a framework for AD research.  
1.3.4 Genetics and AD models 
A small portion of AD cases are caused by autosomal dominant mutations (less than 
5%)170. These are referred to as familial AD (fAD). Patients with fAD have the disease 
onset generally before 65 years of age (depending on the mutation). The rare fAD 
mutations are caused by mutations in genes encoding amyloid precursor protein (APP) 
located on the chromosome 21 (Figure 3), as well as two γ-secretase components, 
presenilin 1 and 2 (PSEN 1 and PSEN2) located on chromosomes 14 respective 1. 
There is a wide variety of different mutations that have been identified for each of the 
genes (see Alzforum for updated list, (https://www.alzforum.org/mutations)).  
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2YHUDOOWKHI$'PXWDWLRQVOHDGWRHLWKHUDQLQFUHDVHLQ$ȕSURGXFWLRQLIWKH\DUH1-
WHUPLQDO RI $ȕ HJ 6ZHGLVK PXWDWLRQ .01/171-174 an increase in the 
SURSHQVLW\RI$ȕWRDJJUHJDWHLIZLWKLQ$ȕVHTXHQFHPXWations (e.g. Arctic mutation, 
E693G) 174-176RUDQLQFUHDVHLQWKHUHODWLYHDPRXQWRI$ȕ-42 production as compared 
WROHVVDJJUHJDWLRQSURQH$ȕSHSWLGHVVXFKDV$ȕ-40, if modifying the C-terminal 
processing (e.g. London mutation V717I in APP, or presenilin mutations)152,174,177-182.  
)LJXUH 6FKHPDWLF RYHUYLHZ RI WKH $33 VHTXHQFH KLJKOLJKWLQJ VRPH RI WKH ZHOO-
NQRZQPXWDWLRQV7KHFOHDYDJHVLWHV ĮȕȖ DUHPDUNHGZLWKVWUDLJKWEODFNOLQHV$33
PXWDWLRQVZKLFKLQFUHDVHWKHDP\ORLGRJHQLFSURFHVVLQJDUHPDUNHGLQUHGWKHVHDUH
SUHVHQW EHIRUH ZLWKLQ DQG DIWHU WKH $ȕ SHSWLGH VHTXHQFH $ UHFHQWO\ GLVFRYHUHG
SURWHFWHGPXWDWLRQLVKLJKOLJKWHGLQJUHHQ 
The etiology of idiopathic AD remains unknown. +RZHYHU Whe pathological and 
clinical symptoms of familial AD (fAD) and sporadic AD (sAD) are similar. 
Therefore, despite the initial trigger, the assumption that downstream events of AD are 
alike between fAD and sAD allows for the use of genetic mutations associated with 
fAD in AD animal modelling (particularly in mice). While these models do not fully 
UHSURGXFHWKHVSHFWUXPRI$'V\PSWRPVWKH\DUHVWLOOXVHIXOIRUH[DPLQLng critical 
aspects and pathology associated with this disease. Importantly, these models develop 
H[WUDFHOOXODU$ȕ plaques, and in specific cases also neurofibrillary tangles (NFTs), in 
an age-dependent manner. 
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1.3.4.1 Mice models 
AD modelling in mice is typically done by overproducing mutant APP183-185. Here, the 
amino acid sequence of Aβ itself is most often humanized through substitution of three 
amino acid substitutions at positions 5, 10 and 13 (respectively G5R, F10Y and 
R13H)184,186. Besides the overexpression of APP, the Aβ associated symptoms of AD 
are modelled using presenilin 1 mutations (PSEN1)183-185. 
Multiple mutations in APP and PSEN1 are often used at the same time. This is in order 
to facilitate either an increase in total Aβ, increase in aggregation propensity, increase 
in Aβ42/40 ratio, or a combination of these options. These models have been used, for 
instance, to demonstrate that elevated levels of the longer, more aggregation prone 
Aβ1-42, lead to earlier and more severe cognitive decline, and more exacerbated Aβ 
plaque pathology. On the other hand, the shorter, less aggregation prone Aβ1-40, 
without a prior Aβ1-42, does not lead to Aβ plaque formation 56. The Swedish mutation 
is most often used for AD modelling, either alone or in combination with other 
mutations183-185.  
Technically, mutations in microtubule associated protein tau (MAPT) gene are not 
linked to fAD, and instead cause other tauopathies (without Aβ plaques), including 
frontotemporal dementia (FTD)187. However, hyperphosphorylation of tau and 
formation of NFTs is central to AD46,188-191. Pathogenic mutations in MAPT can lead 
to an increase in the production of tau isoforms, changes in the microtubule assembly, 
or make tau more prone to aggregate. Given the fact that APP-overexpressing mice do 
not develop NFTs, even though increased hyperphosphorylation has been shown, 
introduction of MAPT mutation (or removal of nitric oxide synthase 2) has been used 
to induce NFT development in mice183,192-194. These mice models have been used to 
demonstrate that Aβ plaque pathology proceeds the NFT development195,196. This, for 
instance, through interference of Aβ oligomers in the ubiquitin protease-based 
degradation of tau.  
In addition to transgenic models overexpressing Aβ and tau, knockout (KO) mice 
lacking AD related genes have also been developed197,198. These mice have no 
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pathological features. Still they have provided useful insight into the molecular 
mechanism underlying AD and the role of the implicated proteins. Here, APP and tau 
KO mice have together been used to demonstrate the necessity of tau, particularly 
soluble tau, for the mediation of APP and Aβ associated negative effects on cognitive 
deficits and long-term potentiation (LTP)199,200. Interestingly, while tau KO mice have 
been shown to exhibit axonal and neuronal defects, app KO mice did not reveal 
abnormalities, including no neuroanatomical changes, at least at a young age197-199.  
Besides APP and tau KO mice, mice lacking APP secretases, including BACE, 
Presenilin 1 and 2, and ADAM 10 and 17 have also been developed201-204. Here, 
Presenilin 1 KO mice were used to demonstrate the crucial role of Presenilin 1 and γ-
secretase, in neuronal and skeletal development, with homozygote KO being lethal201. 
In contrast, while BACE1 KO mice have implicated this protein in myelination or 
regulating the expression of voltage-gated ion channels, these mice were shown to be 
generally healthy203. Importantly, they do not produce any Aβ. Therefore, BACE1, 
rather than Presenilin 1 or γ-secretase complex, appears to be a safer target for drug 
intervention.  
There are many translational concerns regarding the use of animal models and their 
suitability to model human AD183,205,206. Broadly these are associated with the lack of 
concordance with clinical trials, the heterogeneity of patients enrolled in clinical trials 
and homogenous nature of these models, and insufficient cellular and synaptic loss 
compared to human subjects. More specifically, the overexpression of the APP in 
transgenic mouse models pose additional concerns.  
The artificial promoters do affect the gene expression, not only the levels but also the 
site, or cell type of expression. Further, the expression of the gene varies between lines, 
as well as between different time points. Besides the actual gene expression, the 
overexpression itself results in unphysiologically high levels of both APP, but also its 
proteolytic fragments. This may have numerous undesired side effects, and exuberates 
the degree and time-line of pathological feature development183,205,206.  
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In order to address some of these challenges, a novel approach based on knock-in (KI) 
strategy has been developed207,208. In terms of APP KI mouse models, this allowed for 
the identification of APP expression regulatory function of intron 16 spanned by the 
Aβ sequence208. Therefore, the new generation AD KI mouse models exhibit 
physiological levels of Aβ. Still, in order to model the pathology, these mice have fAD 
mutations. Two of these more established models, exhibit Swedish and Iberian 
(APPNL-F); or Swedish, Arctic and Iberian mutations (APPNL-G-F)207,208. These models 
develop significant Aβ pathology and neurodegeneration, have an accumulation of 
both astrocytes and microglia, and eventually also develop memory impairment. 
Depending on the expression of the Arctic mutation (APPNL-G-F) the pathology can be 
present as early as 2-months (or 6-months in APPNL-F), and memory impairment 
already at 6-months (respective 18-months in APPNL-F).    
1.3.5 Other risk factors 
Besides fAD-causing mutations, several gene polymorphisms have been implicated in 
an increased risk of sporadic AD (sAD) or also referred to as late-onset AD (LOAD), 
which accounts for 95% of all AD cases209. These are referred to as “risk” or 
“susceptibility” genes and are identified by genetic association studies. AD genes are 
involved in a wide variety of cellular processes including, for example, lipid 
metabolism and transport, or immune function (e.g. apolipoprotein E [APOE] and 
triggering receptor expressed on myeloid cells 2 [TREM2])170. 
The apolipoprotein E encoding gene APOE is the most important susceptibility gene 
unequivocally associated with AD162. The gene is located on chromosome 19, and 
exhibits three common forms of polymorphism including allele ε2, ε3 and ε4210,211. 
The three ApoE protein isoforms generated by these alleles differ only in single amino 
acids, either the cysteine (Cys) or the arginine (Arg), located on the on positions 112 
or 158 (ε2: (C112, Cys158); ε3: (Cys112, Arg158); ε4: (Arg112, Arg158)). Here, the 
ε3 allele is the most common one. Further, while the ε2 allele has been suggested to 
have a protective role, the ε4 is associated with increased risk of AD161,211-214. This risk 
of AD has been shown to increase 2- to 4-fold in heterozygote carriers, and 8- to 12-
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fold in homozygotes214,215. Besides the increase in AD risk, the ε4 allele appears to 
lower the age of onset of AD in a “dose-dependent” manner162,188.  
In the central nervous system, apoE is produced primarily by astrocytes. It regulates 
lipid homeostasis by mediating lipid transport, in particular that of cholesterol, to 
neurons via the low-density lipoprotein receptors (LDLR) for apoE162,216. Besides 
affecting the risk of AD, peripheral apoE isoforms have also been implicated in 
atherosclerosis, stroke and coronary heart disease, by causing lipidemia and 
hypercholesterolemia210.  
Different APOE alleles influence the way this protein interacts with lipids, receptors 
and the Aβ itself162. This affects the metabolism, aggregation, and deposition of Aβ, 
both in terms of extracellular Aβ plaques, as well as vascular amyloid (the cerebral 
amyloid angiopathy, CAA)217-219. Specifically, the Aβ plaque load has been shown to 
increase in an isoform-dependent manner (ε4 > ε3 > ε2), both in mice and human220. 
In line with this, ε4 carriers have lower Aβ42 concentrations in the CSF, and higher 
amyloid PET (PiB) signal in the brain42,221.  
The isoform effect is believed to stem from the differences in the lipidation status 
between isoforms, which in turn affects the efficiency with which apoE mediates Aβ 
clearance162. Here, differences in both binding efficiency of the apoE isoforms towards 
Aβ and the cellular uptake and degradation of the apoE-Aβ complexes, have been 
demonstrated222,223. In particular, the E4 isoform has been shown to have a lower 
binding affinity towards Aβ than the E3. Interestingly, complete APOE gene knockout 
essentially eliminates Aβ plaque deposition in transgenic AD mice224.  
The triggering receptor expressed on myeloid cells 2 (TREM2) gene is located on 
chromosome 6 and was recently identified as a risk factor for AD225,226. Here, two rare 
arginine to histidine point mutations on positions 47 and 62 (R47H and R62H) have 
been implicated227,228. Both of these mutations lead to loss of function of ligand-
binding. Other mutations in this gene have also been discovered; however, these are 
not considered risk factors for AD229,230. Instead, they have been implicated in 
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microglia dysfunction in the context of other diseases, e.g. FTD, by affecting the trem2 
stability or expression.  
Trem2 is a cell membrane protein present on microglia and myeloid cells225. It is 
involved in innate immune response and cell proliferation231. Activation of trem2 can 
be done by a large range of ligands, both lipids and proteins, including phospholipids, 
HLD and LDL, as well as apoE and Aβ232-236.  
TREM2 deficiency impairs microglia migration towards apoptotic neurons237. TREM2 
knock-out in primary microglia decreases general immune response in aging, but also 
in AD238-240. Intramembrane proteolysis of trem2 by ADAM metalloproteases 
(ADAM10/ADAM17) has been shown to generate a soluble extracellular fragment 
(sTREM2)241. This fragment is elevated in the CSF of early symptomatic stage AD 
patients242. Furthermore, the two mutations involved in AD have been suggested to 
result in impairment of microglia recruitment towards the Aβ in plaque pathology. This 
results in less efficient encapsulation of the Aβ plaques, and thereby decreased efficacy 
with which microglia restrict plaque growth239,240,243.   
In addition to fAD mutations and risk genes, several risk factors have been implicated 
in AD209. The strongest risk factors are aging and gender244,245. Women are more prone 
to develop AD. Other diseases, including heart disease, diabetes, and stroke, as well as 
high blood pressure and high cholesterol, have also been demonstrated to be risk 
factors for AD209,246-248. Epidemiological association studies have further suggested 
head trauma, low education level, as well as low social and/or physical activity to 
increase AD risk209,249,250. However, these studies are not always replicable. 
1.3.6 Role of lipids in AD plaque pathology 
Over 100 years ago, Alois Alzheimer described a third hallmark of AD, the adipose 
inclusions251. While this suggested an abnormal lipid metabolism to be associated with 
the AD pathological progression, the subject of lipids in context of AD has until now 
gained only limited attention of the AD field252. The discovery that the APOE allele 
ε4, a major lipid transporter, directly interacts with Aβ itself (described earlier) and is 
a major risk factor of sAD has however shifted more focus on the matter162. Recently 
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other genes associated in some way with functional lipids mechanisms have been 
elucidated, including TREM2, and also ATP-binding cassette, subfamily A, member 
7 (ABCA7) and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (SHIP1)170.  
Alongside the genetic components, epidemiological studies have shown cholesterol in 
particular and its derivatives play a major role in AD pathogenesis252-254. Further, 
lipidomic studies of brain extracts have now also implicated the majority of other lipid 
classes to be associated with AD253,255. For instance, lipids have been shown to underlie 
the regulation of Aβ trafficking as well as proteolytic activity of membrane bound 
proteins, including APP itself, but also, β- and γ-secretase activities, associated with 
production of the Aβ peptide (described earlier).  
Cholesterol, or rather the balance between cholesterol and the acyl-
coenzymeA:cholesterol acyltransferase (ACAT) converted cholesteryl-esters (and 
possibly also 24(S)-hydroxy cholesterol) has been suggested as a key component 
controlling amyloidogenesis256,257. Here, elevated levels of cholesteryl-ester, have been 
implicated as a driver of the Aβ peptide release from the cells however, the exact 
mechanism remains unknown. Further, cholesterol efflux itself can affect this process 
either by accumulating intracellularly, or indirectly through APOE’s lipidation 
process, which is mediated by the ATP-binding cassette transporter A1 
(ABCA1)258,259.  
In addition to cholesterol’s metabolism and its transport being implicated in AD, 
cholesterol has also been shown to play a crucial role in lipid rafts and modulation of 
the activity of Aβ generating enzymes and APP localization260. In particular, high 
cholesterol content directly regulates β- (BACE1) and γ-secretase (particularly 
Presenilin) activities by affecting the association of these enzymes (enzyme complex) 
with the lipid rafts (and also association of APP with lipid rafts) thereby promoting 
processing along the amyloidogenic pathway, which results in elevated Aβ 
production261-263.  
Alongside cholesterol, sphingolipids (including ceramides, sphingomyelin and 
glycosphingolipids) have also been implicated in AD by modulating the β- (BACE1) 
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and γ-secretase activity253,264. Here ceramides, which are central to the sphingolipid 
metabolism, have been shown to be elevated in the earliest clinical stages of AD, likely 
by mediating the oxidative cell death265. These species have also been demonstrated to 
enhance the stability of the BACE1, thereby affecting Aβ generation266. Further, 
enhanced activity of sphingomyelin phosphodiesterase (SMase), responsible for 
conversion of sphingomyelin to phosphocholine and ceramide, has been shown in cells 
with PSEN1 mutation, suggesting the key role balance between sphingomyelin and 
ceramides plays in AD267,268. Indeed, inhibition of SMase and hence sphingomyelin 
accumulation, results in impairment of γ-secretase activity, and leads to reduction of 
Aβ267.  
Gangliosides, membrane glycosphingolipids, found in cholesterol-rich lipid raft-like 
microdomains, have also been implicated in AD253,269,270. The monosialogangliosides 
(GM, a-series) in particular, species containing single sialic acids, have been suggested 
to play a critical role in Aβ aggregation270,271. In general, the tissue levels of shorter 
GM2 and GM3 species have been demonstrated to be increased in multiple brain 
regions of AD patients272. Interestingly, it is the longest, GM1, that has been suggested 
to act as an aggregation seed by binding Aβ and altering its conformation to an ordered 
β-sheet structure273-276.  
Indeed, the presence of GM1-Aβ complexes has been shown to be associated with the 
early changes in AD277. However, injection of the GM1 has been shown to decrease 
the Aβ burden, likely by promoting Aβ degradation278. Along this line, ablation of the 
GM2 synthase, resulting in loss of GM1 and accumulation of GM3 has been shown to 
result in deposition of Aβ279,280. Further, ablation of the ganglioside GD3 synthase 
(GD3S) responsible for shift towards b- and c-series gangliosides, increases a-series 
gangliosides and has been shown to be protective against Aβ induced neurotoxicity281. 
Therefore, while clearly implicated in the Aβ pathogenesis, the exact role of different 
gangliosides in AD remains unknown.  
Finally, besides cholesterol (and its derivatives) and sphingolipids, a third large class 
of lipids, phospholipids, has also been implicated in AD252-254. Here changes in 
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phosphoinositides (phosphorylated phosphatidylinositols (PIs)), and phosphatidic acid 
(PA) in particular, have been demonstrated to affect the Aβ generation, including the 
APP trafficking and presenilin modulation. Further, alteration of phosphoinositide 
kineases and phosphoinositide phosphatases, as well as phospholipases, including A2, 
C and D (PLA2, PLC and PLD), enzymes responsible for phospholipid metabolism 
have also been demonstrated in AD.  
The phosphatidylinositol 3-kinase (PI3K) pathway has been shown to play a crucial 
role in Aβ production263. Its inhibition results in reduced Aβ levels282,283. Here, the 
phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2] in particulars modulate the γ-
secretase activity by exhibiting competitive binding to this enzyme262,263. Indeed, there 
is an inverse correlation between PI(4,5)P2 and Aβ42 levels in cultured fibroblasts 
cells284. In terms of AD, PSEN1 mutations have been shown to be associated with an 
increased turnover of PI(4,5)P2 through the PLC pathway284,285. Reduction of this 
turnover decreases Aβ42 production. 
The PLD pathway responsible for hydrolysis of phosphatidylcholine to phosphatidic 
acid (PA) and free choline, has been implicated in AD due to its role in modulating the 
APP processing286. In particular, studies have demonstrated that the overexpression of 
PLD1 compensates for the impairment in APP trafficking to cell membrane in fAD 
PSEN1 mutant neurons287. Further, the PLD1 has been shown to negatively regulate 
processing of the APP by the γ-secretase, likely by modulating the PSEN1 activity288.  
Finally, previous studies have revealed that the PLA2 pathway regulates 
neuroinflamation and neurodegeneration in AD289. It has been demonstrated to exhibit 
elevated activity in vicinity of Aβ plaques291. The enzymatic activity of this enzyme 
results in release of the lysophospholipids and polyunsaturated fatty acids (PUFAs) 
such as arachidonic acid (AA)290,291. Indeed, reduced levels of phospholipid bound AA, 
as well as increased levels of AA and metabolites have been observed in AD brain292.  
Further, involvement of PUFAs and their metabolites in AD, in particular the ω-6 (e.g. 
linoleic acid (LA) and arachidonic acid (AA)) as well as ω-3 (docosahexaenoic acid 
(DHA)) acids, have also been shown in relation to the oxidative stress induced lipid 
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peroxidation293-295. Here, this process has been suggested to be either direct oxidation 
of PUFAs by the reactive oxygen species (ROS), or by peroxide mediated oxidation 
which itself can be generated through Aβ induced reduction of metal ions (such as 
copper (Cu2+) or zinc (Zn2+)), or from the PUFAs themselves acting as an electron 
donor to the Aβ-metal ion complex296,297. The oxidized PUFAs degrade to toxic 
metabolites.  
1.3.7 Aβ maturation and conformational polymorphism  
Presence of Aβ plaque pathology is considered the major hallmark of AD45. In sporadic 
AD, Aβ plaque pathology manifests itself in cored, “congophilic”, neurotoxic deposits, 
and diffuse plaques50. As mentioned earlier, diffuse plaques have also been found in 
CU-AP patients (previously known as pathological aging) 54.  
Based on these observations of plaques in CU-AP it has been put forward that at least 
in sAD and CU-AP, diffuse plaques might represent an early, immature state of the Aβ 
plaque pathology that eventually, would progress to the “mature” dense cored Aβ 
plaques 51,54,298. Studies in transgenic animals have suggested that the two types of 
deposits might however be formed through different and independent pathways, and 
might instead represent a neuroprotective mechanism 299.  
Along this typical morphological classification of extracellular amyloid plaques, into 
diffuse and cored/dense/mature deposits, a new focus has emerged, the amyloid 
polymorphism300,301. Here, recent studies of higher order amyloid assemblies 
implicated in neurodegenerative diseases, particularly Aβ, have demonstrated a high 
degree of conformational variation among oligomers, protofibrils, fibrils and even 
plaques301-303. In the context of AD, this polymorphism has been shown to originate 
from the differences in folding of individual peptides and protomers (oligomers), and 
respectively the assembly of individual protofibrils into fibrils and plaques (introduced 
earlier)304.  
Recent cryo-EM and solid-state NMR studies have visualized folding polymorphism 
not only in-between different peptide aggregates, e.g. Aβ1-40 respective Aβ1-42, but 
also that the same peptide, such as Aβ1-42, can fold differently resulting in multiple 
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structural models of Aβ fibrils305,306. In addition to synthetic in-vitro studies, extracts 
of the clinical subtypes of Alzheimer's disease have also demonstrated a high degree 
of conformational polymorphism307. This poses tremendous challenges to 
development of any therapeutics targeting higher order aggregates (e.g. oligomers), as 
these then face issues “fitting” the shape of the amyloid301. Further, it poses problems 
related to the detection and visualization of amyloid structures for diagnostic 
purposes302.  
In clinical diagnosis, Congo Red (CR) is typically used for detection of amyloid 
assemblies. However, a wide variety of other amyloid probes have also been developed 
for more sensitive detection of a small amount of the amyloid structures. In the context 
of AD, CR staining is complemented with more specific peptide directed antibody 
staining (most often toward Aβ1-40 or Aβ1-42), in order to identify less Aβ aggregated 
structures not detected with CR, for instance diffuse plaques. Such antibody-based 
staining is also the golden standard for the visualization of different Aβ truncation 
present in plaques. Together, these approaches offer the possibility to, according with 
current practices, classify detected amyloid into diffuse and compact/mature/cored 
structures. Nevertheless, these cannot distinguish between different degrees of 
aggregation, such as oligomers, protofibrils, and fibrils. Nor can they distinguish 
between the structural and conformational polymorphism of same order structures as 
introduced above.   
An approach to overcome this has been the development of conformation specific 
antibodies that target the aggregated, rather than monomeric structures (e.g. oligomers 
or protofibrils)308,309. While potentially offering the possibility to classify aggregation 
states in pharmaceutical contexts, the conformational antibodies suffer multiple 
limitations. These include the general limitations of antibody-based approaches (e.g. 
affinity, issues caused by post translational modifications, tissue penetration, and 
multiplexing), but also include the challenges associated with their targets’ 
conformational flexibility.    
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An alternative method for sensitive and conformation specific detection of 
polymorphic amyloid structures, is the used of electro-optically active 
chromophores310. Depending on the binding site of their target, these can rotate, 
thereby changing the effective π‐electron conjugation length within their backbone 
structure. This in turn yields different fluorescence emission. Here, luminescent 
conjugated oligothiophene probes (LCO), with such flexible backbones, have been 
used to demonstrate age-dependent changes in conformational polymorphism within 
individual plaques, conformation specific properties of prions, and, most recently, 
variability in Aβ-amyloid aggregate structures between plaques of AD subtypes (e.g. 
fAD, sAD)303,311-313. Still, while these probes can to some extent be multiplexed with 
peptide specific antibodies (and spectrally delineated, described in Method), the degree 
of multiplexing is limited, making it hard to determine the proteomers and peptides 
underlying the amyloid heterogeneity. Therefore, alternative approaches are needed in 
order to investigate the broad diversity of Aβ truncated peptides, as well as other 
biomolecules, in the context of AD.  
Mass spectrometry (MS) offers the possibility of directly identifying tens, and even 
hundreds of different molecular species at the same time (based on their m/z value). 
Further, in contrast to antibodies that might suffer specificity issues, the molecular 
identification in MS is based on the precise mass of the actual molecule (rather than 
indirect detection as with antibodies), which can often be confirmed by the 
fragmentation of the molecule. Indeed, MS has been used in the context of AD, to 
identify a wide diversity of Aβ peptides present in human CSF314-316. Therefore, MS 
should be considered a powerful tool for future investigation of molecular complexing 
in AD.   
Taken as a whole, the Aβ pathogenicity is highly complex with morphologically 
heterogeneous plaques, the structural polymorphism of Aβ fibrils, and complex 
molecular changes. Given the lack of understanding, an integration of recent 
developments needs to be explored. In particular it is crucial to readdress the well 
acknowledged, yet poorly understood, key pathological feature of AD, the Aβ plaques.  
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2 AIMS 
2.1 General aims 
The overall aim of this thesis was to gain a deeper understanding of WHERE, WHEN, 
and HOW Aβ aggregates and precipitates into extracellular Aβ plaques, and what other 
biochemical factors, besides Aβ itself, promote Aβ aggregation in AD pathogenesis.  
Further, the aim was to examine biochemical factors that might underlie amyloid 
plaque polymorphism. In particular, the intent was to elucidate potential factors 
responsible for the formation of Aβ plaque morphotypes associated with neurotoxicity 
in Alzheimer’s disease (AD) patients, which are not observed in cognitively normal 
amyloid positive (CU-AP) individuals.  
2.2 Specific aims  
Paper I 
Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry 
(IMS) has been proven suitable for analysis of protein and peptides directly on tissue 
sections. The aim of this work was therefore to investigate suitability of MALDI-IMS 
to study protein and peptides content within individual Aβ deposits, across different 
brain regions in tgAPPArcSwe mice. 
 
Paper II 
Lipids have been suggested to be involved in AD pathology. Therefore the aim of this 
work was to investigate whether different, complementary IMS techniques can be used 
to probe the lipid-peptide interplay associated with plaque pathology in tgAPPArcSwe 
mice. 
 
Paper III 
Laser irradiation in MALDI IMS could be destructive to tissue morphology. The aim 
of this work was therefore to study the impact of MALDI IMS on tissue surface, and 
establish whether MALDI IMS can be interfaced with immunohistochemical (IHC) 
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analysis and fluorescent microscopy for multimodal, comprehensive chemical 
imaging.  
 
Paper IV 
Structural polymorphism within individual amyloid plaques has been reported to be 
associated with heterogenous AD pathogenenis. Amyloid polymorphism can be 
probed using luminescent conjugated oligothiophenes (LCOs). This work did therefore 
seek to combine MALDI IMS with LCO based structural amyloid imaging to identify 
neuronal lipid patterns associated with intraplaque heterogeneity in-between diffuse 
and cored plaques structures in tgAPPSwe mice.  
 
Paper V 
Diffuse and cored Aβ plaques are both present in AD pathology, while plaques in CU-
AP are predominantly diffuse in morphology, suggesting plaque maturation into cored 
plaques to be critical in AD pathogenesis. Various Aβ truncations have been suggested 
to be responsible for the formation of polymorphic plaques. The goal of this work was 
therefore to identify potential aggregation-promoting Aβ spices associated with plaque 
polymorphism (diffuse and cored plaques) in sAD, CU-AP, as well as tgAPPSwe mice. 
 
Paper VI 
Aβ aggregation is believed to be a continuous process, where Aβ plaque pathology has 
been shown to progressively spread across brain regions. The aim of this work was 
therefore to follow the evolution of plaque pathology in terms of Aβ processing and 
deposition, across main pathologically relevant anatomical regions in tgAPPSwe mouse 
brain over different ages. 
 
Paper VII 
The chain of events underlying Aβ aggregation, plaque formation and plaque growth 
is not well understood. This work therefore sought to establish a novel in vivo stable 
isotope labeling method for spatiotemporal Aβ imaging, to study Aβ plaque deposition, 
from its earliest onset until full development in knock-in mice model of AD.  
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3 METHODS 
3.1 Ethics statements 
Experiments on human post mortem brain tissue were approved by the ethical 
committee in Gothenburg (DNr 012-t5; 150416). The ethical committee at Uppsala 
University has approved all the animal experiments on transgenic mice (#C233/8; 
#C216/11; #C49/10; #C17/14 (Uppsala)) needed to carry out the work in papers I-VI. 
The ethical committee at the University College London (UCL), London, United 
Kingdom, has approved all the experiments based on knock-in mice model needed for 
method development in paper VII (160506). All animal experiments were performed 
in accordance with the principles of the Declaration of Helsinki.  
3.2 Optical light microscopy 
An optical microscope, commonly referred to as a light microscope, relies on the use 
of light, in combination with a lens (or lenses), to generate magnified images of the 
analysed object. While the early microscopes consisted of a single lens, the majority 
of modern microscopes consist of multiple lenses. This includes an objective lens that 
focuses the image of the analysed sample inside the microscope, and ocular lenses, 
also referred to as an eyepiece, that magnify the image.  
In general, there are two basic, common sample illumination principles in light 
microscopy. Either the entire sample is permanently illuminated, referred to as wide-
field microscopy, or a single focal spot is illuminated, which is known as confocal 
microscopy (described in more detail below).  
Wide-field microscopes, are commonly used with transmitted white light. Here 
contrast can be obtained in several ways with the sample either by: absorbing the light 
(bright-field contrast), scattering it (dark-field contrast), or refracting it, which will 
result in a phase shift of the transmitted light (phase contrast). Illumination can be from 
above or below (inverted, respective upright configuration)317.  
  33 
Both confocal and wide-field illumination can also be used for fluorescence imaging 
(described in detail below). Here, rather than white light, only light of specific 
frequencies is used to excite fluorescent molecules present in the sample. This can 
provide specific information about their localization.   
The resolution (δ) of light microscopes is the minimum distance between two points 
that can be viewed as separated. The limit of this distance, referred to as diffraction 
limit, is imposed by the diffraction of light as it passes through a circular aperture. This 
results in the production of diffuse circular discs by the passing light. These are known 
as Airy’s discs. In practice, this implies that image formed in light microscopes is 
generated from the diffraction pattern produced by the circular apparatus at the back 
focal plane, after they been converged on the focal point317,318.  
The resolution for optical microscopy can be described by the Rayleigh Criterion for 
lateral resolution (equation I)317,319. Here, the resolution is limited by the wavelength 
of illumination (λ), and the numerical aperture (N.A.), which is a measure that reflects 
the objective lens’ ability to collect light.  
𝛿𝛿 = 0.61𝜆𝜆
𝑁𝑁.𝐴𝐴.   (I)  
In a simplified view, the numerical aperture is dependent on the refractive index of the 
medium (μ), and the angle subtended by the lens between the sample and objective (α) 
(equation II). Therefore, the equation for resolution (equation I) can be rearranged to 
account for these (equation III).  
𝑁𝑁.𝐴𝐴. = 𝜇𝜇 sin𝛼𝛼  (II)  
𝛿𝛿 = 0.61𝜆𝜆
𝜇𝜇 sin𝛼𝛼
  (III)  
From the equation III it is clear that the resolution is dependent on the wavelength of 
light with shorter wavelength of illumination light yielding higher resolution. Further, 
resolution can also be improved by increasing the refractive index of the medium. This 
refers to the relative ratio of the speed of light through a substance, as compared to 
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vacuum. With increasing μ, the speed of light decreases, shortening the wavelength 
and thereby increasing resolution. This can be achieved through the use of immersion 
oils which have μ around 1.5. Due to obvious reasons, higher resolution is needed for 
smaller objects, which require high magnification. In practice, the high magnification 
objectives (63x, 100x) also have higher N.A. and rely on the use of immersion oils. In 
theory, when simplified, the diffraction limit implies that an optical system has a 
maximal lateral resolution of approximately half the wavelength of light used for 
illumination.  
The N.A. of a lens however also depends on the imperfection in the objective lens 
referred to as aberration320.  These are either the spherical or chromatic aberrations. 
The spherical aberration is caused by the differences in the focusing of the light passing 
through the periphery versus the centre of the lens. This results in the image of an 
object not being in sharp focus. The chromatic aberration originating from the 
differences in refractive indices of light with different wavelengths, is termed 
dispersion (e.g. blue light refracted more than red). This results in light of different 
wavelengths being focused at different focal points.  
The majority of modern microscopes address the problem of spherical aberrations in 
multiple ways317. One of these is simply limiting the light exposure of the lens only to 
its central part using diaphragms. The issues of chromatic aberration are also corrected 
with lens that are either achromatic, converging blue and red light, or even more 
advanced apochromatic, that bring blue, green and red light into a single focal point.  
In light microscopy the limit in lateral resolution is roughly 200nm (fluorescence 
imaging, described in more detail below). This is theoretically the case for both the 
wide-field microscope but also the confocal microscope. In practice however the actual 
resolution of a wide-field microscope is affected by the background fluorescence and 
emission of out-of-focus light, which results in lower signal-to-noise ratio, and hence 
also contrast.  
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3.2.1 Confocal microscopy 
Confocal microscopy refers to an optical imaging technique where a pinhole is used to 
block the light coming from outside of the focus plane317,321,322. This results in the 
illumination of a relatively small volume of the sample, instead of a whole specimen 
being exposed to the light from the light source in a conventional wide-field 
microscope. This allows for the control of depth of field in images, the reduction in 
background, and the possibility to obtain optical sections of specimen. Together, these 
advantages have made the confocal microscope a go-to technique for obtaining high-
quality images in the field of cell biology.  
A typical confocal microscope relies on seven main components. These are the laser, 
the beam splitter, laser scanner, objective lenses, motorized Z-axis control, a pinhole 
and photomultiplier tube (PMT)322.  
The lasers (rather than an e.g. halogen lamp commonly used in wide-field 
microscopes) offer a very intense, bright, stable, narrow, non-divergent and easily 
focusable beam of light (point-like) that comes at a particular wavelength. This is 
necessary to ensure a homogenous illumination. Further, this offers the possibility to 
focus the laser to a diffraction-limited spot. At the same time however, as lasers exhibit 
specific wavelengths, several different laser sources might be needed to cover the wide 
range of excitation wavelengths of the common fluorophores in the visible spectral 
range (ca 350nm – 750nm). This is in contrast to the lamps typically employed in wide-
field microscopes that provide excitation wavelengths across almost entire visible 
spectra.  
A crucial component of a confocal microscope, particularly needed when performing 
fluorescent imaging is a beam splitter (also needed for wide-field fluorescence, 
described below)317,322. The beam splitter, which is typically the first component in the 
laser path, separates the excitation wavelength of light from the light that is emitted 
from the sample.  
After passing through the beam splitter, the laser is directed to a set of scanning mirrors 
that tilt the laser beam in X-Y directions, and raster it pixel-by-pixel across the sample. 
  36 
On its way to the sample surface the beam is passed through the objective lens, where 
it’s focused in the back-focal plane of this lens, before being focused on the sample. 
The level of the optical section at which the laser light will be focused is achieved by 
adjusting the z-control. This can be done with high precision, and hence is employed 
for 3D analysis (referred to as Z-stacks). The reflected light emitted from the specimen 
is then collected back through the objective lens, and passes as a stationary (not 
scanning) light further along the scanning mirrors onto the detection system. Here the 
light is first passed through a pinhole aperture.  
The pinhole is of adjustable size, and is the main component that allows for the 
exclusion of out-of-focus light in a confocal image317,322. It defines the thickness of the 
optical slice, and hence it is also crucial for optical sectioning. In general, the choice 
of the pinhole size reflects a compromise between the efficiency of light collection and 
the optical sectioning. Typically, the size of the pinhole is set to 1 Airy unit (Airy disc). 
It’s an automatically calculated value that is dependent on what objective is used, 
objective’s N.A., and magnification (as described above). This value will correspond 
to the diameter calculated for inner most circle produced as a diffraction patter 
produced by a point light source (the Airy disc).   
After being directed onto the pinhole, only a small central portion of light is used to 
create a point-like image at the detector. Therefore, the detectors in a confocal 
microscope typically consist of photomultiplier tubes (PMT). In simplified terms, 
these are vacuum tubes with electron multiplying components inside. These are 
necessary as the light that reaches past the pinhole might have very low intensity (some 
of the photons that indeed originate from the focal plane, might also have been blocked 
as if out-of-focus). The PMTs are used to amplify the signal, even up to 1,000,000 
times, without introducing additional noise. This is in contrast to wide-field 
microscopes where the image is captured by a camera, such as a Charge Coupled 
Devices (CCD), the Complementary Metal Oxide Semiconductors (CMOS) camera.  
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3.2.2 Fluorescence microscopy 
3.2.2.1 Optical molecular spectroscopy – fluorescence  
Optical spectroscopy deals with the way light interacts with atoms and molecules, such 
as e.g. absorption and emission (or scattering). Here, the visible light corresponds to 
only a small fraction of the electromagnetic spectrum. In general, spectroscopy, deals 
not only with visible light but also longer wavelength radiations, such as for instance 
microwaves or infrared light (IR), and shorter wavelength radiation, such as ultraviolet 
light (UV), or X-rays.  
Absorption of light (photons of distinct energy) by a molecule, leads to the promotion 
of electrons to an energetically higher state, referred to as the excitation state. The 
photoexcited molecules can than undergo several different steps in order to return to 
its ground state. These are commonly described in a Jablonski diagram, and include 
e.g. radiation-less vibrational relaxation or internal conversion, o photoluminescence. 
Photoluminescence refers to the processes where the return of an electron from its 
excited state is accompanied by emission of light. Two common types of 
photoluminescence include fluorescence and phosphorescence.   
Fluorescence, is a type of photoluminescence. It is a process where the return to the 
ground state takes place without the change in electron spin (in difference to 
phosphorescence, where the change in electron spin takes place). It is very short lasting 
(nanoseconds), and typically results in emission of light of lower energy, and longer 
wavelength, than the absorbed light (due to co-occurrence of other processes). 
3.2.2.2 Fluorophores and fluorescence microscopy 
A molecule that can undergo the process of fluorescence is commonly referred to as a 
fluorophore. Such molecules both absorb and emit light of a wide variety of specific 
wavelengths, and therefore exhibit excitation and emission spectra. The difference 
between the maximal excitation and emission wavelength of a molecule is referred to 
as Stokes shift. The spectral properties of fluorophores depend on their structure. 
 
  38 
Fluorophores are typically organic, carbon-based aromatic molecules with π-
conjugation (alternating single and multiple bonds). Such structure allows for 
delocalization of π-electrons along the conjugation backbone, and the emission of light 
in form of fluorescence. In general, the intensity of a fluorescent emission of a 
fluorophore, referred to as quantum efficiency or quantum yield, does depend both on 
the backbone of the molecule, and its side substitutions.   
Knowledge of the excitation and emission spectra of fluorophores is critical when 
dealing with fluorophores, in particular in the context of fluorescent microscopy, 
where light filters limiting the wavelengths need to be chosen (described in more detail 
below). If dealing with multiple fluorophores whose spectra overlap, the signals might 
“bleed through”.  
For analytical purposes, fluorophores are attached to biological molecules, or other 
targets of interest, in order to enable identification, quantification, and even real-time 
observation of their biological/chemical activity.  Fluorescence is widely used in 
biotechnology and analytical applications due to its extraordinary sensitivity, high 
specificity, and simplicity. Fluorescence microscopy is one of the most common 
applications. Regardless of the technique when working with fluorescence one needs 
to keep in mind potential photo-bleaching of the fluorophore, its brightness, and 
contrast that it can generate.  
Fluorescence imaging can be performed on both a wide-field and confocal microscope. 
In the case of a wide-field microscope, fluoresce imaging is referred to as Epi-
fluorescence. For both types of instruments, the illumination and collection of 
fluorescent emission is performed through the objective lens.  
For the light to efficiently excite the fluorophore of interest only light of specific 
wavelengths (usually excitation maxima peak) should reach the sample. For an Epi-
fluorescent microscope, this is achieved by passing the white light coming from the 
light source via a set of filters, before letting it into the objective for magnification and 
focusing (nowadays these are often confined in a single filter cube).  After reaching, 
and being reflected back from the sample, the light again passes first through the 
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objective, and then through the filter cube, before it is finally imaged either by a 
camera, or visualized directly in the eyepieces. In a modern microscope, there is 
typically more than one filter cube, allowing for the detection of signals from several 
fluorophores distinct spectral properties. 
The filter cube consists of three main components: the exciter filter, a dichromatic 
beamsplitter, and a barrier filter. Dichromatic beamsplitters, and nowadays also 
majority of the exciter and barrier filters, rely on so called interference filters. 
Interference filters are made of glass that has a dielectric coating. This gives the filter 
highly specific refractive and reflective properties. These filters are designed to reflect 
certain spectral bands (wavelengths), and efficiently transmit others. 
The exciter filters (excitation filter) are responsible for selection of the illumination 
wavelengths. Here, either short pass filters (SP), which efficiently block light of longer 
wavelengths than the wavelength of maximum transmission, or band pass (BP) filters, 
which cut-off light both at shorter and longer wavelengths, are commonly used. These 
are especially useful when a given fluorophore has only small Stokes’ shift.  
The dichromatic beamsplitters, more commonly known as dichroic mirrors, are 
specialized interference filters. Their role however is to selectively reflect the 
excitation wavelengths of light and direct them towards the sample, while letting the 
fluorescence emission wavelengths coming from the sample to pass. They are 
positioned in the light path, between the exciter filter and the barrier filter, and are 
mounted at a 45° angle in relation to these two filters.   
The barrier filter (emission filter) selectively permits certain emission wavelengths to 
pass towards the eyepiece/camera (while also suppressing or blocking the excitation 
wavelength). Just like exciter filters, the barrier filters are often BP filters. 
Alternatively, they can also be long pass filters (LP), which selectively block or 
suppress shorter wavelengths.  
In terms of fluorescent imaging, confocal microscopes offer several advantages. These 
originate from the use of lasers and the pinhole. Given that lasers generate light of 
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distinct wavelength, selection of an excitation band using a filter cube is not necessary. 
Instead, a laser of appropriate wavelength is chosen in order to excite the fluorophore 
of interest (this can sometimes be problematic).  
Given that the lasers do yield a point-like illumination, and that confocal systems rely 
on the use of a pinhole, such microscopes can be used to illuminate selected regions 
and focal planes in the specimen. Therefore, a general decrease of photo-bleaching of 
the sample will be observed. Further, reduced background fluorescence and increase 
contrast thanks to optical sectioning will be obtained. Still, modern wide-field 
microscopes are able to perform post-acquisition deconvolution of the images (by 
reassigning the origin of fluorescent signal) and remove a large majority of blurring, 
generating improved sharpened images. 
3.2.2.3 Hyperspectral fluorescent imaging  
Luminescence conjugated oligothiophenes (LCO) are a special type of fluorophores 
used for detection of amyloid aggregates311,323,324. They have been shown to display 
unique spectral shifts upon binding to amyloid structures, both in solution, cells, and 
tissue sections. Further, they are particularly useful, due to their ability to recognize 
both the different aggregation state of same amyloidogenic protein, but also in some 
cases are specific for different amyloid proteins (e.g. amyloid-β respective tau)324-326.   
In comparison to conventional amyloid ligands, which possess sterically rigid 
structures due to their conjugated polymer backbone, LCOs display high 
conformational freedom 310,327. The polar and hydrophobic character of LCOs 
backbone enables the probes to intercalate in the binding pockets of the fibrils, in a 
fashion similar to that proposed for Congo Red 324,328. Upon interaction with the 
cationic residues present in the groves of the fibrils, a change of net charge on the 
acetic acid side chains occurs. This leads to the restriction of conformational freedom 
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of the probes, more planar arrangement, a change of effective conjugation, and hence 
a VKLIWLQH[FLWDWLRQHPLVVLRQRIWKHSUREH324. 
)LJXUH 6FKHPDWLFRIQRUPDOL]HGVSHFWUDRIT)7$$JUHHQDQGK)7$$UHGDQG
WKHLUPDWKHPDWLFDOVXP\HOORZREWDLQHGIURPDP\ORLGSODTXHVLVWLVVXH&KHPLFDO
VWUXFWXUHVRIWKHWZRIOXRURSKRUHVGLVSOD\VWKHLUIRXUTXDGUR– T)7$$UHVSHFWLYH
VHYHQKHSWD– K)7$$WKLRSKHQHULQJEDFNERQH$GDSWHGIURP 3DSHU,9)LJXUH 
In general, the distance along the conjugation backbone along which the electrons can 
move, known as conjugation length, is the primary variable that gives the LCOs their 
distinct electrical and optical properties. The longer the conjugation, the longer the 
wavelength of light emitted by the LCO probe. Therefore, when in planar conjugation 
the emission is red-shifted, while in the twisted arrangement, the emission is blue-
shifted. 
+\SHUVSHFWUDO LPDJLQJ UHSUHVHQWs a combination of light microscopy and 
spectroscopy. It relies on the use of a spectral detector for collection of spectrally 
separated emission light for each DQGHYHU\SL[HOLQDQLPDJH7KLVLPDJLQJWHFKQLTXH
has emerged to tackle the problem of overlapping fluorophores (which emission bands 
often span around 100nm) leading to signal bleed-through, and the limited possibilities 
RIIOXRURSKRUHPXOWLSOH[LQJ317.  
Imaging based on spectral collection enables high-speed acquisition of multiple 
spectral profiles at the same time. If the emission spectra of individual fluorophores 
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have previously been acquired, these can be separated from a combined single spectral 
scan using software-based linear-unmixing algorithms (possible even when a high 
degree of spectral overlap exists between multiple fluorophores). This approach can 
further be employed to distinguish imaging artefacts from the real fluorophore signal 
in the sample (e.g. auto-fluorescence).  
Even though most commonly performed using a confocal microscope, hyperspectral 
imaging can also be performed using a wide-field microscope. For this task, several 
different methodologies for spectral separation, and multiple detector designs, have 
been developed. Typically, spectral collection in hyperspectral imaging is performed 
by generating so called Spectral Image Lambda Stacks. These are three-dimensional 
datasets, where the same image field is acquired at different wavelengths that span 
over selected spectral regions. This is in comparison to a single or successive group of 
images as acquired in a conventional fluorescence imaging experiment.  
In order for this to be possible, the emission light that emerges from the sample, is 
dispersed by either a diffraction grating or a prism. This light is then directed and 
focused at a multi-anode photomultiplier with the help of multiple mirrors. Such multi-
anode photomultiplier most often consists of 32-channels. If operating in parallel with 
other detectors, such as PMT (typically present at the confocal microscopes), this can 
potentially offer more detection channels (often up to 34-channels). Depending on the 
spectral range in the hyperspectral imaging experiment, the spacing of the collection 
wavelength will differ (the range divided by number of detectors). This is referred to 
as wavelength resolution (spectral resolution). Depending on the instrument, this 
spacing can be brought down to a few nanometres. 
3.3 Electron microscopy 
Electron microscopy is a high resolution imaging technique, which relies on the use of 
accelerated beams of electrons rather than photons for sample illumination. The first 
electron microscope was built in 1932 by Knoll and Ruska330,331. Since than a wide 
variety of applications for the electron microscopes have been developed, allowing for 
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the study of structure-function relationship both in material sciences but also in biology 
and medicine332,333.  
Electron microscopes utilize a beam of electrons as the sources of illumination. Here, 
several different beam source are used. These include heated tungsten filament, a more 
efficient thermal lanthanum hexaboride (LaB6), or tungsten field emission gun (FEG) 
that uses a powerful electric field to expel electrons from filament tip. The energy 
distribution of the electron sources as a fraction of the average energy varies, with the 
smallest being most optimal for high resolution imagining. Here, FEG electron guns 
are most coherent when it comes to electron energy distribution and are therefore used 
for high resolution imaging.   
The generated electron beam is then accelerated towards the target surface guided by 
the positive electric potential. Along the way the beam is focused and confined with 
the help of lenses and apertures. Here, the electron lenses are composed of magnetic 
coils tuned to focus electrons of a particular wavelength, and bend away electrons of 
other wavelengths. The apertures on the other hand are metal holes that limit the 
diameter of the electron beam and are located after the lenses. Depending on their 
positioning they can for instance: adjust the coherence of the beam (condenser 
aperture), or the contrast of the image (objective aperture). Finally, “fine-tuning” of 
the electron beam’s asymmetric astigmatism, can be performed using weak electric 
and magnetic stigmators. Together, all these components are referred to as the column 
of the electron microscope.  
Upon interaction of the incident electron beam with the matter in the sample, a wide 
variety of signals, (in the form of scattered or generated electrons, and radiation) can 
be detected. Broadly, these can be divided into signals that are either scattered back, 
and signals that are transmitted. In general, while signals that are scattered back are 
commonly analysed using a scanning electron microscope (SEM), the signals that are 
transmitted are analysed using a transmission electron microscope (TEM) (described 
in detail below). Together collection of these signals can provide unique information 
about the specimen and its properties in form of images.  
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Contrast in the electron microscopy images (commonly referred to as micrographs) 
arises from interference between the electrons. Here, the electron scattered from the 
sample, interfere with the primary electron beam coming from the electron source. 
Depending on the constructive or destructive interference of the electrons, darker and 
brighter regions in the image will be present. In general, electrons are more scattered 
by heavy elements, and only weakly scattered by light elements (such as Carbon or 
Nitrogen). Therefore, methods for enhanced contrast, such as staining with heavy 
elements, are often used when needed, especially in biology (described in detail 
below).  
The column of the electron microscope, and in the majority of the set-ups the entire 
system including the sample chamber, are operated in a high vacuum. An exception to 
this is e.g. environmental scanning electron microscope (ESEM), where the sample 
chamber can be filled with a gas vapour, such as H2O.  
Thanks to the use of electrons as a source of sample illumination, an electron 
microscope can achieve a much higher resolution than a conventional light 
microscope. This is clear when one considers the simplified version of the de Broglie 
relations, and the Rayleigh Criterion for lateral resolution described before. According 
the de Broglie hypothesis, electrons have a wave-particle duality. Here, the de Broglie 
wavelength on an electron (λ) is related to its momentum (ρ) through the Planck’s 
constant (h) (equation I). Where the momentum of the electron is related its velocity 
(v) and mass (m) (equation II).   
𝜆𝜆 = ℎ
𝜌𝜌
  (I)  
𝜌𝜌 = 𝑚𝑚𝑚𝑚  (II)  
Given that the electrons potential energy of the electron (reflected in the acceleration 
voltage) (equation III) is converted to kinetic energy (equation IV), the wavelength of 
electron can be calculated by rearrangement of these equations and by substituting 
them into the de Broglie wavelength equation (equation V). This is the simplified 
version not taking into consideration special relativity theory.   
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𝐸𝐸𝑃𝑃𝑃𝑃 = 𝑒𝑒𝑒𝑒  (III)  
𝐸𝐸𝐾𝐾𝑃𝑃 = 12𝑚𝑚𝑚𝑚2  (IV)  
𝜆𝜆 = ℎ
√2𝑚𝑚𝑚𝑚𝑚𝑚
  (V)  
Now, recalling the Rayleigh Criterion (equation VI), the refractive index (μ) for TEM 
corresponds to vacuum and is therefore equal to 1. Furthermore, given that the half 
angle of collection (β) for electron beam is very narrow the entire denominator can 
generally be approximated to β. Therefore, for an electron microscope the simplified 
theoretical resolution is directly related to the wavelength of the electron (equation 
VII), and can be in the sub Angstrom range (less than a nanometre). As seen in the 
equation for the de Broglie wavelength, it will depend on the acceleration of 
acceleration voltage of the beam.    
𝛿𝛿 = 0.61𝜆𝜆
𝜇𝜇 sin𝛽𝛽
  (VI)  
𝛿𝛿 = 0.61𝜆𝜆
𝛽𝛽
  (VI)  
The practical resolution of an electron microscope is however lower than this due to 
the imperfection of the electron optical system. In particular, spherical and chromatic 
aberrations of the lenses affect the sharpness and size of the beam. The spherical 
aberrations originate from the difference in the strength of the lens, across the plane of 
the lens. Here, electrons that are further away from the optical axis, are deflected more 
than those closer to it.  The Chromatic aberrations on the other hand come from the 
energy spread of the electrons. Electrons of higher energy move faster, and therefore 
are less deflected by the lens. Together, these result in the electrons being focused in 
different planes. Today, spherical aberration correction is common and is based on the 
introduction of additional multipole lenses (typically a hexapoles), either only to pre- 
but also to post specimen lenses depending on the microscope setup/operation mode 
(described in more detail below).   
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3.3.1 Scanning electron microscope (SEM) 
Scanning electron microscope is one of the two common electron microscope setups, 
and is commonly used to analyse the surface and composition of a sample. Here the 
electron beam that exits the column is scanned across the sample with help of 
electromagnets/coils. This is done in a raster-like pattern across a rectangular area. 
Electron detectors capture the generated electrons and, when sent through a 
photomultiplier, the signal is converted into a voltage signal, which eventually is used 
to generate an image. Due to this setup, the area of analysis, referred to as the field of 
view (FOV), can be very large in an SEM instrument (in difference to TEM, discussed 
below).  
The majority of the electrons detected in SEM are either secondary electrons (SE), or 
backscattered electrons (BSE), for surface analysis, as well as energy dispersive x-rays 
(EDX), which are useful for analysis of the composition of the samples (particularly 
in material science, details in TEM section). An SEM instrument is most often operated 
at voltages up to 30kV, which results in it having the maximal resolution of down to 
sub-nanometre. While this is much less than a TEM (discussed below) SEM does have 
its advantages.  
The SE generated in SEM can produce images that appear to have a topographic 
contrast. This takes place due to the fact that even though the SE are generated 
throughout the entire interaction volume of the electron beam, they can only escape if 
they are near the surface. As a result, brighter and darker regions appear in the image 
due to the topography of the sample. Further, topographic contrast is also obtained 
thanks to the great depth-of-field of an SEM (as compared to a conventional optical 
microscope). An SEM is also able to provide surface atomic number contrast thanks 
to the detection of the BSE. As described above, this arises due to the fact that heavier 
elements scatter electrons more efficiently than lighter elements. These show up as 
brighter regions when the BSE detector is used.    
An important advantage of an SEM is the simplicity of the sample preparation needed, 
namely minimal or no sample processing is needed. Instead the samples are typically 
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mounted, and maybe sputter coated. Sample sputter coating is done through the 
deposition of a very thin (nm thick) layer of, for instance, gold, carbon or palladium. 
This increases the surface conductivity and decreases the surface charging, which 
otherwise would perturbate the primary beam and affect image generation.   
Biological samples are typically not very conductive, and sputter coating is thus very 
useful. Further, they are often “hydrated”. In those instances, the use of an 
environmental scanning electron microscope (ESEM), mentioned above, can be very 
beneficial when working with such samples. An ionization gas (such as H2O) is used 
to amplify the SE signal and suppress surface charging artefacts as the positive gas 
ions that get attracted to the negatively charged surface. This Setup removes the need 
for sputter coating. Importantly, samples can be analysed without vacuum. 
Unfortunately, this comes at the cost of resolution.   
3.3.2 Transmission electron microscope (TEM) 
Transmission electron microscope (TEM) is the second of two common electron 
microscope setups334. As suggested by the name, the electrons that have been 
passed/transmitted through the sample are collected. These can provide information 
about the inner structure of the sample, such as the morphology in a biological sample, 
or the crystal structures and stress mechanics that are often of interest in material 
sciences.  
In a TEM a broad stationary electron beam is focused on the samples, rather than 
scanned as is done in a SEM. Further, the image generation is done directly, either by 
projecting the electrons through intermediate and projection lenses (located below the 
sample) onto a fluorescent screen or a charge-coupled device (CCD) camera. As a 
result, the field of view (FOV) of a TEM is much smaller than that of an SEM. This 
also implies that only two-dimensional projections are generated, with no depth-of-
field which is maintained in SEM.   
In contrast to an SEM, a TEM is also operated at a much higher voltage of 60-100 kV, 
but measurements at 300kV have also been performed. The higher acceleration voltage 
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implies that the TEM can achieve a significantly higher resolution. With the use of 
pre-and post-sample aberration correction of the beam, a resolution down to as low as 
tens-of-picometres has been achieved (below 1 Angstrom). Typically, the images 
generated in a TEM result from the electrons that are transmitted through the entire 
thickness of the sample. Therefore, the samples need to be very thin (around 100nm), 
otherwise many electrons from the primary electron beam will be absorbed. TEM is 
always operated at a high vacuum, and therefore requires much more sophisticated 
sample preparation than SEM. This is particularly important for biological samples 
(described in detail below).   
Generally, the number of transmitted electrons in a TEM is proportional to the 
brightness. The contrast on the other hand can be obtained by monitoring the electron 
scattering (as well as the phase of diffracted electron in a more advanced analysis). 
The principle behind the scattering contrast is that the electrons that are scattered at a 
large enough angle will not reach the detector (darker). Obviously the thickness of the 
sample will affect the scattering, but importantly, the contrast will also depend on the 
atomic number of the elements in the sample. As mentioned above, heavier elements 
will scatter electrons more broadly. In biological samples, the scattering contrast is 
most commonly used and is achieved by the means of sample staining with heavy 
metals (described later). 
Importantly, the scattering can be both inelastic and elastic. The inelastic scattering 
implies that the electrons lose energy. This loss can be characteristic to particular 
atoms, and can be analysed by earlier mentioned energy dispersive x-ray (EDX) 
spectroscopy, or Electron energy loss spectroscopy (EELS). Together, these 
spectroscopic approaches can be useful in identifying chemical composition of the 
materials.  
If the scattering is elastic, diffraction contrast can also be obtained in TEM. Here the 
contrast is obtained from the constructive interference of electrons that have not lost 
their energy. This approach is particularly useful for the analysis of atom organization 
in a crystal lattice. Finally, due to the fact that the transmitted electrons and diffracted 
  49 
electrons are not in phase, an interference pattern is generated. This pattern is referred 
to as a phase contrast. Together, diffraction contrast and phase contrast are extremely 
useful in material sciences (particularly nanoscience), not only to analyse earlier 
mentioned crystal structures, but also to identify dislocations, boundaries or areas of 
mechanistic stress in the samples. 
3.3.3 Scanning transmission electron microscope (STEM) 
The scanning transmission electron microscope is a third “setup” on an electron 
microscope. Technically, however, it is not an independent electron microscope, but 
rather a mode of operation. It is compatible with both the TEM and SEM system. In 
fact, it is a combination of both these systems. In the STEM, the beam is finely focused 
and scanned across the sample (as in SEM), the image generated however is that of 
transmission electrons (like in TEM), rather than that of SE or BSE. Therefore, the 
sample preparation for STEM is similar to that of TEM (discussed below).  
STEM can take advantage of both setups, such as operating at both low and high 
voltages. At the same time, it is still possible to be used in combination with the earlier 
mentioned spectroscopic techniques such as EDX and EELS. The true advantage of 
STEM originates however from the fact that this setup uses scientillators, rather than 
a CCD camera (as in TEM), to collect transmitted and scattered electrons. As a result, 
the image is constructed on a pixel-by-pixel basis (similarly to SEM), and is therefore 
capable of providing information about the inner structure of the samples at an 
extremely high resolution (even higher than that of TEM)335.  
In detail, if the electrons are scattered at a low angle, a standard fixed scientillator is 
used for collection (bright field, BF).  The BF-STEM signal relies on phase contrast, 
and hence the signal intensity is not directly proportional to either the thickness or the 
atomic number. Therefore, it is more suited for use when the contrast dependent on 
elemental composition is less relevant. This is typically the case for biological samples.   
When electrons are scattered at a higher angle, they are collected using a movable 
annular (ring shaped) scintillator (high angle annular dark field, HAADF). The signal 
in these images is not dependent on the phase contrast, but is rather directly 
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proportional to the atomic number. This allows for quantitative analysis, such as mass 
measurements, also shown to be possible in biological setting.  
3.3.4 EM preparation of biological samples 
As mentioned above, both TEM and STEM analysis require very thin samples. There 
exists a wide variety of sample preparation methods available, some of them are 
tailored to biological analysis, others to the analysis of materials334,336,337. The focus 
here lies on biological sample processing.   
Biological samples must be able to sustain high vacuum of the electron microscope. In 
order to do so they must be fixed and immobilized. Typically this is achieved through 
chemical fixation (described in detail below). Alternatively, given the recent 
developments of cryogenic (Cryo-) SEM and TEM, samples can be immobilized in the 
hydrated state by freezing. This approach offers tremendous advantages for the 
analysis of small molecules, such as proteins, where the native structure and 
conformation are of interest. Further, it offers the possibility to maintain the native 
localization of small molecules and ions in the specimen. However, the Cryo 
approaches are not very useful for large samples (beyond >500nm), such as tissue 
pieces. 
3.3.4.1 Fixation 
Tissue samples (and commonly also cells) are typically prepared through chemical 
fixation. This involves chemical stabilization/fixation of the sample, followed by 
dehydration, embedding in plastic resin and sectioning (typically on a scale of few 
100-200nm). Often this is also complemented with contrasting.  
The aim of chemical fixation is to protect the sample from any kind of damage that 
could occur during follow up dehydration and embedding. Two of the major 
commonly used groups of fixatives include aldehydes (paraformaldehyde (PFA) and 
glutaraldehyde (GA)), and oxidizing agents (osmium tetroxide (OsO4), and potassium 
permanganate (KMnO4)). These stabilize the tissue by cross-linking proteins. The 
fixatives are typically buffered and also include substrates such as electrolytes and 
non-electrolytes, or even dyes.  
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The idea behind fixatives is that they will preserve morphology and structure by 
preserving the cellular components. This is done by stabilizing the main 
macromolecules, particularly through cross-lining of proteins. Other macromolecules, 
such as carbohydrates, lipids or chromatin network (RNA, DNA) are typically less 
preserved. PFA is the smallest molecule, and also the fastest penetrating fixative, 
however its chemical reaction with the substrate is reversible. GA, on the other hand, 
is much slower, but its reactions with the substrate are irreversible and stabilization of 
the substrate is facilitated through cross-linking reactions with the amino groups. The 
OsO4 is the slowest of these fixatives. It is a heavy metal that denatures the proteins, 
by causing them to unfold. Unfolding exposes the interaction sites for osmium, and 
hence OsO4 acts as a contrasting agent. It is however not able to cross-link the majority 
of proteins, and is therefore used as a post-fixative.  
Optimization of chemical fixation is not easy as the process can introduce different 
artefacts. These can be distinguished from disease related processes by, the changes in 
size, shape, electron density or the location of the cellular components within the cell. 
Therefore, in order for the chemical fixatives to achieve their aim several aspects need 
to be considered. These include osmolality, pH and temperature.  
Given that cells have semipermeable membranes that discriminate between molecules 
and ions, the concentration of these outside and inside the cells can differ. Together 
they will exert osmotic pressure that might lead to either the swelling or the shrinkage 
of the cells. Therefore fixatives (and buffers they are dissolved in) need to be adjusted 
to compensate for this effect. This can be done with help of electrolyte salts (e.g. NaCl), 
or non-electrolyte molecules (e.g. sucrose). The osmolarity needed depends on the type 
of the tissue, as well as the fixation method (perfusion, immersion etc.). Generally, for 
tissue a total osmolarity of ca 700 mOsm is used, and effective of 300 mOsm is used.  
The pH of the fixative affects the nature of the proteins, their structure and 
conformation, and thereby the cellular morphology. The charge on the proteins reflects 
the content of the basic and acidic groups present. When the protein is at its isoelectric 
point, it is least soluble. While the isoelectric point of the majority of the proteins is 4-
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7, the pH of the cellular components is slightly higher at a range of 7-8. At a higher 
pH, the hydroxide ions react with positively charged groups on the protein, making it 
negatively charged. The pH of the fixative has to be close to the physiological pH of 
the cells or tissue, otherwise it will affect the structure and properties of the protein, 
thereby affecting its morphology. The pH of the fixative is generally adjusted 
depending on the tissue, cells and the target analysis, e.g. cytoplastic vs nuclear 
constituents. 
Temperature affects the majority of cellular processes that take place after death, e.g. 
speed of leakage of cellular components or rate of enzymatic degradation processes. 
These processes, which result in the deterioration of ultra-structures, proceed faster at 
higher temperatures. At the same time however there is a trade-off, the temperature 
also affects the speed of chemical reactions between the fixative and cellular 
constituents, and the speed of a fixative’s penetration. These processes advance more 
quickly at high temperatures. Optimally, the fixation should be carried out in as close 
to the physiological temperature of the specimen as possible. Depending on the 
fixative, what specimen is analysed, a combination of cold and long fixation, as well 
as the length of exposure to these, is typically determined. Commonly, quickly 
penetrating fixatives are used at room temperature for a short period of time (e.g. PFA), 
whereas slowly penetrating fixatives are used over a long period of time at low 
temperatures, 4°C.  (e.g. OsO4).  
As mentioned above, fixatives are prepared in buffers. These ensure that no 
acidification of cellular components takes place in the specimen. The majority of the 
buffers used are most effective in the physiological range (pH 7.2-7.4). Hence, 
dimethylarsinic acid sodium salt trihydrate, known as the sodium cacodylate, is most 
commonly used. While toxic, this buffer offers great buffering capacity (pH 5-7.4), 
can be stored for long periods of time, typically does not form precipitates, and can be 
spiked with divalent ions (such as Ca2+ or Mn2+) in order to adjust osmolarity, and is 
compatible with PFA, GA, and OsO4.  
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A common, non-toxic alternative is the phosphate buffer, either Millonig’s, or 
Sörensen. While these mimic the extracellular fluids, they are hypotonic (low osmotic 
pressure), and therefore need to be supplemented with sodium chloride. Further, during 
fixation they can form precipitates, in particular in the presence of calcium ions, or 
uranyl acetate (UA) during en bloc staining (described below). Few other buffers 
include veronal-acetate buffer (useful for UA en bloc staining, but reactive with 
aldehydes), toxic collidine buffer (useful for post-fixation with OsO4, but works 
poorly with PFA, and with GA), and Tris buffer (has great buffering capacity at higher 
pH, which is sometimes needed, but contains primary amines that react with GA).  
3.3.4.2 Dehydration 
Dehydration is a crucial step before the specimen enters the vacuum of the electron 
microscope. It is also important since the majority of the embedding media that are 
used for further processing are non-polar, and hence not soluble in water. The 
dehydration process does however destabilize the interactions of the non-polar chains 
on the inside of the protein, which makes it unfold and more likely to be extracted. In 
general, it is responsible for significant tissue shrinkage and a loss of proteins, lipids 
and carbohydrates. Therefore, it should be carried out at low temperatures (ca 4°C), 
and be performed quickly. A prior fixation (as described above) is also crucial for 
proper tissue preservation due to this reason. At the same time, however, the specimen 
needs to be rinsed in buffer between fixation and dehydration steps. This is done 
because the fixative and the dehydrating agents might interact with one another. This 
should also be done at a low temperature (ca 4°C), with a few quick rinses, to minimize 
protein denaturation.  
Dehydration is carried out is several steps. Here the specimen is subjected to serial 
rinsing in increasing concentration of solvent(s) that gradually remove the water. These 
can be ethanol, methanol, or acetone. While an increasing gradient of ethanol is very 
effective to remove water, ethanol is not optimal to dissolve the embedding media. 
Therefore, following the rinses with an increasing gradient of ethanol, specimens are 
often rinsed in absolute acetone (water free). Not only is it compatible with the 
majority of embedding media, it also causes less shrinkage of the specimen, and retains 
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more macromolecules, such as phospholipids. An alternative to acetone that is often 
used is 1,2-epoxy propane (propylene oxide). It is very efficient at dissolving many of 
the embedding media, however it is also very reactive and can interact directly with 
cell constituents, or even the embedding media itself, preventing its polymerization. 
Therefore, acetone is often recommended as the intermediate between dehydration and 
embedding. 
3.3.4.3 Embedding 
Embedding of the specimen is done in an embedding media, known as resin. The aim 
of using a resin for embedding is to stabilize the specimen and help to preserve fine 
structure (by further cross-linking). This means that the resin should induce as little 
changes in the specimen as possible during the embedding, while providing it with 
stability both for sectioning but also exposure to electron beam. Resins are typically 
described in terms of their polarity, viscosity, and hardness. Polar resins are compatible 
with water, and often can be used for embedding without prior fixation. Less viscous 
resins (before polymerization) penetrate the specimen quicker. The resin’s hardness 
will affect how easy it will be to section the specimen.  
There are a wide variety of resins available, and their use depends on the purpose of 
the study. However, the majority of the resins belong to either epoxy or acrylic resins. 
These are typically prepared by mixing the resin itself with a plasticizer, hardener and 
an accelerator, which modify the properties of the resin during the infiltration, 
polymerization, sectioning and analysis.  All of the resins are strong irritants  
Infiltration with the resin is typically done in several steps, where ratio of the 
intermediate solvent to resin is gradually decreased, and is finished off with a few 
exchanges of pure resin.  Following the infiltration, resins are polymerized (cured) 
with the help of either heat (at around 60°C) or UV light in small capsules (these aid 
in further sectioning). In some cases, resin can also be polymerized at low temperatures 
(-40°C to -80°C) with the help of UV and accelerator (e.g. Lowicryl resin). This is 
typically done through freeze substitution, where a frozen thin specimen is processed 
at negative temperatures until fully embedded in resin. Though expensive, this 
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approach offers the possibility to obtain samples of extremely high morphological 
preservation (often not needed).        
Among epoxy resins, Epon- and Araldite resins are the most commonly used 338-340. 
These resins are well suited for high resolution EM analysis.  Further, Spurr’s resin is 
compatible with ethanol and has very low viscosity. Therefore, it can be used for quick 
preparation of the sample339,341, but it is highly carcinogenic. Among acrylic resins, LR 
White and LR Gold have the advantage of being hydrophilic, having low viscosity and 
being suitable for cold polymerization342,343. Another acrylic resin, Lowicryl, can be 
either hydrophilic or hydrophobic, and polymerizes at low temperatures339,344.  
In general, the hydrophilic acrylic resins, such are LR White and LR Gold are well 
suited for follow-up immunolabelling, without the need for special treatment of the 
tissue that could affect the antigens339,345. However, staining of highly cross-linked and 
very stable epoxy resin is also possible, but requires sample pre-treatment346,347.  
3.3.4.4 Sectioning 
Following embedding the capsules with the specimen are sectioned. This is done on 
an ultramicrotome. Here the capsules/blocks are typically first trimmed using a glass 
knife. The glass knives are not very durable, but are cheap. They are useful for 
obtaining 1-4μm thick sections, which can be used for finding regions of interest in the 
specimen. The edges of the specimen block can then be trimmed and a diamond knife 
can be used to cut very thin (several tens of nm, generally 80-150nm) sections. 
Diamond knives are very expensive and can easily be damaged; therefore they should 
only be used for cutting sections up to 500nm in thickness. Generally, while trimming 
with the glass knife can be performed at a fairly high speed, cutting with the diamond 
knife should be done much more slowly.  
Once cut, the ultra-thin sections are typically mounted on grids. These are usually 
made of copper or nickel, however gold grids are also available. These are typically 
3.05 mm in diameter. The number of bars present in the grid, per inch of the grid, is 
referred to as mesh. A smaller number means fewer squares (but often thicker 
individual bars), and hence a larger percent of the area is open. However, this implies 
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that the grid provides less support for the sample. Generally, the number of mesh in 
the grid ranges from 50-1000 mesh. In order to provide extra support, grids can be 
coated with new nanometre thick layers of, for example, carbon or plastic (formvar) or 
even both. While these support films improve sample stability, they might negatively 
affect the final resolution, cause charging or even interact with contrasting agents if 
such are used.  
3.3.4.5 Staining 
Generally, biological sections have poor contrast (although osmium tetroxide often 
used as post-fixative is a heavy metal and does provide some contrast)348,349. Therefore, 
they are often stained/contrasted. This can be done during the chemical preparation 
(after dehydration but prior to infiltration), referred to as en bloc contrasting, or after 
sectioning (by floating the grids with the sections upside-down in the contrasting 
agent). Staining of the samples after embedding however is generally not the easiest. 
This is due to the fact that the commonly used embedding media (e.g. Epon och 
Araldite) are non-polar, while the stains are most often polar. Further, in ideal case, 
contrasting should be specific to certain components in the specimen. It is however 
generally not the case and the commonly used staining solutions contrast several 
different components of the specimen at the same time. Therefore, staining recipes and 
protocols are often adjusted based on the type of specimen and its processing.  
Contrasting is categorized into negative staining (where the background is stained) and 
positive staining (where the actual specimen is stained). The interaction of the stain 
with the specimen depends on several different factors. In particular, the pH of the 
stain and sample, and to some extent the isoelectric point of the proteins, will 
significantly influence the staining. These are in turn affected by the fixation and 
buffers used. Further, even the support film (if used) might modify the way the stain 
interacts with the sample.  
In general, if the pH of the stain is higher than the isoelectric point of the protein, this 
will result in an overall negative charge on the protein, making it more prone to interact 
with cations in the stain. If the stain pH is lower, the opposite will be the case. The pH 
  57 
of the stain also has a broad effect on the overall staining efficiency. Generally, at low 
pH, the staining agent will interact with the acidic environment on the surface making 
the surface detail well pronounced. On the other hand, at a high pH the staining agent 
will penetrate better. Taken together, the same stain at different pH values might 
actually stain different cellular constituents.  
Two of the typically used stains have either lead or uranium as their contrasting 
agents350,351. Both of these stains come in different solutions, and therefore have 
different pH values. Lead is always alkaline, and is used for instance as lead acetate, 
lead hydroxide, or lead citrate (in increasing pH order). The higher the pH, the higher 
the binding capacity of the Pb2+ ion. It interacts for instance with –SH groups of 
proteins, -OH groups of carbohydrates, forms complexes with nucleotides and nucleic 
acids, and results in strong staining of extracellular membranes.   
Uranyl, the oxycation of Uranium, is mostly available as an acetate or a nitrate. It is 
acidic and the acetate salt of uranyl (UA) is widely used for negative staining. In fact, 
the solution typically contains both positively and negatively charged ions, which can 
interact with not only positive but also negative side-chains of a protein, providing 
stark contrast. UA can be used for both staining of cut sections but also for en bloc 
staining. En bloc staining with UA might however enhance the extraction of the 
membranes during dehydration. UA has a high affinity for phosphate groups in 
phospholipids, and even more so for the nucleic acid. Often, lead citrate and uranyl 
acetate are used together for tissue staining in order to enhance contrast (lead interacts 
with uranyl). In such case, however, uranyl acetate has to be used first, and the 
specimen needs to be thoroughly rinsed with an alkaline solution before and after lead 
citrate staining. Otherwise, lead precipitation at low pH will result in artefacts.  
In addition to the more general contrast staining agents used in electron microscopy, 
more targeted approaches have also been developed. One of these is immunogold 
labelling352. Here, following the sectioning, the specimen is incubated with gold-
nanoparticle conjugated antibodies. The electron dense gold-nanoparticle appear as 
dark spots at the regions of antibody binding. While useful, this approach is suitable 
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primarily with polar resins, such as LR White. Unfortunately, it suffers penetrability 
and specificity issues, associated with extensive tissue fixation, dehydration and 
embedding.  
Another approach is a 3,3′-diaminobenzidine (DAB) photooxidation-guided 
analysis353. Here, selective fluorescence labelling of a particular tissue structure prior 
to chemical fixation is combined with photo-oxidation of osmiophylic DAB. The 
precipitated DAB is prone to interact with OsO4 during fixation, resulting in localized 
electron dense features. This approach has been recently expanded to facilitate 
“multicolor EM” analysis, through the use of electron energy-loss spectroscopy 
(EELS) (mentioned above)354. The authors generated DAB-Metal Chelate Conjugates 
that contain different lanthanides (Ln). Through subsequent fluorescent stainings, and 
photooxidation of DAB-Ln conjugates, the metals are deposited at the selected 
location. The conventional TEM analysis can then be complemented with an EELS 
analysis of these rare metals. This enables visualization of specific cellular constituents 
at the electron microscopy resolution. 
3.4 Mass spectrometry  
Mass spectrometry (MS) is a powerful analytical technique that has become a valuable 
tool in bioscientific research. MS analysis offers the possibility to determine the 
molecular mass of a variety of compounds, including among others, metabolites, 
lipids, peptides, intact proteins, and even protein complexes355. An MS instrument 
consists of 3 major parts: a source, an analyser and a detector. In the source, the 
analytes are ionized (gaining either a positive or negative charge), and transferred into 
the gas-phase. Generated ions are then separated according to their mass-to-charge 
ratio (expressed as m/z value) in the mass analyser. Finally, they are measured when 
they reach the detector. Given that the ions are very reactive species, mass analysis 
operation requires a very low pressure.  
The expression m/z that is commonly used in mass spectrometry is considered a 
dimensionless quantity that corresponds to the mass of an ion (in unified atomic mass 
units (u)), divided by the charge of that ion (regardless of its polarity). This can be 
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confusing as neither mass nor charge are dimensionless. The z value however, which 
represents the number of charges, is indeed dimensionless. In MS, the unified atomic 
mass unit will most often not be written as “u”, but rather as Dalton (Da). Therefore, 
when the mass of the parent neutral molecule detected in an MS experiment is 
calculated from the m/z value, it will be expressed simply in Da units.  
For a spectral peak in MS to be considered an actual signal, it is should preferably be 
Gaussian shaped, and consists of at least 3 sampling points. That being said, a greater 
number of sampling points is desired. Further, these peaks should be at least 3 times 
the size of standard deviation of the background noise (referred to as signal-to-noise 
(S/N) ratio). This is also considered the general detection limit in MS.  
When working with MS, there are often discrepancies between the measured mass and 
the actual theoretical mass of an analyte. This deviation is referred to as mass accuracy. 
Mass accuracy is represented in terms of mass error. This is calculated as the difference 
between the monoisotopic mass of the theoretical exact mass, and the measured 
accurate mass (equation 1). By convention, it is however often expressed as mass error 
in parts per million (ppm) (equation 2).  
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 = (𝐸𝐸𝐸𝐸𝑀𝑀𝐸𝐸𝐸𝐸 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀) − (𝑀𝑀𝑒𝑒𝑀𝑀𝑀𝑀𝑀𝑀𝐸𝐸𝑒𝑒𝑀𝑀 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀) (I) 
 𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 (𝑝𝑝𝑝𝑝𝑚𝑚) = �(𝑃𝑃𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑀𝑀𝐸𝐸𝑀𝑀𝑀𝑀)−(𝑀𝑀𝑚𝑚𝐸𝐸𝑀𝑀𝑀𝑀𝑀𝑀𝑚𝑚𝑀𝑀 𝑀𝑀𝐸𝐸𝑀𝑀𝑀𝑀)(𝑃𝑃𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑀𝑀𝐸𝐸𝑀𝑀𝑀𝑀) � 106 (II) 
Often, one mass spectrometry approach cannot handle all the demands posed by the 
problem. Therefore, one often needs to prioritize the parameters of an analysis based 
on the target. Sometimes, it is also useful to combine several different techniques. This 
allows for the utilization of technique-specific advantages for confident and sensitive 
identification of target analytes in complex settings. 
3.4.1 Ionization techniques and mass analysers   
In order to perform an analysis of analytes by mass spectrometry these need to be 
introduced into the gas-phase and ionized. Sometimes, the analytes are already in the 
gas-phase and require only ionization. Oftentimes, however, samples are introduced as 
  60 
either solids or liquids and therefore need to be volatilized either prior to or during the 
ionization process.   
There exists a variety of ionization techniques. Depending on the analytes of interest, 
different ionization approaches need to be chosen (for volatile/non-volatile and 
atomic/molecular ions etc). Here, one typically refers to either “soft” or “hard” 
ionization techniques. Soft ion sources produce intact ions of large molecules, e.g. 
intact proteins. Hard ion sources yield fragmented molecules. The “softness” and 
“hardness” of an ionization approach can vary ranging from enabling characterization 
of weak molecular interactions in clusters formed by aggregation, to isotopic ratio 
measurements by atomizing the analyte. There are a large number of methods for ion 
generation, and new ion sources are constantly being developed. These are then 
coupled to a variety of different mass analysers and, later, detectors, to make the highly 
complex mass spectrometer suitable for different purposes.  
When it comes to intact peptide and protein analysis, two techniques are commonly 
used: the soft ionization techniques are electrospray ionization (ESI) and matrix-
assisted laser desorption/ionization (MALDI). These approaches have also been 
extended to apply in form of imaging mass spectrometry (IMS). Another, technique 
used in the context of imaging MS is the secondary ion mass spectrometry (SIMS). 
MALDI and SIMS are discussed in detail below. 
Mass analysers are used to separate ions according to their mass-to-charge ratio 
(expressed as m/z value). There are multiple different mass analysers used at MS 
instruments (and often their combinations). These include low-resolution analysers 
such as quadruples and iontraps, medium resolution time-of-flight (TOF) analysers and 
high-resolution magnetic sector, orbitrap, or fourier transform ion cyclotron resonance 
(FTICR) analysers. The use of different analysers often represents a trade of between 
their cost, and size, speed of operation and mass range suitable for analysis, and ability 
to separate, two closely spaced in mass, analytes (mass resolution). 
The measure of the smallest difference in mass between two spectral peaks that can be 
separated by a mass analyser is referred to as mass resolution. In this context, the mass 
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resolving power is a term used as an indicator of performance of an instrument. The 
mass resolution, or mass resolving power, are reported using a dimensionless ratio 
m/Δm. There are more than one ways to establish the Δm and thereby the ratio. A 
commonly used peak width definition, is based on the full width at half-maximum 
(FWHM) measurement. Here the peak width, Δm, of a given m/z is measured at 50% 
of the peak height. This value is easy to obtain; however, it does not directly address 
the peak separating capability. Mass analyser common for MALDI and SIMS are 
discussed below.  
3.4.1.1 Matrix-assisted laser desorption/ionization MS (MALDI-MS) 
Matrix-Assisted Laser Desorption/Ionization (MALDI) is a special case of laser 
desorption/ionization (LDI), where a chemical compound (matrix) is used to assist 
sample ionization and desorption. Here, two related approaches were independently 
introduced in 1988. One was created by Karas and Hillenkamp (organic matrix), and 
the other by Tanaka et al (inorganic matrix)356,357.Since its development, MALDI 
revolutionized the biological research by allowing the detection of analytes in complex 
mixtures that contain large amount of salts. MALDI has been demonstrated to be 
suitable for analysis of not only non-volatile, but thermally labile compounds without 
the need for derivatization. This even includes proteins and peptides with 
posttranslational modifications (PTMs).  Further, it has been shown to be suitable to 
produce gas-phase ions of intact, high molecular weight molecules, even up to few 
hundred kDa.  
The idea behind matrix assisted LDI is that the sample is prepared with an excess of 
matrix-to-analyte ratio. Upon irradiation laser energy delivered to the surface, rather 
than directly impacting the analyte (like in LDI), is dispersed as vibrational energy 
across the matrix molecules. Consequently, this affects binding forces and the integrity 
of the co-crystalized matrix and analyte molecules. Their reduction results in an 
explosive breakup, with the matrix and the analytes (previously trapped in the crystals) 
being ejected. These can be either neutral or charged. As the ejected matrix and analyte 
might interact with one another in the ion source, the source is typically operated at a 
high vacuum (ca 10-6 torr).   
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In MALDI (just like in LDI) the sample is irradiated with short and intense laser pulses 
(typically in nanosecond range). In general, two types of lasers are used for this 
purpose, either the IR or the UV wavelength range lasers. While the IR lasers have 
several advantages, the UV lasers are most commonly used.  
There is a wide variety of sample preparation methods available for MALDI that have 
been used. Commonly solid matrix-analyte based deposition approaches are used 
(some described in more detail below). In addition, the use of liquid matrices has also 
been demonstrated358. While less common, the liquid matrices offer the possibility to 
obtain a very even distribution of the analyte-matrix mix.  
One of the most common methods (and simplest) used for MALDI sample preparation 
of the solid matrix- analyte mixes is the dry-droplet method359. It involves mixing the 
matrix with the analyte and then depositing the combined solution at the target surface. 
When on target, the droplet starts to crystalize due to evaporation. Here the 
crystallization process is initiated at the surface of the droplet where it is in contact 
with air. From there, the crystallization progresses throughout the sample by 
convective heat transfer. This method, while easy to perform, results in the formation 
of a highly inhomogeneous surface, where larger crystals are typically formed at the 
edges of the dried droplet, and the crystal size and numbers varies greatly, both within 
and between preparations. Of course, this process is dependent on the type and amount 
of solvents and matrix used. Overall, the dry-droplet method does however suffer from 
poor spectra quality and mass accuracy. Worth mentioning is a modification of this 
method, namely the vacuum drying method. Here, instead of free evaporation, the drop 
is instead rapidly dried under a vacuum360. This has been shown to yield a better mass 
accuracy and resolution, which has been attributed to a decrease in the size of 
individual crystals and an increase in overall crystal homogeneity.  
In order to further improve the signal strength and quality, several multi-layer 
approaches have been developed. Here a common technique is the seed-layer method 
which involves pre-deposition of a matrix layer (with the matrix being dissolved in a 
highly volatile solvent, e.g. acetone), prior to standard dry-droplet deposition of the 
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analyte-matrix mix361. Similarly, in the crushed-crystal approach, twisting a flat glass 
object on top first crushes the “seed”. The loose material is then brushed away before 
the dry-droplet deposition is performed362. The crushed crystals function as the seed 
and shift the crystallization process away from the top liquid-air interface towards the 
bottom and the pre-formed microcrystals. Both approaches yield a more uniform 
analyte surface, facilitate ion formation, and result in improved mass accuracy and 
resolution. Finally, derived from the vacuum drying and seed-layer method, comes the 
sandwich method where the matrix, then analyte, and then the matrix again, are 
deposited separately363.  
Finally, worthy of mention are the electrospray and the airbrush methods. In an 
electrospray, the matrix or the matrix-analyte mixture are ejected from a stainless-steel 
capillary onto a grounded target plate by applying a high voltage potential364. The 
airbrush, which is considered a simpler and cheaper version of the electrospray, uses a 
compressed airbrush to spray the solution onto the target plate365. Both have shown 
excellent reproducibility and superior crystal homogeneity. Airbrush is commonly 
used in sample preparation for MALDI based imaging mass spectrometry (IMS, 
discussed below).  
MALDI matrix compounds should be able to facilitate ionization of the analytes they 
surround without excessive heating (analytes are often thermally labile). They should 
reproducibly provide maximum possible ion intensity, while minimizing analyte 
fragmentation, and adduct formation (which reduces sensitivity and accuracy). Most 
importantly, due to obvious reasons, MALDI matrices themselves should not produce 
ions of the same m/z value as the analytes of interests.  
For their optimal performance, matrix molecules have to incorporate the analyte 
molecules into the lattice structure during the crystallization. In order to do so, they 
have to reduce the intermolecular forces between the analyte molecules to prevent their 
precipitation and/or aggregation. Therefore, matrix compounds and analyte have to be 
soluble in the same solvent. At the same time, they should not react with the analyte, 
as this might result in undesirable modifications. Further, they must also be relatively 
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vacuum stable, as majority of the instruments used (UV-MALDI) are operated at high 
vacuum.  
There is a wide variety of matrix compounds available. The UV-MALDI matrixes are 
typically low molecular weight organic aromatic compounds (in IR-MALDI H2O ice 
or glycerol are often used). Different matrices (and their derivatives) are more or less 
suitable for the analysis of various analytes. Typically, they are small molecules that 
yield high background/interference (overlapping m/z values), up to 500Da. Several of 
the common matrices, and their use is provided below (Table 1). The ionization 
processes are not well understood; therefore, most often the choice of the matrix, and 
optimization of the solvent system is based on an educated trial-and-error approach. 
The key characteristic of MALDI matrices is their high molar absorptivity at a certain 
laser wavelength that allows for their easy transfer into the gas-phase. Given that the 
majority of the instruments have a fixed wavelength laser, matrices might more or less 
efficiently absorb the laser light and may require an adjustment in the laser fluence. 
This will in turn affect the mass resolving power, as higher velocity ions will be 
generated (this is particularly true in axial TOF mass analyser, for detail see below).  
Different matrices form different lattice structures during the crystallization process. 
In fact, the resulting crystals are dependent on the nature of the matrix-analyte 
combination, their concentration (absolute and relative), solvent used, as well as 
additives and/or contaminations (such as salts - can cause adduct formation and/or peak 
broadening). Indeed, modifying the matrix/solvent system has been shown to yield 
different relative intensities of various analyte components. Therefore, when 
optimizing the use of certain MALDI matrix one needs to consider these factors in 
order to achieve the best possible result. This is particularly the case when performing 
MALDI Imaging MS analysis where the spatial aspect is important (described in more 
detail below).  
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7DEOH &RPPRQ0$/',PDWULFHVDQGWKHLUXVH 
MALDI generates primarily singly and doubly charged positive and negative ions. 
+RZHYHU WKH LRQL]DWLRQ SURFHVV WUDQVIHU RI FKDUJH EHWZHHQ PDWUL[ DQG DQDO\WH
which is believed to take place following the generation of the plasma cloud by the 
laser, is generally considered to be highly inefficient. Recently, MALDI-2, an 
approach relying on secondary, laser induced ionization has been developed to 
improve the ion generation 366-368. 
The charge on the ions generated through MALDI (+/-1, +/-2), also imposes 
limitations when it comes to which mass analysers can be used. As mentioned above, 
DQD[LDO72)PDVVDQDO\VHULVW\SLFDOO\XVHG7KLVEHFDXVHWKHLRQVDUHJHQHUDWHGLQ
VKRUW EXUVWV IROORZLQJ WKH ODVHU SXOVHV +RZHYHU Fourier-transform ion cyclotron 
resonance (FTICR) instruments are the go-to standard when it comes to high resolution 
analysis. The FTICR instruments do however suffer from mass to charge range 
limitation (suitable for smaller molecules, but not proteins). Since the introduction of 
atmospheric pressure MALDI (AP-MALDI), where the ejected ions enter the vacuum 
through an orifice, other analysers, such as e.g. Orbitraps, have been used369.  
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3.4.1.2 Secondary ion mass spectrometry (SIMS) 
Secondary ion mass spectrometry (SIMS) is an ionization technique that relies on the 
use of an ion beam (primary ions) for the desorption of molecules (secondary ions) 
from a given surface355. Typically, SIMS does not require any prior sample 
preparation. This with the exception of Nano-resolution SIMS (NanoSIMS, described 
below), and matrix-enhanced SIMS370-373. The applications of SIMS in a biological 
setting are much more limited than those of MALDI, or ESI, due to the high degree of 
molecular fragmentation induced by the primary ion beam (limited m/z range). In 
recent years, a growing number of imaging mass spectrometry (IMS) studies of 
biological samples have taken place. Here the profiling of lipids by TOF-SIMS, or 
isotopic distribution by NanoSIMS is most common. This profiling became possible 
mainly due to the development of new primary ion sources. 
Upon interaction of the primary ions with the surface of the sample, the energy of the 
primary ions is transferred to the analysed material through a collision cascade, 
resulting in ions being sputtered away. The process of secondary ion generation is 
described in the SIMS equation (equation I). 
𝐼𝐼𝑚𝑚 = 𝐼𝐼𝑝𝑝𝑌𝑌𝑚𝑚𝛼𝛼𝜃𝜃𝑚𝑚𝜂𝜂 (I)  
Here, the secondary ion current of a species m (Im), depends on the primary ion flux 
(Ip), the sputter yield (Ym), the ionization probability (α), the concentration of the 
species m in the surface layer (θm), and the transmission of the analysis instrument 
(η)374.  
Given that the SIMS is typically operated on the order of several tens of keV, the 
majority of the molecular bonds (e.g. covalent, ionic etc.) in proximity of the impacted 
area are broken, resulting in extensive molecular fragmentation (with mainly atomic 
secondary ions being generated). The further from the impact area, the lesser the 
molecular fragmentation, and the higher chance that an intact molecular species will 
be detected. Overall, the process of secondary ion generation can therefore be 
considered rather destructive in nature. However, as the degree of surface damage 
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depends on the ion dose of the primary beam, SIMS can be categorized into static and 
dynamic SIMS.  
For an analysis to be considered static, the instrument needs to be operated below the 
“static limit”, that is where the primary ion is below approximately 1013 ions/cm2 (the 
estimated 1% of surface atoms). Such analysis is considered “soft”, leaving the area 
generally unaffected, and yielding minimal molecular fragmentation. Unfortunately, 
this mode of operation is not very sensitive (less sample desorbed). When the primary 
ion dose exceeds the “static limit”, that is when the number of primary beam ions 
exceeds that of the surface atoms, and the analysis is referred to as dynamic SIMS. 
Dynamic SIMS results in both erosion of the sample, and high fragmentation of 
molecules.  
SIMS analysis initially relied on the use of monatomic primary ion sources (e.g. 
gallium ions, Ga+). These ions, however, penetrated deeply below the surface, causing 
extensive fragmentation, and resulting in low secondary ion yield. Recently, the 
monoatomic ion probes have been complemented by cluster ion sources (e.g. Bismuth, 
Bin, Argon, Arn). These have been shown to induce a much lesser degree of 
fragmentation (and hence be much more suitable for the analysis of organic 
biomolecules), while also improving the yield of secondary ions. The introduction of 
these polyatomic cluster ion sources have also enabled the so called “depth profiling” 
(that is dynamic SIMS analysis) of biological samples, thanks to their lesser 
penetration depth upon impact. Lesser penetration, implies lesser degree of interlayer 
mixing, and lesser damage of the “deeper” atomic layers. In practice, this implies that 
the data is obtained as a function of depth, rather than a representative of the 
characteristic of the surface. This is of particular importance for 3-dimensional (3D) 
analysis in the context of SIMS based IMS.  
The nature of the primary ion beam used in a SIMS analysis, that is for instance, size 
(mono-/poly-atomic, atomic number), charge, and current, result in a trade-off between 
resolution, sensitivity, and molecular fragmentation. The higher the energy of the 
primary electron beam, the more it can be focused. This concept is of particular 
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importance in IMS setting. At the same time, higher energy causes a higher degree of 
fragmentation. Here, in static SIMS, molecular ions above 300Da are often 
fragmented, while the dynamic SIMS produces primarily atomic secondary ions. As a 
result, SIMS has a relatively low mass range limitation (approximately m/z 1000-
1500).   
Most often in the biological context, the SIMS is equipped with a pulsed ion source. 
Use of a pulsed ion offers several advantages, in particular when performing IMS. 
Most importantly, it allows for an effective compensation of surface charging 
(prominent in biological samples). This can be done by employing a low-energy 
electron gun (still, this can cause additional surface damage). Furthermore, instead of 
an electron gun, a second, interlaced ion gun can be employed to etch away the 
damaged surface. Here, a high sputtering rate, low penetration gun causing low 
damage (e.g. fullerene, C60+) can be used. This can be particularly helpful for depth 
profiling (e.g. when performing IMS) in static SIMS mode. 
The use of pulsed ion source also impacts the mass resolution and, in the context of 
IMS, the spatial resolution. In general, higher mass resolution is obtained with 
shortened ion beam impulses (e.g. in bunched mode with narrow, hundreds of 
picosecond long impulses). The result is a smaller spread in the energy distribution of 
the ions (especially important with TOF mass analyser, described below). However, 
this small distribution will negatively affect the spatial resolution, as the primary ion 
beam cannot be focused to the same extent. Hence, operating in non-bunched mode, 
with tens of nanoseconds impulses is better for spatial resolution (sub-micrometre).  
The phenomenon of secondary ion generation greatly depends on the inner 
environment of the analysed material (both the chemical and electric). Therefore, it is 
important to consider these when designing an analysis. In the context of biological 
samples, aspects such charge compensation are important. Further, to correlate the 
concentration of an analyte with the intensity of the secondary ions generated, it’s 
important to keep the ionization efficiency and extraction constant across the samples 
(important in IMS, and particularly in NanoSIMS). To facilitate this, SIMS 
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instruments are operated at ultrahigh vacuum. Working in ultrahigh vacuum conditions 
also helps preserve the morphology of the sample and analytes. 
3.4.1.3 Time of flight (TOF) 
First introduced by Stephens in 1946, the time-of-flight (TOF or ToF) mass analyser 
determines mass (m) to charge (z) values of analytes based on the flight time between 
the initial ionization event (e.g. laser pulse in case of MALDI, or primary ion beam 
pulses in SIMS) and the generation of an electric pulse when they hit a detector375.  
Here, following the ionization, all ions with the same charge are accelerated towards 
the TOF mass analyser by applying an electrostatic extraction potential (either positive 
or negative, U) between the sample (referred commonly to as target) plate and the 
ground potential at the mass spectrometer inlet. When leaving the acceleration region 
of the applied electric field, the electric potential energy (EPE) of the analyses (equation 
I) is converted into kinetic energy (EKE) (equation II). This conversion allows for 
correlation of the mass-to-charge (m/z; where z is charge on the ion in electrostatic 
units +/-1e) to the velocity (v) of the ions (equation III).  
𝐸𝐸𝑃𝑃𝑃𝑃 = 𝑧𝑧𝑧𝑧  (I)  
𝐸𝐸𝐾𝐾𝑃𝑃 = 12𝑚𝑚𝑚𝑚2  (II)  
𝑚𝑚
𝑧𝑧
= 2𝑈𝑈
𝑣𝑣2
  (III)  
Given that the ions are passing through a fixed length field-free tube (l), and the 
electrostatic extraction energy (U) is kept constant, a quadratic relation of time of flight 
(t) with m/z can be established (equation IV).   
𝑚𝑚
𝑧𝑧
= 2𝑈𝑈
𝑙𝑙2
𝐸𝐸2  (IV)  
𝑚𝑚
𝑧𝑧
∝  𝐸𝐸2  (V)  
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Therefore, given the direct proportional of mass-to-charge ratio to the square of time-
of-flight (equation V), the smaller the mass-to-charge ratio of the ion, the faster the 
ions will arrive at the detector. In principle, this operational setup allows for the 
analysis of all ions that are fed into the MS instrument in a single experimental cycle.   
Ideally, all ions of the same m/z value would leave the electrostatic extraction potential 
region at the same time. For this to be possible, ions should be extracted in a pulsed, 
rather than continuous matter. Here, both MALDI, and most often also SIMS, are 
pulsed sources and hence highly suitable sources for use with a TOF. This is in contrast 
to continuous sources, such as electrospray ionization (ESI).  
MALDI-TOF (and SIMS) instruments, are typically set up in an axial configuration 
that allows ions to be directly accelerated into the TOF mass analyser, making them 
highly sensitive. An orthogonal set up of the TOF mass analyser, on the other hand, 
allows overcome the limitation of the continuous nature of a source, such as ESI. Here, 
trapping continuously generated ions and splitting them into small packages before 
sending them into the orthogonally set up TOF tube can be performed. Such orthogonal 
set up does however sacrifice sensitivity and speed of analysis. On the other hand, it 
provides higher resolution of the spectra by compensating for any spread of energy in 
the extracted ions.   
In general, pulsed ion sources, such as MALDI, generate ions with a rather 
inhomogeneous energy profile due to the uneven spatial distribution and initial 
velocity of the analyte ions. This impacts both the inner energy and the kinetic energy 
of the generated ions, right at the moment of desorption. In order to compensate for 
this, two approaches have been developed: one is the delayed extraction (also known 
as time-lag focusing) and the other is the use of electrostatic ion reflectors (also known 
as mirrors). 
The delayed extraction was introduced in 1955 by Wiley and McLaren, and is 
nowadays commonly used in MALDI-TOF instruments 376. Here, the single-stage 
acceleration region was replaced by two-stage region. First, no electric field is applied 
at the time of desorption, but is instead switched on with a few nanoseconds delay. In 
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practice, this implies that before the acceleration voltage is switched on, ions of lower 
energy will travel less far towards the mass analyser inlet, than those of high energy. 
As a result, the slower ions of lower initial energy end up at a higher potential, and 
thereby are more accelerated than those of higher initial energy. When properly set up, 
WKHGHOD\HGH[WUDFWLRQFDQFRPSHQVDWHIRUWKHLQLWLDOHQHUJ\GLVFULPLQDWLRQEHWZHHQ
the same m/z ions that originates from both the velocity spread and spatial dispersion. 
This seWXS UHVXOWV LQ KLJKHU PDVV UHVROXWLRQ 7KH GHOD\ H[WUDFWLRQ WLPH LV PDVV
dependent and hence the optimum settings will vary with the mass range of interest.    
)LJXUH 6FKHPDWLFYLHZRI0$/',72)06LQVWUXPHQWLQFOXGLQJWKHFRPSRQHQWIRU
/,)7-0606)ROORZLQJGHVRUSWLRQLRQVDUHDFFHOHUDWHGDFFHOHUDWLRQUHJLRQDQG
HQWHUWKHIOLJKWWXEHGULIWUHJLRQZKHUHWKH\DUHVHSDUDWHGEDVHGRQWKHLUP]YDOXHV
:KHQRSHUDWHGLQWKHQRUPDOPRGH WKHy FDQEHHLWKHUGHWHFWHGXVLQJOLQHDUGHWHFWRU
RU UHIOHFWHG DQG GHWHFWHG XVLQJ WKH UHIOHFWRU GHWHFWRU :KHQ SHUIRUPLQJ 0606
DQDO\VLVSRVWVRXUFHGHFD\36'LQGXFHGIUDJPHQWDWLRQLVXVHG+HUH a SUHFXUVRU
LRQVHOHFWRU3&,6LVXVHGWRVHOHFWSUHFXUVRUPRWKHULRQVDQGWKHLUIUDJPHQWV$OOWKH
IUDJPHQWLRQVDUHWKDQUHDFFHOHUDWHGLQWKH/,)7FHOO7KHSUHFXUVRULRQVVWLOOKLJKO\
DEXQGDQW DUH WKDQ GHIOHFWHG WKURXJK WKH SRVW /,)7 PHWDVWDEOH LRQ VXSSUHVVLRQ
3/06)LJXUHPRGLILHGIURP%UXNHU'DOWRQLFV8OWUDIOH[,,0DQXDO 
The use of reflector in addition to the classical linear TOF setting was first introduced 
in 1973 by Mamyrin et al 377+HUHDUHIOHFWRUPDGHXSRIDVHWRIHOHFWURGHVRIYDULDEOH
electric potential, opposite to that of acceleration potential. is utilized. Ions with the 
same m/z, but different EKE penetrate iQWRWKHUHIOHFWRUWRDYDU\LQJGHJUHH+LJKHU(KE 
ions, penetrate deeper, and thereby have an increased flight path, compared to ions of 
lower EKE. This results in compensation for the initial velocity spread, and refocusing 
of all ions for a given m/z value before they hit the detector.  
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 In comparison to delayed extraction, a reflector is mass independent so the optimal 
settings apply across the entire mass range. At the same time, it does result in a loss of 
sensitivity, particularly for larger molecular species. This is associated with a longer 
flight path, as well as insource or post source molecular fragmentation. This loss of 
sensitivity is not the case in linear mode as the molecular fragments will arrive at the 
detector at the same time as the intact species. For smaller molecules on the other hand, 
the reflector is actually more sensitive, as the time focusing lowers the time spread of 
ions, resulting in the generation of narrower and thus higher peaks (for a given number 
of ions).  
Theoretically a TOF analyser does not have any limit in mass range (neither low nor 
high), however the detection capabilities generally decrease as mass range increases. 
This is largely dependent on the type of detector employed (typically microchannel 
plate, MCP) and of course the mode of operation (linear, respective reflector). 
However, other factors such as broadening of the peaks with increased mass, increased 
isotopic spread, adduct formation and the above mentioned fragmentation sets the 
practical maximum mass range. At the low range, the practical limitation is generally 
associated with interference from the matrix generated signal.  
3.4.1.4 NanoSIMS 
NanoSIMS (e.g. Cameca NanoSIMS 50 or 50L) is a special case of SIMS, used for 
nanoscale analysis. It is a scanning ion microprobe that operates in dynamic SIMS 
mode, while using a continuous primary ion beam, and relies on the use of magnetic 
sector mass analyser (rather than TOF analyser in conventional SIMS). NanoSIMS is 
able to obtain significantly higher secondary ion yield than conventional SIMS. It 
offers high mass resolution, high transmission, and high sensitivity, making it perfectly 
suitable for precision measurements of majority of the periodic table elements at a 
subcellular scale (down to 40nm, reviewed in detail in 373,378).  
The use of dual focusing magnetic sector analyser (electrostatic and magnetic, 
described below), yields a mass resolution of several thousands (M/ΔM). This is 
sufficient to resolve isobaric interference, particularly for low atomic number 
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elements, making it suitable for isotopic labelling experiments in biological settings 
(such as e.g. stable isotopic labelling, described later).    
The key feature separating NanoSIMS from conventional SIMS instruments which use 
TOF mass analysers (TOF-SIMS) lies in the co-axial optics configuration. Here the 
primary ion beam forming optics and the secondary ion beam extraction optics are co-
linear, and can be placed very close to one another, and perpendicularly to the sample 
being analysed (ca 400μm).  This allows for the generation of a small and strong 
primary ion beam, and hence an increase of lateral resolution (for IMS). At the same 
time, this does not only reduce the broadening of secondary ion beam caused by 
angular differences and the energy spread of extracted ions, but also enables higher 
extraction efficiency of the energetically spread ions (almost all secondary ions 
generated are collected). This co-axial design however imposes certain constraints. 
Here the primary and secondary ions have to carry opposite charges (and be of the 
same energy).  
NanoSIMS typically employs a caesium (Cs+) primary ion beam for negative mode 
analysis. This beam can be focused down to 50nm, has a high sputtering efficiency, 
and gives a high yield of elements such as carbon (C), oxygen (O) or sulfur (S). 
However, an oxygen duoplasmatron that generates both positively (O+, O2+) and 
negatively (O-, O2-) charged species can also be used as a primary ion source. These 
are then selected for analysis of electronegative elements (O2+) or electronegative 
elements (O-).The extent to which these can be focused is however much more limited, 
as compared to caesium source (down to ca 150nm). Further, the duoplasmatron is less 
sensitive for analysis of electronegative elements than caesium source. In order to 
achieve a higher primary ion beam focus radio frequency (RF), an oxygen (O-) source 
has been developed. This source can be focused down to 40nm, offering similar 
sensitivity for the electropositive elements as caesium source for electronegative373.  
Due to the use of magnetic sector mass analyser, NanoSIMS does not scan masses (as 
done in TOF), instead several electron multiplier (EM) detectors and faraday cups (FC) 
are used that yield an increased sensitivity. The currently produced instruments employ 
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six movable and one stationary EM/FC combination. This usually allows for the 
detection of up to seven species at the same time, with the mass range of approximately 
20 fold, allowing for the detection for multiple isotopes of a single element up to m/z 
58 (iron, Fe). This is however often sufficient for use in biological setting.  As 
NanoSIMS relies on the use of high energy primary ion beams, the majority of detected 
ions are either monoatomic or diatomic. In terms of biological samples, this implies 
that biomolecules are highly fragmented. Therefore, rather than execute the analysis 
of individual molecular species, analysis (mainly IMS) based on stable isotopic 
labelling is performed (described below).  
3.4.1.5 Sector field detector 
The first high-resolution magnetic sector instrument was introduced in the 1936s by 
Mattauch and Herzog379. However, Thomson and later Dempster had already begun 
working on such a separation approach in the early 1900s 380,381. As suggested by the 
name, magnetic sector instruments use a magnetic sector (sometimes in combination 
with a static electric sector) to focus the direction and velocity of the ion beam355.  
In detail, similarly to TOF instruments after ionization, ions are accelerated before they 
enter the magnetic sector mass analyser. Once in the analyser, they are exposed to a 
homogenous magnetic field that is perpendicular to their flight path. This will force 
the ions into a circular motion (the radius of which depends on magnetic field strength), 
without changing the velocity of individual ions. Again, after leaving the acceleration 
region, the potential energy of the ions is converted to the kinetic energy (Equation I).   
𝐸𝐸𝐾𝐾𝑃𝑃 = 𝑧𝑧𝑧𝑧 = 12𝑚𝑚𝑚𝑚2 (I)  
In the magnetic sector mass analyser, only ions of mass-to-charge ratio whose 
centripetal (inwards) and centrifugal (outwards) forces are equal will be able to pass. 
This is where the centrifugal force (𝑚𝑚𝑣𝑣2
𝑀𝑀
)  is equal force excreted by the magnetic field 
on the moving change (𝑧𝑧𝑚𝑚𝑧𝑧) (equation II). After solving the equation I for the velocity 
(v) of the ions, substituting the velocity (v) into the equations II, and rearranging this 
equation, this shows that the m/z value of an ion analysed in a magnetic sector can be 
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calculated based on the strength of the magnetic field (B), radius of the path produced 
by the field (r) and the acceleration potential (U) (equation III). It is clear from the 
equations III that the m/z in the magnetic sector does not depend on the velocity (v) of 
the ions. By rearranging equation III, the radius of arc of the ions deflected by the 
magnetic sector can be obtained (equation IV).  
In the magnetic sector mass analyser, only ions of mass-to-charge ratio whose 
centripetal (inwards) and centrifugal (outwards) forces are equal will be able to pass. 
This is where the centrifugal force (𝑚𝑚𝑣𝑣2
𝑀𝑀
)  is equal force excreted by the magnetic field 
on the moving change (𝑧𝑧𝑚𝑚𝑧𝑧) (equation II). After solving the equation I for the velocity 
(v) of the ions, substituting the velocity (v) into the equations II, and rearranging this 
equation, this shows that the m/z value of an ion analysed in a magnetic sector can be 
calculated based on the strength of the magnetic field (B), radius of the path produced 
by the field (r) and the acceleration potential (U) (equation III). It is clear from the 
equations III that the m/z in the magnetic sector does not depend on the velocity (v) of 
the ions. By rearranging equation III, the radius of arc of the ions deflected by the 
magnetic sector can be obtained (equation IV).  
𝑚𝑚𝑣𝑣2
𝑀𝑀
= 𝑧𝑧𝑚𝑚𝑧𝑧  (II)  
𝑚𝑚
𝑧𝑧
= 𝐵𝐵2𝑀𝑀2
2𝑈𝑈
  (III)  
𝐸𝐸 = 1
𝐵𝐵
�
2𝑈𝑈𝑚𝑚
𝑧𝑧
  (IV)  
Further, even though the magnetic sector does act as a focusing lens for the ions 
(equation IV), these will not be focused at the same point if their initial energy (and 
hence velocity) varies. Therefore the resolution of a magnetic sector analysed is 
negatively affected by the spread in initial energy of the ions. In order to correct for 
this, magnetic sectors instruments often also incorporate an electric sector.  
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Electric sectors (also known as electro static analyser, ESA) consists of two curved 
plates, which likewise the magnetic sector, apply a force on the ions that is 
perpendicular to their flight path. This bend the ion beam to a lesser or greater extend 
depending on the kinetic energy spread of the ions. The ability of the electric sector to 
focus ions, can again be expressed in terms of centrifugal force and now the force 
exerted of the moving ions in the electric field (𝑧𝑧𝐸𝐸) (equation V).  
𝑚𝑚𝑣𝑣2
𝑀𝑀
= 𝑧𝑧𝐸𝐸  (V)  
Again, after solving the equation I for the velocity (v) of the ions, substituting it into 
the equation V, and rearranging this equation, it becomes clear that the focusing of 
ions by the electric sector (equation VI), is independent of mass or charge, but varies 
only with the strength of the accelerating potential (U) and the electric potential of the 
electric sector (E).  
𝐸𝐸 = 2𝑈𝑈
𝑃𝑃
  (VI)  
This makes the electric sector a great focusing device, which improves the mass 
resolution of the magnetic sector (reducing initial energy spread). It cannot however 
be used independently as a mass analyser. The combined setup can be made in both 
directions, with either electric sector being first (forward instrument geometry), or the 
opposite (reverse geometry).  
Magnetic sector mass analysers are commonly used in either the magnetic scan mode 
or voltage scan mode. The choice between these will influence the mass resolving 
power and mass accuracy of the measurement.  
The magnetic scan mode implies that the acceleration potential and the electric sector 
potential are kept constant, while the magnet is scanned. In this operational mode, a 
wide range of m/z values can be covered. Here, the sensitivity of the instrument is 
independent of the m/z, however due to the magnetic reluctance, the sensitivity in 
general will be relatively “suboptimal”. However, it can be improved by either 
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changing the magnetic field in steps instead of scanning or by using an array detector, 
for example.  
The use of an array detector potentially offers the possibility to use a magnetic sector 
instrument with a pulsed ion source. However, the mass range of such a setup would 
be highly limited. Therefore, in general magnetic sectors instruments are used with 
continuous ion sources.     
The voltage scanning mode implies that the magnetic field is kept constant while the 
acceleration voltage is changed (with the electric sector potential being coupled). In 
this mode of operation, the m/z values and the accelerating voltage have a linear 
relationship.  Operating in this mode also typically yields higher mass accuracy. At the 
same time, however, it has the disadvantage that the sensitivity of the analysis is 
proportional to the m/z.  
An extension to this operation mode is the peak-matching mode, where both the 
electric sector and acceleration voltages are varied (they are not coupled). This mode 
typically yields both the best mass accuracy and optimal resolving power. It is 
particularly useful when trying to separate two ions which both possess an m/z that is 
very close to one another. The scan is however limited to a small m/z range.  
In general, mass resolution and sensitivity are mutually limiting in a magnetic sector 
instrument. The optimal ion transmission and thereby sensitivity, is typically obtained 
at the maximum working acceleration potential. This however, limits the obtainable 
mass range for the analysis. At the same time, the mass resolution in a magnetic sector 
instrument is determined by the slit width that is present before the detector. Smaller 
slit width implies a higher mass resolution, however it also implies lower ion 
transmission.  
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3.4.2 Imaging mass spectrometry (IMS) – molecular histology 
Imaging mass spectrometry (IMS) is a broad term used to describe several mass 
spectrometry techniques that can be used to generate molecular images of analyte 
distributions across a sample. Unlike other biochemical imaging techniques, such as 
e.g. immunohistochemistry, IMS enables label-free analysis without any prior 
knowledge of the potential target species382. Still, one can tailor sample preparation in 
such way to facilitate detection of different classes of target molecular species (e.g. 
choice of matrix as described above).  
The most common IMS techniques are based on either matrix-assisted laser desorption 
ionization (MALDI), secondary ion mass spectrometry (SIMS) or desorption 
electrospray ionization (DESI)382,383. Recently, a special case of SIMS, nanoscale 
SIMS (NanoSIMS) based IMS has gained popularity373,382. Here, DESI, which was not 
previously described, is based on focusing an electrospray on the sample surface. This 
is done at atmospheric pressure. Below, exploration of these techniques will focus 
primarily on MALDI and SIMS (and NanoSIMS) based IMS. 
IMS data acquisition based on both MALDI and SIMS is typically done in so-called 
microprobe mode. Here, a sample that has been placed on a target surface is scanned 
in a pre-defined raster pattern (or array) using either a laser (MALDI), or an ion beam 
(SIMS) (see ionization techniques above). The majority of IMS bio analyses performed 
with MALDI-TOF and TOF-SIMS are acquired using a discontinuous microprobe. In 
contrast, microprobes in NanoSIMS are typically operated in a continuous fashion. 
The images are then constructed pixel-by-pixel by mapping the intensity of an 
individual ion signal (m/z; relative intensity), obtained through acquisition of a 
spectrum for every x-and y-coordinate.  
In principle, IMS could also be performed as ion microscopy, where a wide field of 
view is desorbed by an unfocused source, followed by the transfer and visualization of 
the desorbed ions using electromagnetic lenses. Indeed, efforts have been made to 
enable IMS analysis in microscope mode, both for MALDI, and SIMS. While having 
the advantage of the spatial resolution independent of the ionization probe, the 
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microscopy approach suffers several disadvantages, these being primarily the mass 
accuracy and mass precision due to the restricted choice of detectors (microchannel 
plates).    
Just as any conventional MS technique, the aforementioned IMS techniques have their 
complementary strengths and limitations, which concern mass accuracy, mass 
resolution, mass range, chemical specificity and selectivity. Further, in terms of IMS, 
these also differ in terms of spatial resolution.  
Spatial resolution in an IMS experiment based on a discontinuous microprobe is often 
used interchangeably with the pixel resolution. Here, it is defined as the distance 
between adjacent pixels for which the intensity distribution data is obtained. Definition 
of spatial resolution gets complicated when an acquisition relies on oversampling, and 
the pixel resolution is smaller than the size of the probe.  
In principle, for a discontinuous probe, spatial resolution should correspond to the size 
of the probe, and the distance between two beam impact points, which can be 
“resolved” (where signal can be acquired) without interference of the adjacent spot. 
For a continuous probe, the resolution will depend on the frequency of the probe, and 
the velocity of stage (or beam movement). In either of the cases, the true resolution 
will depend more or less on the sample preparation, which might in fact influence the 
analyte distribution (e.g. by diffusion particularly during MALDI matrix application).  
MALDI analysis typically affords a lateral resolution of 1-10μm, while SIMS allows 
for imaging at 50-100nm spatial resolution. Improvement in lateral resolution, 
generally results in lower sensitivity for both IMS techniques. The choice of ionization 
technique for biological analysis is often limited not by the spatial resolution but rather 
the class and size of the analyte. While both MALDI and SIMS can be operated with 
a TOF detector, which in principle has unlimited mass range, the actual mass range 
(and hence target analytes that can be detected) are limited by the ionization techniques 
themselves. SIMS based ionization results in much higher fragmentation than MALDI 
(see ionization techniques for more detail).  
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Both MALDI and SIMS analysis can result in the generation of tremendous amounts 
of data (NanoSIMS files are generally smaller due to only selected few masses). The 
size of the files will depend on the spatial resolution of the analysis, the number of 
SL[HOVDQGWKHVDPSOLQJUDWHRIWKHLQVWUXPHQW:KLOHMXVWDIHZ\HDUVDJRWKHVL]H of 
typical data from a TOF based instrument resulted in files “only” a few gigabytes in 
size, the improvements in probe focusing, acquisition speed, as well as employment of 
high resolution analyser such as Fourier transform ion cyclotron resonance (FT-ICR), 
have driven the size of generated datasets to tens, or even hundreds of gigabytes. This 
poses significant challenges to computing power of acquisition and data analysis 
computers. Therefore, often a compromise needs to be made with regard to acquisition 
SDUDPHWHUVIRUDQDQDO\VLV$VWKLVLVRIWHQVXERSWLPDOQHZDSSURDFKHVIRUH[WHUQDO
data acquisition system and advanced data processing are constantly developed 385. 
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Given that the IMS data can comprise hundreds of variables, data analysis of IMS data 
is typically performed using multivariate analysis (MVA). There are several different 
multivariate analysis approaches (described later), with common ones including 
principal component analysis (PCA) or partial least squares discriminant analysis 
(PLS-DA). These methods represent excellent tools for unbiased data interrogation, 
which often help reveal anatomical, or disease characteristic regions, based on 
histology associated chemical changes (mass peaks). Still, although highly useful, the 
person performing the analysis needs to be able to differentiate the true histological 
features and chemical changes, from sample preparation artefacts. 
3.4.2.1 MALDI imaging MS 
Application of MALDI for spatial profiling, therefore referred to as MALDI imaging 
MS, was first introduced by Caprioli et al. in 1997386. Since then it has been shown to 
be well-suited for imaging of both large biomolecules such as proteins, peptides, and 
glycolipids, as well as small ones, including metabolites, neurotransmitters, and in the 
context of pharmaceutical work, particularly drugs.  
However, resembling conventional on target MALDI analysis, mass resolution for 
larger intact molecules (large proteins) is limited due to the use of a linear detector 
(rather than reflector mode). On the other hand, matrix clusters typically interfere with 
the detection of small molecules. Both of these challenges have been addressed to some 
extent through the development of sample preparation methods, including on tissue 
tryptic digestion for large proteins, or the use of, for instance, stable isotope modified 
matrices, together with MS/MS methodologies, and high resolution analysers (e.g. FT-
ICR).  
As mentioned above, the spatial resolution in MALDI is not only dependent on the 
laser beam focus but also on sample preparation, including matrix crystal size and 
lateral diffusion of analyte molecules. While the majority of the matrices used for non-
IMS based MALDI can be also be used for IMS (see Table 1), IMS application, these 
matrices need to be homogenously deposited on the sample surface. This can be 
challenging, and often requires an extensive optimization. Some matrices also produce 
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generally larger crystals than others. Further, given the relatively long IMS analysis, 
as compared to a simple target analysis, one needs to consider the relative vacuum 
stability of the matrix in the context of the IMS acquisition time.   
MALDI IMS sample preparation generally begins with sample collection. Here, both 
chemically fixed tissue, such as formalin-fixed paraffin-embedded (FFPA), and frozen 
tissue is used (preferred). While fixed tissue offers the possibility of simple long-term 
storage, and therefore access to large amounts of tissue stored in biobanks, its use for 
MS analysis is limited due to the MS interference caused by the polymeric fixation and 
embedding agents. Still, there are possibilities to overcome these challenges previously 
demonstrated, for example through the exclusion of paraffin embedding for lipid IMS 
(still formalin fixation), dewaxing for metabolite IMS, or complementation of 
conventional dewaxing, rehydration and antigen retrieval, with tryptic digestion for 
peptide analysis.  
Frozen tissue, being the to-go standard for IMS, is typically prepared by submersion 
of freshly dissected tissue in liquid nitrogen (or dry ice), an approach referred to as 
“snap-freezing” or “flash-freezing”. It is performed within 3-minutes of tissue isolation 
in order to minimize the protein and peptide degradation by proteases. This rapid 
freezing, which leads to the direct transition of water from its liquid state into an 
amorphous solid state, prevents cell wall rupture that would otherwise occur due to ice 
crystal formation during slow freezing. Therefore, this method of freezing offers, in 
principle, the most efficient cooling of the tissue by maximizing the interaction with 
the tissue surface area. Still, the relatively high temperature of the freshly isolated 
surface might lead to vapour formation directly at the surface, resulting in different 
freezing rates for different tissue regions. Therefore, liquid nitrogen cooled (or dry ice 
cooled) isopentane is often used for optimal morphological preservation.  
Following isolation, and either chemical fixation or freezing, sectioning of the tissue 
is typically performed using a cryo-microtome (or occasionally microtome of 
chemically fixed tissue) operating at approximately -20°C. Here, contact with the cryo-
protectant, commonly used in immunohistochemistry (such as optimal cutting 
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temperature medium, OCT), is generally avoided, as it will introduce impurities into 
the sample. The cryo-sections are then collected onto either a metal target, or more 
frequently, onto conductive microscope glasses (Indium tin oxide (ITO) coated 
glasses), by thaw-mounting. Glasses offer the possibility for subsequent staining, and 
light microscopy analysis. 
If proper care is not taken to ensure the “dryness” of the collected frozen sample before 
its storage, condensation might occur. This will lead to ice formation and thereby 
freeze damage of the sample (observable in MALDI IMS data). Condensation will also 
occur once the tissue is taken out from the freezer. Therefore, given that sample 
preparations and matrix applications for MALDI IMS are typically performed at room 
temperature, samples are typically dissected when removed from the cold.   
Depending on the target of the MALDI IMS analysis, processing of the sample might 
be necessary prior to matrix application. This typically involves a series of washes in 
organic solvents and/or aqueous solutions, and results in an improvement of the quality 
of the signal and removal of interfering components. Given that the majority of the 
organic solvents can dissolve lipids, these are generally not used prior to lipid imaging. 
Instead, use of simple aqueous washes, for instance using ammonium acetate, has been 
reported for the purpose of sample desalting. Up until now, however, the majority of 
lipid IMS studies are performed without any prior sample clean-up.   
In comparison to lipid imaging, analysis of proteins, peptides and drugs with IMS 
typically requires several washing steps in order to remove lipids and salts that 
otherwise would cause signal interference. These are pH optimized and often involve 
washes with gradient alcohol, shown to yield significant improvements in quality of 
target protein/peptide, respective drug signals.  
Finally, the matrix is deposited on the sample. Here, common approaches include 
either spraying the matrix, or sublimating it. Regardless of the approach applied, 
matrix that is deposited on the sample has to be highly homogenous. This homogeneity 
ensures that the detected signal difference corresponds to the accurate molecular 
content of the sample, and is not an artefact associated with matrix distribution. 
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Furthermore, the approach used needs to maximize the analyte extraction and 
incorporation into the crystal, while minimizing analyte delocalization that can occur 
during these processes as a result of solvation (and diffusion) caused by the used 
solvent. 
Spraying of the matrix onto the samples is most commonly done using automated-
sprayers. Commercial nebulizers, such as TM sprayer (HTX, Technologies Carrboro, 
NC, USA) or SunCollect (Sunchrome, Napa, CA, USA), and even open-access 
instruments, such as iMatrixSpray are becoming more and more popular 387. These 
instruments move across the sample at a constant speed while consistently nebulizing 
the matrix solution. Adjusting various parameters of the sprayers, including e.g. the 
flowrate, movement velocity, drying gas flow or spacing between passes, as well as 
choosing the appropriate matrix solvent composition, can be used to influence the 
“wetness” of the spray and the crystallization. These adjustments can be particularly 
useful when trying to perform on-tissue digestion.  
These instruments offer a high degree of reproducibility, and when optimized properly 
also homogeneity of the deposited matrix. Still, while potentially highly robust, matrix 
spraying using automated nebulizers is limited in terms of how small the individual 
matrix crystals, can be obtained. Further, in order to ensure the homogeneity in 
deposited matrix as well as sufficient thickness, numerous passes across the tissue must 
be performed. This can be time consuming.  
One technique developed to overcome these limitations is matrix sublimation388. Using 
this technique, many matrix compounds can be sublimated without decomposing and 
their vapour is then deposited directly onto the tissue through condensation. This 
solvent-free matrix deposition method results in an even layer of fine crystals (and 
hence theoretically superior resolution). It is particularly useful for lipid imaging, 
however sublimation followed by recrystallization has also been used for high spatial 
resolution protein imaging389.  
 A neat comparison of two automated sprayers (TM sprayer and SunCollect) as well 
as sublimation, in terms of throughput, reproducibility, sensitivity, and degree of 
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spatial detail, and their application for high throughput IMS in clinical context has 
recently been performed390. While sublimation was shown to result in simple overall 
improvement in IMS data quality, sprayers with the wide variety of adjustable settings 
offer better opportunity for fine-tuning the analysis towards the target molecules (e.g. 
by changing the solvent system, adjusting wetness and hence extraction).  
Solvent systems for the MALDI matrix solutions need to be adjusted depending on the 
properties of the matrix used and the analytes of interest. These adjustments will affect 
the solubility of the matrix, the analyte extraction properties of the matrix-solvent 
solution, and, importantly, the size of matrix crystals generated and the efficiency with 
which the matrix will aid in ionization of the analytes. This optimization is crucial for 
both the spatial resolution and signal intensity. A typical matrix solvent system consists 
of water and a water-miscible organic solvent (e.g. methanol or ethanol). This solvent 
system is adjusted with acid(s) or base(s) (e.g. formic acid (FA) or tri-fluoro acetic 
acid (TFA) and ammonium-bicarbonate (Ambic)) to an optimal pH, which can yield 
both an improved solubility of the matrix, but also an increased extraction and 
ionization of the analyte.  
In general, dryer solvent systems, for the same sprayer parameters, will result in lesser 
extraction. Such dry solvent system will be better for resolution, but generally it will 
also be less suitable for IMS of larger molecules, such as proteins as these typically 
require more extensive dissolvation. Still, the limited dissolvation with dry solven 
system has been to some extent overcome by the earlier mentioned recrystallization of 
the relatively dry-deposited matrix, through its solvent based dissolvation directly on 
sample surface.   
3.4.2.2 SIMS and NanoSIMS imaging 
Imaging through conventional SIMS (TOF-SIMS) and NanoSIMS is similar to 
MALDI, with the exception that generally, no matrix compound is used. Still, matrices 
have been used to enhance the signal intensity for a wide range of analytes in so-called 
matrix enhanced-SIMS (ME-SIMS) 370-372.  
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For the conventional SIMS, minimal processing (such as washes etc.) is needed, and 
the samples can be theoretically mounted on any kind of surface (typically a glass slide 
or silica wafer to ensure flatness of the surface). Yet, given the inherited high surface 
sensitivity of the technique, both in terms of the topology and the surface contaminants 
(which might cause ion suppression), one needs to ensure superior sample quality and 
means of its collection and deposition on the target.  
A sample for SIMS analysis needs to withstand very high vacuum. Therefore the 
samples have to either be dry (either with or without fixative), or be present in a frozen 
hydrated state. These samples are then cut on a microtome/ultramicrotome (or their 
cryo equivalent for frozen hydrated samples) to a thickness ranging between 12μm and 
400nm. Following sectioning, the frozen hydrated samples, can be kept in such a state 
by performing the analysis in cryo conditions, while keeping the sample at around -
120°C. This approach, even though rarely used, is particularly applicable in the 
analysis of the life-like state of individual cells.  
An alternative to the frozen hydrated state is high pressure freezing followed by freeze-
fracturing the sample. This offers a high degree of morphological preservation, and 
ideal spatial preservation of subcellular water, salts and lipids. However, due to the 
unpredictable cracking pattern, topographical artefacts might be introduced.  
For NanoSIMS imaging, additional tissue processing is generally needed. Here, the 
flatness of the surface is even more important than in the case of conventional TOF-
SIMS imaging. Therefore, most often electron microscopy preparation, comprising 
chemical fixation and embedding (described earlier), is used. These preparations are 
optimized for the preservation of macromolecules, particularly proteins through their 
crosslinking. As a result the majority of water-soluble species, in particular 
physiologically relevant metal ions (e.g. Zn2+, Cu2+, Ca2+ etc.), are either lost or 
delocalized due to diffusion. While cryogenic approaches, such as freeze substitution, 
improve both tissue morphology, and to some extent, preservation of such species, true 
maintenance of their physiological localization and concentrations is practically 
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possible only if the samples were to be analysed in cryo conditions (e.g. high pressure 
freezing or freeze-fracture). 
As described earlier, the practical mass range of a NanoSIMS analysis is that of the 
monoatomic and diatomic species. Therefore, biological studies with NanoSIMS often 
rely on the use of isotopic labelling, for instance with 2H, 13C, 15N, 18O. Even though 
these can theoretically be well maintained within the sample, a significant decrease in 
their actual signal can be caused by the introduction of background during the sample 
preparation procedures (e.g. conventional fixation and embedding media might contain 
large amounts of 13C but also common isotopes such as 19F). Therefore, appropriate 
controls need to be used. Still, when proper caution is taken, the NanoSIMS analysis, 
including multi-isotope imaging mass spectrometer (MIMS), where sample labelling 
with both 13C and 15N (e.g. through SILAC, described below) at the same time is 
performed, is possible due to the superior mass resolution of the instrument391.  
Samples for NanoSIMS analysis are generally prepared on an ultramicrotome to a 
thickness on an order of a few hundreds of nanometres (typically around 400nm). 
While this thickness ensures sufficient sample thickness for the analysis, it 
compromises the quality of the transmission electron microscopy (TEM) images that 
are usually obtained from consecutive sections. Therefore, switching between semi-
thin (e.g. 400nm) and ultra-thin (e.g. 70nm) sections is often performed in order to 
enable co-registration of NanoSIMS data to TEM data.  
In general, NanoSIMS samples should be mounted on a conductive surface, due to the 
high degree of surface charging that takes place during analysis (even with charge 
neutralization during the analysis). Therefore, silicon wafer, conductive coverslips, 
and even Indium tin oxide (ITO)-coated glass slides (like in MALDI) are used. The 
latter’s transparency provides the possibility to perform correlative microscopy. 
Alternatively, transmission electron microscopy (TEM) grids are often used. This 
technique is particularly useful when TEM ultra-thin sections are collected at the same 
time. In some cases, coating of the substrate is needed in order to ensure sample 
adhesion (e.g. glass slides/wafers) or to stabilize the sample (e.g. TEM grids). This 
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process is typically done with poly-L-lysine, respective formvar or carbon film (other 
films are also available), that are highly transparent to electrons.  
Finally, in order to further compensate for the surface charging, NanoSIMS samples 
are often conductively coated (typically using Au, C or Pd atoms). This coating is done 
either by a sputter coater or evaporator depending on the choice of coating. The 
thickness of such coating layer is generally on the order of a few nanometres (e.g. 10-
20nm).  
3.4.3 Stable isotope labelling with amino acids  
Stable Isotope labelling with amino acids in cell cultures (SILAC), or of mammals 
(SILAM), are analytical approaches to interrogate reactions, metabolic pathways, 
physiological and recently even pathophysiological processes in cell and mammillary 
tissue392-394. In comparison to other approaches used to monitor synthesis, turnover, 
clearance or transport, this approach does not introduce any tags that might interfere 
with native structure or function of the protein.  
SILAC/SILAM instead relies on the introduction of fractionally heavier, non-
radioactive isotopes of natural elements (e.g. 13C, 15N, 2H) into the amino acid structure 
that is supplemented as the growth media/feeding diet to the cells/animal. These amino 
acids become incorporated into the newly synthesized proteins, and participate in 
exactly the same reactions and processes as the endogenous ones. Heavier isotopes 
such as these are naturally abundant, however only in relatively low amounts (13C-
1.109%; 15N-0.364%; 2H-0.012%). Still, this natural abundance needs to be accounted 
for as potential background during the analysis. Assessment of the stable isotope 
incorporation is typically done through mass spectrometer (MS) based quantitative 
proteomics.  
SILAC experiments generally rely on differentially labelled cell cultures. Here, one 
batch of cells is grown on the natural (light) amino acids, while the second one is grown 
on stable isotope labelled (heavy) amino acids. Commonly one introduces only isotope 
labels to specific amino acids (e.g. 15N213C6-lysine and 15N413C6-arginine) which, in 
stark contrast to general nitrogen or carbon labelling, creates distinct mass shifts that 
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can easily be calculated. Upon mixing, possible purification, digestion (typically with 
trypsin) and MS analysis, this amino acid specific labelling allows for an easy, and 
accurate interpretation as well as the quantification of the heavy to light peptide ratio. 
Such quantification is possible thanks to the fact that the heavy and light peptides will 
co-elute due to their identical chemical properties. In the case of complete nitrogen or 
carbon labelling, such analysis is not as straight forward as different amino acids are 
incorporated at different rates. Still, work around approaches to address the issues 
associated with general labelling have been developed. Modelling the isotope 
incorporation and fitting it into the individual isotope envelopes can be done.  
Working with individual amino acids also has its drawbacks. In terms of general 
challenges, possible metabolic conversions of amino acids, such as arginine to proline, 
might cause inaccuracies in terms of quantification when compared to peptide signal 
from non-labelled cell culture395. Further, heavy stable isotope labelling of both amino 
acids, lipid precursors, and even drugs has been used to study cellular localization of 
these molecules or their metabolites on a single cell level using NanoSIMS or in terms 
of broader tissue structures MALDI-IMS. Insufficient 15N or 13C labelling associated 
with single amino acid labelling in such cases is more likely to take place, as compared 
to general nitrogen or carbon labelling. Therefore, if not compromising the aim of the 
experiment, a general nitrogen or carbon might be more suitable for these experiments.   
Generally, the stable isotopic labelling experiments rely on the full incorporation of 
amino acids into protein structures in either cells or mammals. While in cells, one 
generation is typically sufficient to replace the entire proteome, advanced organisms 
require labelling for several generations (at least 2 generations for mice). In order to 
address the limitation associated with such multigenerational labelling, two alternative 
SILAC approaches have been develop. The use of SILAC as a “spike in” standard, 
where SILAC standard is produced separately and spiked in for the analysis itself; and 
a “pulsed” approach, where the labelled amino acids are added to the grown media 
(cells) or replaced in protein diet (mammals) for a shorter period of time 396,397.  
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The “spike-in” approach allows for the preparation of the sample of interest without 
any restriction potentially imposed by the SILAC. The peptide ratios between the 
sample (light) and the SILAC standard (heavy) is determined 396. The “pulsed” 
approach, on the other hand, allows for monitoring of the de novo protein production 
rather than simply quantifying the relative amounts of heavy to light peptide for the 
purpose of their quantification 397.  
Finally, the number of isotopes available limits the degree of multiplexing in stable 
isotope labelling experiments. Recently, the introduction of neutron encoding, that is 
an increase in possible mass defects based on the addition of extra neutrons, has been 
developed (NeuCode)398,399.This new approach is compatible with existing labelled 
amino acids used for SILAC, and expands the possible level of multiplexing398. The 
extremely small mass differences however need to be resolved on a high resolution 
mass spectrometer398,399.  
3.4.4 Laser microdissection   
Laser microdissection refers to the isolation/dissection of microscopic objects of 
interest with the help of laser. Using this method, subpopulations of cells or 
morphological features can be collected directly during the visualization in a 
microscope. This non-contact sampling approach provides an indispensable tool for 
downstream genomics and proteomics, allowing for the bimolecular analysis of the 
extracted object in their physiological context.  
During the procedure, a laser is moved along a pre-defined pattern in order to cut out 
the feature of interest in the specimen, which has previously been mounted on a thin 
membrane (to aid the transport). Following cutting, transport of the dissected element 
is typically performed in either of the following fashions: in an upright microscope 
simply with the help of gravity (as the glass/dish is facing downwards), or in an 
inverted microscope with the help of laser microdissection pressure catapulting 
(LMPC). In the LMPC setup, a laser pulse is used to transport the cut specimen. The 
cut out specimen is collected either directly into a tube (in upright setup), or into an 
adhesive cup when an inverted microscope is used. 
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3.5 Immuno-based analysis  
3.5.1 Immunoprecipitation  
Immunopreciptation (IP) is an antibody based affinity purification method400-403. The 
aim of IP is typically to isolate the proteins or peptide of interest for further semi-
quantitative or quantitative analysis, using western blot or MS. This approach can, for 
example, be used to study structure or modifications of a protein/peptide, but also to 
investigate the interactions of this protein/peptide (as primary IP target) with other 
proteins/peptides.  
When the target antigen of the IP is used to co-precipitate its own binding targets, this 
is referred to as co-IP. For instance, IP can be used to study the interactions between 
proteins and DNA (known as chromatin IP (ChIP)) or RNA (known as RNA IP (RIP)). 
Here the DNA (or RNA) are temporarily cross-linked with the proteins, cells are lysed, 
the IP target proteins are precipitated, the DNA (or RNA) is removed by digestion 
usually using proteinase K, purified and sequenced (typically through quantitative 
polymerase chain reaction (qPCR)).  
IP can generally be performed in two ways. Either through pre-immobilization, where 
the antibody is first immobilized to the support bead before interacting with the target 
(Figure 4), or by the free antibody approach, where interaction with the target is done 
prior to interaction with the support bead. While the pre-immobilization approach is 
most common, the free antibody approach generally works better if the target is present 
at very low concentrations, if the binding between the antibody and the target is weak, 
or if the binding kinetics is slow. Once the IP target-antibody-bead complex is 
generated, it is washed (sometimes cross-linking is preformed beforehand) in order to 
remove the undesired matrix, and eluted in order to release the affinity purified IP 
target (e.g. protein or peptide). The performance of an IP depends on multiple factors, 
these include the choice of beads, choice of antibodies and their concentration, possibly 
a cross-linking agent, in case of cell lysis also a lysis buffer, as well as the choice of 
binding, washing and elution buffers. Optimization of the IP is therefore often 
empirical, and relies on the use of a control to assess the non-specific interactions (if 
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mass spectrometry as means of detection is used, this process can be much easier 
controlled). 
Two common types of beads include the agarose beads and magnetic beads. These 
differ primarily in terms of binding capacity and means of separation from the sample. 
The agarose resin beads are useful for large-scale purification (few mL) as they have 
to be separated by centrifugation. They are porous, and hence offer a large binding 
capacity per bead. Magnetic beads have limited binding capacity, as the sites of 
antibody interactions with the bead are confined only to the surface. These beads are 
theoretically much smaller than the agarose beads and theoretically display a smaller 
binding capacity per bead. In practice however, given that the orientation of the 
antibody is outwards (typically immunoglobulin-binding protein is used), and the 
magnetic separation is more efficient than centrifugation, the yield can be similar, if 
not better. Further, the magnetic beads typically offer shorter incubation times, less 
pre-cleaning of the beads, ease of use (including possible full automation) and 
multiplexing; making them more reproducible and hence more commonly used 
approach, especially for small volumes.  
Binding of the antibody to the bead can be performed in a multitude of ways. Most 
commonly, immunoglobulin-binding protein (Ig) coated beads, including protein A 
(IgA) or G (IgG), are used. These are specific to the heavy chain of the fragment 
crystallizable (Fc) region of the antibody, allowing for the outwards orientation of the 
antigen-binding site. Alternatively, streptavidin beads can be used in combination with 
biotinylated antibodies.  
In some cases, antibodies can be chemically bound to the beads by establishing a 
permanent, covalent binding. This is referred to as direct IP and can be performed for 
instance by establishing a link with primary amines (-NH2). Given that an antibody 
displays many surface amines, the antibodies will have a random orientation on the 
bead in this approach. This random orientation typically does not have any major effect 
on the antigen binding. The covalently bound antibody-bead complex is very stable 
and unless a reducing elution is performed, the antibody will not co-elute with the 
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target antigen. An alternative approach used in the indirect IP to prevent the antibody 
from eluting with the target, is to covalently bind the antibody to the Ig protein that the 
bead is coated with. This is done by crosslinking the adjacent amines on the antibody 
and the Ig protein using cross-linkers such as N-+\GUR[\VXFFLQLPLGHHVWHUV 1+6
This cross-linking will result in the formation of covalent amide bonds, primarily of 
the lysine side chains. In both of these cases, the antibody-EHDGFRPSOH[FDQRIWHQEH
reused. 
)LJXUH 6FKHPDWLF SLFWXUH RI DQ ,3 EDVHG RQ SUH-LPPRELOL]HG DQWLERGLHV DQG
PDJQHWLFEHDGV7KHLPPXQRJOREXOLQ-bindiQJSURWHLQ,JFRDWHGPDJQHWLFEHDGV
DUHSUH-LQFXEDWHGZLWKHSLWRSHVSHFLILFDQWLERGLHV7KHEHDGVDUH WKHQSXOOHGGRZQ
ZLWKKHOSRIPDJQHWDQGWKHXQERXQGDQWLERGLHVDUHZDVKHGDZD\%HDG-DQWLERG\
FRPSOH[LVDGGHGWRWKHVDPSOHDQGLQFXEDWHG $QWLERGLHVUHFRJQL]HWKHWDUJHWHSLWRSHV
UHG7KHEHDG-DQWLERG\-DQWLJHQFRPSOH[HV DUHWKHQ SXOOHGGRZQZLWKWKHKHOSRI a 
PDJQHW DQG WKH UHVW RI WKH VDPSOH FRQVWLWXHQWV DUH ZDVKHG DZD\  (OXWLRQ LV
SHUIRUPHGVHSDUDWLQJ WKH WDUJHWDQWLJHQHJSHSWLGHVSURWHLQV IURPWKHEHDGV 
3XULILHGWDUJHWPROHFXOHVHJSHSWLGHVZLWKYDU\LQJDPLQRDFLGOHQJWKDUHFROOHFWHG
DQGFDQ EHDQDO\VHGXVLQJPDVVVSHFWURPHWU\06 
Finally, choice of buffers (lysis, washing, and elution) is crucial to obtain the optimal 
purification of the target. In the case of lysis buffers, their components often depend 
on the target antigen, conformation and its location within the cell. Its aim is to 
PD[LPL]H WKH UHOHDVHRI WKH WDUJHW IURP WKH FHOO DQG LQKLELW HQ]\PDWLF DFWLYLW\ WKDW 
could degrade the target. If the native state of the target is of interest, or if antibody’s 
specificity towards the target depends on its native conformation, the lysis buffer 
should be non-GHQDWXULQJ+HUHW\SLFDOO\QRQ-ionic detergents (such as Triton X-100) 
are used. If denaturation is desired or needed, as is often the case with nuclear proteins, 
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denaturing buffers containing ionic detergents (such as sodium dodecyl sulfate, SDS) 
are used. If mechanical homogenization of the sample is used or release of the target 
is performed with the help of heat, detergents are often omitted, and protease inhibition 
and agents protecting against oxidative damage are used. Here protease inhibitor 
cocktails and EDTA are often added.   
Given that the stability of the antibody-target antigen complex depends on the 
environment, samples are often washed in ionic strength buffers with nearly neutral 
pH, which stabilize these complexes (typically phosphate-buffered saline (PBS), with 
small amount of detergent). This aids in the removal of non-specifically bound 
antibody complexes, undesired matrix components, and in some cases, also the lysis 
buffer itself, if such was used. Efficiency of this process will affect the purity of the 
elution.  
Finally, the choice of elution buffer depends on the type of downstream analysis. If 
one plans to perform SDS-PAGE separation, elution with the SDS-PAGE buffer is the 
natural choice. This buffer is very effective at dissociating the antigen from the 
antibody, however it also results in the denaturation and reduction of the protein, and 
contamination of the sample with the antibody. It is therefore not easily compatible 
with other analysis methods, unless removed. A common alternative to SDS-PAGE is 
the use of low pH, non-denaturation buffers such as 0.1 glycine-HCl. Still, even this 
buffer can cause denaturation, and also results in elution of the antibody together with 
the antigen. Therefore, optimization of the elution step often includes a choice of one 
of many other elution buffers, including others at low pH (e.g. formic acid (FA)), those 
at high pH (e.g. ammonium hydroxide), or for instance organics.  
3.5.2 Immunohistochemistry 
Immunohistochemistry (IHC) refers to an antibody-based method for the detection, 
visualization and localization of specific molecular components (antigens) in their 
proper cellular/tissue context402-406. IHC is often performed both in research, but also 
in clinical settings. The success of this analysis method depends on good sample 
quality, sample preparation and proper staining. If these are not properly optimized 
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and controlled, the staining process might introduce a lot of artefacts, hampering the 
interpretation of the images.  
3.5.2.1 Tissue isolation and storage 
When it comes to choosing tissue, the best quality of tissue is usually obtained from 
biopsies or from animal models. Here, the time of isolation, methods of preservation 
as well as approaches for long term storage can be easily controlled. On the other hand, 
autopsies provide tissues that are much more degraded, including both a loss of tissue 
integrity but also the disappearance of the antigens. When it comes to cells, storage 
and their preservation can easily be controlled, therefore the biggest challenge lies in 
the proper means of preserving their integrity during the staining. If the cells are 
adherent, one should preferably grow the cells directly on the culture plates that are 
suitable for microscopy. If the cells are in suspension, these need to be carefully 
adhered to the coverslips.   
In order to preserve the morphology and epitopes, both cells and tissue can be either 
frozen or fixed directly. Freezing can be performed by submerging the sample in liquid 
nitrogen, or by covering it with the cryo-protective medium (e.g. optimal cutting 
temperature, OCT) and then freezing. The sectioning is then performed using a cryo-
microtome below zero. The actual temperature depends on the tissue, particularly its 
on fat content, but is usually around -20°C. Post sectioning and prior to staining, tissue 
sections need to be fixed. This fixation can be done using either aldehydes (e.g. 
paraformaldehyde (PFA)), or organic solvents (e.g. acetone, ethanol, methanol). 
Freezing has the great advantage of shorter processing times, and is better for the 
preservation of sensitive epitopes.  
An alternative approach is to directly fix the specimen using chemical fixatives, here 
a common approach includes formalin fixation paraffin embedding (FFPE), and 
alternatively PFA is sometimes used (particularly in research setting). Formalin 
crosslinks the proteins, terminates all cellular processes and immobilizes the cellular 
components. The major advantage of this approach is the ease of storage and 
sectioning, both of which can be performed at room temperature. Further, direct 
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chemical fixation for instance with FFPE offers superior preservation of morphology 
of the tissue. At the same time, this approach unfortunately adds several preparation 
steps to the staining procedure.  
Broadly, this includes deparaffinization, but often also the reversal of crosslinking and 
antigen (epitope) retrieval. The latter is might be necessary as the crosslinking with 
formalin generally masks the epitopes of interest, which in turn obstructs antibody 
binding. Antigen retrieval is typically done through the treatment of the sample with 
either proteolytic enzymes (e.g. trypsin or proteinase K) or detergent, or by boiling the 
sample in a buffer (often citrate buffer, approach referred to as heat-induced epitope 
retrieval (HIER)), or through a combination of these.  
3.5.2.2 Antibody based antigen detection 
Immunohistochemistry staining is generally performed using antibodies (either 
polyclonal or monoclonal), however small antibody fragments, fluorophores, peptides, 
and affibody molecules can also be used. Polyclonal antibodies, typically derived from 
serum, represent a mixture of heterogenous antibodies with different, but poorly 
defined, target epitopes. Because of this mixture, they are very potent, which can be 
both advantageous, for instance if the antigen is abundant in low concentrations, but 
also disadvantageous, as they will display relatively high unspecific binding and 
background.  
This stands in contrast to monoclonal antibodies. These, produced in a hybridoma cell 
line, have well defined target epitopes. Therefore, they are considered much more 
specific than polyclonal antibodies and typically display less “off-target” binding and 
background. Still, even their specificity can be limited, especially if they have to detect 
subtle difference (e.g. single amino acid differences), or if the target antigen is present 
in very small amounts.  
Therefore, regardless of whether polyclonal or monoclonal antibodies are used, IHC 
requires careful optimization in order to prevent the generation of false positive or false 
negative results. This includes the titration of the antibodies, choice of appropriate 
buffers and additives (e.g. detergents to help permeabilization), and optimization of 
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incubation times. Buffer and additives both help to dilute antibodies and stabilize them, 
but are also used for rinsing/washing in-between the steps in order to remove unbound 
or weakly bound unspecific interactions. Further, any kind of IHC experiment requires 
pre-intubation of the sample with a blocking buffer in order to prevent non-specific 
binding of the antibody (typically contain few percentages normal serum, and bovine 
serum albumin (BSA)). No rinsing is done after the blocking.   
3.5.2.3 Antigen visualization 
Detection of the antibody staining in IHC can be performed either in a direct or indirect 
fashion. The choice of detection system depends primarily on the expression levels of 
the target antigen. In a direct detection system the primary antibody is directly 
conjugated to a reporter (enzyme or fluorophore). In indirect setup, a secondary 
antibody is raised in a species different than the primary antibody (carrying a reporter), 
which targets the host species of the primary antibody is used.   
The direct system is simpler, both in terms of having fewer steps, as incubation with a 
secondary antibody is not needed, but also in terms of multiplexing, as combination of 
many more fluorophores can be used without binding interference (since these are 
directly conjugated to the antibodies). This setup it more suitable for the detection of 
highly expressed antigens.  
If the antigens are expressed at relatively low levels, the indirect detection system 
might be more suitable as a signal amplification step is directly incorporated (multiple 
secondary antibodies can bind a single primary antibody). Further, additional 
amplification can be done for instance through the incorporation of a biotinylated 
secondary antibody. Here, either an avidin-biotin-enzyme (Avidin-biotin complex 
(ABC)), a streptavidin-biotin-enzyme complex (labelled streptavidin-biotin (LSAB)), 
or an equivalent of such complex conjugated to a fluorophore rather than an enzyme, 
can be used. When using either ABC or LSAB, however, one needs to take additional 
precautions and block endogenous biotin present in the tissue (particularly important 
in frozen tissue).    
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As mentioned earlier, visualization in IHC is performed either using enzymes or 
fluorophores. The common enzymes comprise horse radish peroxidase (HRP) and 
alkaline phosphatase (AP). HRP can precipitate chromogens such as 3,3'-
Diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC), while AP precipitates 
chromogens such as 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro blue 
tetrazolium chloride (NBT) into very stable, insoluble, coloured precipitates that can 
be observed directly in a light microscope. This method of detection is more common 
for the FFPE tissue.  
When it comes to fluorophores there is a wide variety of molecules that can be used 
for this purpose. These can differ both in excitation and emission wavelength 
(described above). Fluorophores have the advantage of possible multiplexing, as 
compared to chromogens. Still, at least when using the secondary antibody conjugated 
fluorophores, one needs to take into consideration that the secondary antibodies must 
target different primary antibodies. Further, one needs to consider the emission overlap 
(discussed above). One large disadvantage of fluorophores as a visualization method 
is their relative instability, as compared to chromogens. Fluorophores fade with time, 
and also might be bleached during analysis. Fluorescence visualization is more 
commonly used for frozen tissue (chemical crosslinking, e.g. PFA can introduce 
background fluorescence).  
Following staining and visualization of the target antigen(s), counterstaining is 
performed in order to provide additional contrast/information, typically about general 
sample morphology, primarily by labelling cell nuclei. Common counterstains for light 
microscopy include for instance haematoxylin and eosin (staining cell nuclei, 
respective extracellular matrix and cytoplasm) or nuclear fast red (staining nuclear 
chromatin), and for fluorescence microscopy the 4′,6-diamidino-2-phenylindole 
(DAPI, staining AT region of DNA) or the Hoechst stain (also used to stain DNA). 
Finally, following counterstaining, the sample is protected for long term storage by 
mounting it on a coverslip with the help of solvent or water based mounting media. 
These often include antifade agents to prolong fluorescence.   
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3.6 Multivariate analysis (MVA) 
Many chemical analysis techniques, including mass spectrometry and spectroscopy, 
result in datasets that contain hundreds to thousands of variables. This poses challenges 
to data evaluation and interpretation since classical univariate statistical analysis 
approaches are no longer suitable. Therefore, multivariate data analysis (MVA) 
approaches are used to extract relevant information from large datasets of these 
chemical analysis.   
Two common multivariate projection methods used to analyse MS data are principal 
component analysis (PCA) and partial least square regression (PLS). These, rather than 
being based on standard deviation or variance that only operate in a single dimension 
(assuming independence of variables), rely instead on covariance of variables with one 
another (which is often the case in these datasets), and projections of the covariance 
matrices. An alternative approach for data mining in MS is cluster analysis. Here, 
classification of observations is performed based on the combination of interval 
variables describing the distance between given observations and the nearest cluster 
mean. 
3.6.1 Principal component analysis (PCA) 
The principal component analysis (PCA) is one of the most commonly used methods 
for unsupervised multivariate approach for reducing data dimensionality and creating 
linearly uncorrelated variables, known as principal components (PC)407,408. This is 
done by extracting the systematic variation in measured variables (in the X-covariance 
matrix) using eigenvectors. These eigenvectors are non-zero vectors, which under 
linear transformation only change by a scalar factor (eigenvalues). These are 
orthogonal to one another, creating a multivariate space based on the linear 
combination of variable and observation. Their direction describes the largest possible 
variance. Hence the 1st PC accounts for as much variation in the data as possible, and 
each successive PC represents the next largest variation that is orthogonal to that 
represented in the proceeding PC.  
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Projection of individual observations on these PCs allows one to obtain an overview 
of how different observations are similar or dissimilar to one another. This overview 
is typically done by investigating the score plots. Here objects that are close to one 
another in the plot have similar characteristics. Further, in order to reveal what these 
characteristic are, one can investigate the loading plots. These represent the 
relationship between the variables underlying a given PC. In order to aid the 
interpretation of the PCA, each of the variables should be mean subtracted prior to 
PCA. This processing will produce a dataset with a mean of zero. Here, the objects 
that are furthest from the origin are the ones that contribute the most to the PC 
generated by this model. PCA models are sensitive to scaling.  
3.6.2 Partial least square (PLS) and orthogonal PLS 
Partial least square regression, or formally known as projections to latent structures 
(PLS) is a supervised multivariate approach and an extension of multiple regression 
modelling408-410, In contrast to the multiple regression modelling, that relies purely on 
factors extracted from predictive (X) and observed variables (Y), PLS also performs 
regression modelling of covariance in these predictive and observed variables (X/Y) 
and projects these into a new space. The use of both predictive but also observed 
variables makes PLS different from PCA (which relies purely on modelling of 
covariance in measured variables, X). Recall that in PCA, the loading vectors are 
eigenvectors of covariance in X (maximizing the covariance), whereas in PLS they are 
eigenvectors of covariance in X and Y.   
In order to maximize the covariance, PLS divides the sum of squares of X into two 
parts, the systemic variation and residual. However, the model does not indicate how 
much of this systemic variability is actually predictive of Y and how much is not 
(orthogonal variability), i.e. the loading weights express both the predictive and 
orthogonal variation. Thus, problems can arise when trying to interpret the graphical 
representation of PLS.  
Similarly to the score and the loading plots in PCA, the components in PLS maximize 
the covariance, in this case including both X and Y. In practice, this makes the 
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interpretation relatively simple only in the case when X and Y overlap, that is when 
there is a large correlation between X and Y. However, when there are large orthogonal 
components present in X, i.e. when there is a large variation in X that is not linearly 
related to Y, there will be little overlap with Y. This lack of overlap will hamper the 
interpretation of PLS graphical representation, as these plots will be heavily influenced 
by variation that is not really true for the X/Y correlation. In short, there is no-direct 
correspondence between score-loadings in PCA and PLS.  
There are multiple extensions to the PLS modelling. One of these is referred to as 
Orthogonal PLS (OPLS)411,412. OPLS, divides the sum of square into three rather than 
two parts, thereby additionally separating the systematic variation in predictive 
variables (X) into those that are truly correlative (predictive) of the observed variables 
(Y), and those that are uncorrelated (orthogonal) to the observed variables. Through 
this, OPLS addresses the challenges associated with a simple PLS described above. 
Overall, this yields a good interpretability where, at least in a single observable 
variable case (Y), the first component in OPLS is equivalent to the first PC in PCA 
model. Any successive components in OPLS model will reflect the orthogonal 
variation. This is particularly useful when the observed variability is categorical and 
discriminant analysis (DA) is used for class-separation. OPLS can be expanded to 
multiple-Y cases.  In that case, there will be more than one predictive OPLS 
component. 
3.6.3 Clustering analysis 
Clustering analysis is a general term for iterative processes that are used to partition a 
data set into two or more mutually exclusive clusters/classes, based on a measure of 
their similarity/dissimilarity, referred to as “interval variable”408,413. There is a wide 
variety of algorithms that can used for this purpose, with K-means and hierarchical 
clustering being common. Further, in context of IMS data a combination of these, 
referred to as bisecting k-means, is used.  
The k-means clustering is a partitional, centroid based clustering approach, which tries 
to divide the dataset into k-sets simultaneously, based on the similarity/dissimilarity of 
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the objects. Any given object end up in only one cluster. It does so by finding k 
randomly generated cluster centres (that is they may not necessarily be members of the 
data), and while minimizing the squared distance (“interval variable”) of the object to 
the clusters, the data is assigned to closest clusters. Upon object assignment, the 
centroid of a given cluster becomes the new centre. This process is iterative, and 
continues until convergence. The result is represented in so called Voronoi diagrams.  
A large drawback of k-means clustering is the need to predefine how many k-clusters 
the algorithm should find. Furthermore, given that the algorithm optimizes the cluster 
centres rather than the borders, the objects on the borders might not be optimally 
defined. The algorithm is also sensitive to the outliers, making these the cluster centres.  
The hierarchical clustering analysis (HCA) on the other hand is a connectivity-based 
algorithm that aims to decompose the data and build a hierarchy of clusters. This 
decomposition is done under the assumption that objects that are closer to one another 
in terms of the “interval variable” are more related. The result of HCA is a “parent-
child” structure, where the two most similar objects combine together to form a tree-
based structure, a dendrogram. In this dendrogram, the objects are placed on the x-
axis, organized in such fashion that the generated clusters don’t mix. The y-axis on the 
other hand measures the distance at which the clusters merge together. Any valid 
measure of distance can be used in this case.  
Division into hierarchical clusters can be done either in agglomerative (bottom-up) or 
divisive (top-down) fashion. In the agglomerative approach, objects are first separated 
and then merged in a pair-wise fashion forming clusters based on their proximity. This 
process continues with the assessment of the proximity of newly formed clusters, and 
moves up in the hierarchy until all objects are merged into one cluster. In the divisive 
approach, the opposite is true. One cluster is divided into smaller clusters based on the 
largest distance (smallest similarity between the clusters). This process continues until 
each cluster is composed of a single object.  
Given the limitations associated with both the HCA (required knowledge of distances 
between all pairs - can be computationally challenging) and the k-means (required 
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knowledge of the number of clusters), an approach based on the combination of strong 
features of both the HCA and k-means has been developed. It is referred to as bisecting 
k-means (or two step clustering)413,414. In this approach, no raw data (as it would in 
HCA) is used. Instead, all the objects start in a single cluster, which is then 
separated/bisected into two clusters using the centroid-based approach (k-means). 
Within each of these clusters, all the object are treated as the same entity. This process 
is then repeated by splitting one of the formed clusters. At any given point, the cluster’s 
centres, as defined by the k-means algorithm, are discarded. The clusters themselves 
are, however, retained.  
Since role of individual objects in the given clusters is trivial, each subsequent division 
step decides on either merging subsequent clusters with previous ones, or forming new 
clusters, purely based on the measure of the distance between clusters and not objects 
(just like in HCA). In that way, the algorithm builds a random binary tree, similar to 
the dendrogram in HCA. This aids in the interpretation, simplifies data exploration, 
and saves computational power (particularly useful in IMS studies where large 
amounts of data are generated in individual experiments).  
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4 RESULTS AND DISCUSSION  
4.1 Paper I: Evaluation of MALDI IMS for protein and peptide 
analysis in AD on single plaque level 
Commonly, biochemical characterization of Aβ plaque pathology is typically 
performed through immunohistochemistry of Aβ deposits, using different anti-Aβ 
antibodies and histological amyloid probes, such as Congo Red and Thioflavin. While 
IHC targets specific epitopes, histochemical stains are often used to discriminate 
between cored and diffuse plaques based on positive staining only of cored deposits. 
Both methods suffer from limitations, with respect primarily to chemical specificity 
and throughput, as these do not allow for comprehensive molecular analysis of more 
than 3-4 target species (such as epitopes) at a time.   
Imaging mass spectrometry is a powerful approach for concurrent probing of chemical 
distribution in complex biological tissue samples 415-417. In particular, previous proof 
of principle applications of MALDI imaging MS to AD patients and transgenic APP 
mouse brain sections demonstrated this technique is well-suited for the detection of 
Aβ peptide truncation in situ 418-420. Given the proposed brain-region specific variations 
in Aβ peptides and suggested heterogeneity in Aβ plaques, the aim of the present study 
was to investigate the applicability of MALDI-IMS to specifically evaluate 
biochemical microenvironment changes associated with the individual Aβ plaques.  
Therefore, we employed MALDI imaging for probing plaque pathology associated 
peptide and protein distributions in a transgenic APP mice model carrying the Arctic 
and Swedish mutation of amyloid-beta precursor protein (tgAPPArcSwe). Cryo-sections, 
collected from fresh frozen mouse brain tissue, were washed and coated with α-cyano-
4-hydroxycinnamic acid (CHCA) matrix using an automated nebulizer sprayer 
(ImagePrep II) and MALDI IMS was performed at a lateral resolution of 50 μm. 
Following MALDI IMS, multivariate image analysis was used to interrogate the 
obtained data in order to identify anatomical features as well as the Aβ pathological 
deposits based on their chemical identity. Spatial Segmentation using bisecting k-
means clustering (Figure 8B-D) helped outline cortical and hippocampal regions and 
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allowed identification of $ȕSODTXHVLQWKHVHDUHDV (Figure 8E-G)7KH$ȕGHSRVLWV
DQGFRQWURODUHDV$ȕSODTXHIUHHZHUHDQQRWDWHGDVUHJLRQVRILQWHUHVW52,VAn in-
house developed R script was used for data binning in order to perform data reduction 
and account for mass shifts.  
)LJXUH $-1&MRXUQDOFRYHUGLVSOD\LQJVHJPHQWDWLRQRI0$/',,06GDWDIURPWKH
VWXG\ (%-' ,PDJH VHJPHQWDWLRQ DQG VSDWLDO FRUUHODWLRQ RI 0$/', ,06 GDWD
LGHQWLILHGLQGLYLGXDO$ȕSODTXHV(E-GDQGVHYHUDO$ȕSHSWLGHWUXQFDWLRQVDVVRFLDWHG
ZLWKWKHVHGHSRVLWV $GDSWHGIURP 3DSHU,)LJXUH   
Plaque ROIs from all brain regions were subjected to correlation analysis in order to 
identify highly co-localized m/z values in each of the sub-regions, the hippocampus, 
VRPDWRVHQVRU\ FRUWH[ DQG VRPDWRPRWRU DVVRFLDWHG FRUWH[ The results show an 
HQULFKPHQWRI$ȕ-DUFDQG$ȕ-DUFLQDOO$ȕGHSRVLWVacross all brain areas. In 
contrast, $ȕ-42arc was found to be significantly elevated only in the hippocampus 
and the VRPDWRVHQVRU\DVVRFLDWHGFRUWH[EXWQRWLQWKHVRPDWRPRWRUDVVRFLDWHGFRUWH[
Further, based on accurate mass assignment and previously reported MALDI imaging 
data 422, one peak at m/z 6175, which localized to hippocampal plaques, could be 
putatively attributed to macrophage migration inhibitory factor protein (MIF).  
,QRUGHU WRYHULI\ WKH LGHQWLW\RI WKH$ȕGHSRsits, immunohistochemical analysis of 
MALDI imaged tissue sections was performed subsequently after PDWUL[UHPRYDO. ,+& 
was also used to verify the involvement of MIF positive, activated microglia, in the 
plaque vicinity. The individual $ȕSHSWLGHVSHFLHVdetected in the plaques were further 
verified through off-WLVVXHDQDO\VLV+HUHVLQJOHamyloid-positive (h-FTAA) stained 
plaques were collected using laser microdissection pressure catapulting (LMPC) 
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followed by MALDI MS/MS analysis. The LMPC-MALDI MS approach identified 
several more Aβ species than MALDI-IMS had identified, likely due to an increased 
concentration of the peptides in the extracts. This confirmed the amount of analyte in 
tissue, as one of the major factors limiting MALDI-IMS Aβ peptide detection. On the 
other side, the LMPC based approach (here used only for verification) is limited due 
to the loss of spatial information of the individual Aβ peptide distributions. 
The results presented in this work demonstrate that MALDI IMS is able to detect 
different Aβ peptide species localizing to Aβ plaques directly in situ. This approach 
allowed for the observation of brain-region specific differences in Aβ peptide 
distribution. Further, in difference to more commonly used biochemical imaging, IMS 
allowed for both the preservation of spatial distribution of a wide array of Aβ peptide 
and most importantly the individual Aβ peptide localizations to individual plaques in 
different brain areas.  
The MALDI IMS analyses performed here are based on the relative signal intensities 
between different ROIs. Hence, the lack of significant Aβ1-42 accumulation in 
somatosensory associated cortex, in contrast to other regions observed here, could be 
explained by the disperse distribution of the peptide forming soluble intra- and extra-
neuronal accumulations that are not specific to plaque. Likewise, regional differences 
in aggregation and peptide production could underlie these observed results. Indeed, 
as accumulation of Aβ1-42 is considered the initial driver of Aβ plaque formation, 
these findings support the theory that Aβ1-42 might comprise the initial seed for plaque 
formation 125. 
Finally, MIF is a pro-inflammatory cytokine expressed in microglia and is considered 
to play an important role in brain inflammatory processes 423,424. The characteristic 
localization of MIF to Aβ plaques confirms a high degree of microglial activation, 
which is suggested to be an important factor in AD pathology. In combination with 
previous IHC and LMPC-MS plaque studies, this verifies the presence of a variety of 
other molecular species, in addition to Aβ itself, in Aβ plaque formation. 
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4.2 Paper II: Use of MALDI and SIMS IMS to study Aβ 
peptide-lipid interplay in AD 
In Paper I we demonstrated that MALDI IMS can be used to study Aβ peptides 
associated with individual Aβ plaques. However, MALDI IMS has previously been 
demonstrated to be suitable for the analysis of other biomolecules, such as lipids. 
Similar to MALDI, TOF-SIMS is another IMS modality that has been demonstrated 
as suitable for tissue analysis, in particular when operated in a static mode (majority of 
biological studies), which does not result in molecular tissue distortion. These two IMS 
ionization techniques can be highly complementary. SIMS offers submicron imaging 
(<1μm), however is limited by relatively low mass range (m/z <1500 Da) making it 
suitable mainly for the analysis of metabolites, drugs and lipids as well as inorganics. 
MALDI, on the other hand is suitable for the analysis of intact proteins and peptides, 
including Aβ peptides (as demonstrated in Paper I), however at a much lower lateral 
resolution (down to 5-10μm). 
Therefore, we performed multimodal IMS, using TOF SIMS and MALDI IMS of 
lipids, and subsequently performed a MALDI IMS analysis of proteins and peptides 
on the same tissue section. The aim was to receive a comprehensive molecular insight 
into brain tissue from transgenic AD mice in order to elucidate potential Aβ peptide-
lipid interplay specific for Aβ plaque pathology. SIMS imaging of lipids was 
performed using ION-TOF V ToF-SIMS instrument equipped with a Bi3+ ion source. 
MALDI IMS was then performed for a subsequent analysis of lipids (using 1,5-DAN 
as matrix). Following sublimation of the DAN matrix, a second coating with 2,5-
DHAP was performed for subsequent MALDI IMS based-protein analysis. The data 
collected from modalities were then subjected to multivariate image analysis using 
both PCA and bisecting k-mean clustering.  
Here, both SIMS and MALDI IMS identified general depletion of sulfatides in the 
cortical regions. No Aβ plaque resembling features were observed in the TOF-SIMS 
data. In line with previous observations, MALDI IMS enabled the detection of plaque-
like features in lipid data. These were further verified as Aβ plaques by subsequent 
peptide analysis.  
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)LJXUH +HWHURJHQHRXV JDQJOLRVLGHGLVWULEXWLRQZLWKLQDVLQJOHSODTXHVLVDVVRFLDWHG
ZLWK GLVWLQFW $ȕ SHSWLGH SURILOHV $-E ,QVSHFWLRQ RI LQGLYLGXDO VLQJOH LRQ LPDJHV
UHYHDOHGFRUHVSHFLILFORFDOL]DWLRQRI*0DQGDFRPSOHPHQWDU\ORFDOL]DWLRQRIWKH
*0 DQG*0 VSHFLHV )* )XUWKHU ZKLOH VRPH $ȕ VSHFLHV LQFOXGLQJ $ȕ-
GLVSOD\HG D UDWKHU KRPRJHQRXV GLVWULEXWLRQ DFURVV LQGLYLGXDO SODTXHV D FOHDU
JUDGLHQW RI $ȕ–DUF VLJQDO IURP FHQWHU WR WKH SHULSKHU\ ZDV REVHUYHG +
&RUUHODWLRQ DQDO\VLV EHWZHHQ LQGLYLGXDO OLSLG DQG SHSWLGHV VSHFLHV UHYHDOHG D
VLJQLILFDQW UHODWLRQVKLSEHWZHHQ WKH*0DQG$ȕ–DUF 5  S
VFDOHEDU ȝP $GDSWHGIURP 3DSHU,,)LJXUH 
Several ceramides (Cer), gangliosides (GM) and anionic phosphoinositols (PI) were 
REVHUYHGWRORFDOL]HWRWKH$ȕSODTXH,QWHUHVWLQJO\FORVHHYDOXDWLRQRIWKHVLQJOHLRQ
images revealed distinct localization of GM1 mainly to the center of the deposits 
(Figure 9A). In contrast, shorter in GM2 and GM3 displayed a complementary spatial 
distribution pattern, with localization primarily to the periphery of the plaques (Figure 
9B-E). Similarly, although not as pronounced, differences in the $ȕSHSWLGHSDWWHUQ
ZHUHDOVRREVHUYHG+HUHWKH$ȕ-40arc appeared to strongly localize to the center of 
the plaques, while other species displayed a more homogenous signal across the 
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plaques (Figure 9F,G). Correlation analysis of the GM1 and Aβ1-40arc confirmed their 
significant association (Figure 9H). 
The data presented here yet again demonstrated the potential of IMS to elucidate 
potential mechanism underlying the AD pathology. As revealed by MALDI IMS, GM 
metabolism seems to be associated with core formation in Aβ plaques. Indeed, GM1 
has been implicated in the AD pathology, through formation of GM1-Aβ complexes, 
which both promote aggregation (demonstrated in particular for the Aβ1-40), but 
might also function as a neuroprotective mechanism.  Therefore, findings observed 
here support the idea that the role of GM-Aβ interactions are critical for AD.  
Both TOF-SIMS, and MALDI IMS proved useful for studying various molecular 
species in AD. Even though the ion probe used for analysis with TOF-SIMS (here 
operated in high current bunched mode (HBC)) was much smaller, allowing for pixel 
resolution of 5μm compared to 15μm with MALDI, TOF-SIMS did not allow for the 
visualization of individual amyloid deposits. This lack of signal likely has to do with 
the sensitivity of the instrument, the amount of extracted material, and, perhaps most 
importantly, the fact that the matrix used for MALDI analysis likely helps with 
ionization of the lipid species detected.  
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4.3 Paper III: Compatibility of MALDI IMS with fluorescent 
IHC  
While offering an immense potential for molecular histology, to interface MALDI IMS 
with (immune-) fluorescent staining is challenging as the laser ablation process in 
MALDI analysis can induce tissue distortions. These distortions are caused by 
mechanical stress and thermal denaturation resulting from the laser pulses. Still, 
histological staining based on chromogens, in particular haematoxylin and eosin 
(H&E) staining, is typically performed following an MALDI IMS data acquisition. 
These stains do not target specific biomolecules but rather stain a broad class of 
biomolecules. In comparison to H&E staining, highly specific epitope-directed 
immunohistochemistry analysis is rarely performed in pathology. Similarly, only a few 
studies demonstrated MALDI IMS with subsequent IHC analysis 421,426,427 While 
inconclusive, visual inspection of images from these studies suggest that laser 
abolitions in MALDI IMS might impact subsequent staining, in particular that which 
is based on fluorescence detection.  
Presence of such visual tissue distortion highlights the need for determining the impact 
of MALDI IMS analysis on subsequent fluorescent detection. Since laser ablation 
during MALDI is indeed detrimental for tissue morphology, we asked whether it was 
possible to optimize IMS analysis such that it would not impair subsequent fluorescent-
based IHC analysis.  
In order to assess the compatibility of MALDI IMS with subsequent fluorescent IHC, 
we evaluated three commonly used matrix compounds, 1,5-DAN, 2,5-DHB and 
CHCA.  While all of these are suitable for the analysis of lipids, they possess different 
physiochemical properties, which affect their interaction with the laser. Indeed, in 
alignment with previous observations428,429, 1,5-DAN appeared to result in best 
spectral quality at a given laser energy (fluence). Given that laser fluence, and possibly 
the number of shots per pixel, would influence tissue distortion, we proceeded with 
1,5-DAN for subsequent assessment of tissue integrity.  
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Similar to previously reported results, we observed an increase in 1,5-'$1PDWUL[
clusters with increased laser fluence. This increase in clusters was also the present 
when the number of laser shots was increased. For both, the effect was more prominent 
in the negative ion mode. We therefore assessed the effect of gradual changes in both 
laser fluence and the QXPEHURIVKRWVDWDJLYHQSL[HO on the general integrity of the 
tissue. This was done through fluorescent staining using both antibodies (toward glial 
ILEULOODU\DFLGLFSURWHLQ*)$3ȕ,,,-tubulin) as well as a fluorophore (DNA specific 
4,6-diamidino-2-phenylindole (DAPI)) (Figure 10). 
 
)LJXUH $%0$/',,06OLSLGDQDO\VLV P] DQGVXEVHTXHQW,+& *)$3-
JUHHQ ȕ,,,-WXEXOLQ-UHG '$3,-EOXH EDVHG IOXRUHVFHQW VWDLQLQJ DV GHPRQVWUDWHG
WKURXJKWKHDFTXLVLWLRQRIIRXUUHJLRQVXVLQJGLIIHUHQWVHWWLQJV,VKRWVDW
ODVHUHQHUJ\,, VKRWVDW,,,VKRWVDWWKUHVKROG-HQHUJ\,9VKRUWVDW
WKUHVKROG-HQHUJ\&'=RRPVRIVPDOOUHJLRQLQWKHUHJLRQV,,,DQG,9GHPRQVWUDWH
KLVWRORJ\ SUHVHUYDWLRQRIWKHWLVVXHZKHQDFTXLVLWLRQRIWKHGDWDLVGRQHZLWKPLQLPDO
QXPEHURIVKRWVVKRWVDWWKUHVKROG-HQHUJ\6FDOHEDUV$ȝP&ȝPDQG
]RRPȝP $GDSWHGIURP 3DSHU,,,)LJXUHDQG  
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Indeed, maintaining threshold laser energy and a minimal number of shots yielded the 
best quality of single ion images (Figure 10 A,B). At the same time, this resulted in the 
preservation of the tissue, which otherwise appeared more or less deteriorated, ranging 
from individual laser ablation spots (little laser impact) to general tissue cracking 
(Figure 10 C,D). In contrast, we observed no tissue distortions in the H&E stain, even 
when using more “harsh” acquisition parameters. Finally, we demonstrated the 
possibility to use a fluorescent amyloid probe in combination with the “gentle” 1,5-
DAN acquisition parameters for combined MALDI-IMS and subsequent fluorescent 
staining of Aβ plaques.  
The results obtained in this study demonstrate that histological staining, including that 
done with fluorescence-based detection, can be performed following MALDI IMS 
analysis. The differences observed on tissue morphology, as visualized through the use 
of chromogens (H&E staining) as compared to fluorescence, demonstrate the need to 
use fluorescence detection as the method of choice to truly assess morphological 
integrity of a tissue following a MALDI IMS experiment.  
The 1,5-DAN has relatively low ionization energy and therefore proved to be highly 
suitable for subsequent analysis. Since only few shots per pixel were used when 
analysing the sample with 1,5-DAN, an increase in the general speed of acquisition 
could also observed. While the use of other matrices for combined MALDI IMS – 
fluorescent IHC studies might be possible, this might require elaborate optimization 
(including e.g. thicker matrix layer deposition). Further, this might be especially 
challenging if attempted in combination with protein IMS rather than lipid IMS. Here, 
extraction of tissue proteins requires extensive sample washes, which might already 
impact the tissue. Further, protein desorption during the MALDI IMS, might also 
require higher laser fluence due to their size. Still, the use of MALDI-IMS and 
Fluorescent IMS, even when used only for lipids, offers tremendous possibilities for 
probing pathology of neurodegenerative diseases.   
  
  113 
4.4 Paper IV: Combination of MALDI IMS and structural LCO 
staining to study Aβ aggregation state associated neuronal 
lipids  
Structurally heterogeneous amyloid beta (Aβ) plaque pathology is considered one of 
the major pathological features of Alzheimer’s disease 431,432. This has been suggested 
to be associated with differential deposition of truncated Aβ peptides. Structural 
analysis of individual polymorphic Aβ plaques requires either multiplexing of 
aggregation state specific antibodies (and fluorescence detection), or the use of 
structure specific fluorescent amyloid probes (e.g. luminescent conjugated 
oligothiophenes, LCOs). In order to identify what chemical species underlie the 
amyloid polymorphism it is of great interest to interface MALDI IMS with subsequent 
fluorescent imaging both using IHC and chemical amyloid staining (LCO). This 
interface would allow us to perform structure specific analysis of Aβ plaques and 
enable accurate correlation between IMS data and the subsequent histological 
assessment.   
MALDI-IMS analysis of proteins/peptides (as performed in Paper I) requires analysis 
conditions that are harsh for the analysed tissue and do not allow subsequent 
fluorescent imaging. In contrast, lipid imaging using 1,5-diaminonaphthalene (1,5-
DAN) as the matrix as demonstrated in Paper III is a much gentler approach.  MALDI-
IMS lipid analysis with follow up histological and structural amyloid staining using 
LCO amyloid probes. These LCO probes offer the possibility to investigate the 
different aggregation state of the same amyloidogenic protein. Here, concomitant 
staining with q-FTAA visualizes mature Aβ fibrils and h-FTAA, which furthermore 
allows for the recognition of the protofibrillar and prefibrillar Aβ aggregation 
intermediates311,312.  
We therefore wondered whether performing multimodal data analysis using MALDI-
IMS imaging of lipid, with subsequent structural LCO staining, could yield additional 
information about lipid involvement in structural diversity in Aβ plaque pathology of 
AD. For this purpose, tgAPPSwe mice, rather than the tgAPPArcSwe, mice were chosen 
for analysis. These mice display a systematic structural diversity among plaques, with 
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both cored and diffuse present in full-blown plaque pathology reached at 18 months 
433,434. 
Following MALDI based-lipid imaging, the analysed sections were double stained 
with q-FTAA and h-FTAA (Figure 11A-F). Spectral imaging was performed using 
LSM 710 NLO laser-scanning microscope equipped with a 34-channel QUASAR 
detector (Zeiss), using 405nm laser for qFTAA and 480nm laser for hFTA$H[FLWDWLRQ 
(Figure 11G). Individual plaques could then be classified based on their hyperspectral 
emission profiles )LJXUH(+-K). IMS data was subjected to multivariate image 
analysis using spatial segmentation and PCA (Figure 10L-N). ,+& Vtaining of the 
consecutive section was performed in order to verify the identity of the inclusions as 
$ȕ SRVLWLYH 7KLV staining was done using antibody-EDVHG ,+& DQG ODVHU
PLFURGLVVHFWLRQSUHVVXUHFDWDSXOWLQJ/03&IORZHGE\$ȕLPPXQRSUHFLSLWDWLRQDQG
MS analysis (IP-MS).  
)LJXUH $-& ]RRP '-F +LVWRORJ\ FRPSDWLEOH 0$/', ,06 RI OLSLGV ZLWK
VXEVHTXHQW /&2 GRXEOH VWDLQLQJ DOORZV a KLJK GHJUHH RI FR-ORFDOL]DWLRQ EHWZHHQ
LPDJLQJPRGDOLWLHV+-. 7KHT-)7$$DQGK-)7$$GRXEOHVWDLQLQJZLWKVXEVHTXHQW
KHDWPDS-EDVHG K\SHUVSHFWUDO DQDO\VLV RI FURVV-VHFWLRQDO HPLVVLRQ SURILOHV from 
LQGLYLGXDOGHSRVLWVDOORZHGIRU WKH LGHQWLILFDWLRQRIFRUHGEOXHVKLIWHGWRSDQGGLIIXVH
SODTXHV/-10XOWLYDULDWHDQDO\VLVWKURXJKVSDWLDOVHJPHQWDWLRQDQG3&$UHYHDOHG
OLSLGGLVWULEXWLRQSDWWHUQVDVVRFLDWHGZLWKDP\ORLGVWUXFWXUDOSRO\PRUSKLVPGLIIXVH
UHVSHFWLYHGHQVHFRUHGVWUXFWXUHV $GDSWHGIURP 3DSHU,9)LJXUH  
  115 
Investigation of hyperspectral imaging data and lipid IMS data revealed that distinct 
fluorescence emission and mass spectral features were present across individual Aβ 
plaques. Here, a spectral shift towards shorter wavelengths, corresponding to q-FTAA 
staining, appeared to be present in the dense core. A general h-FTAA staining was 
associated with more diffuse structures. In terms of lipids, three distinct lipid 
localization patterns were present. 
First, a general plaque accumulation of gangliosides (GM2/GM3) and ceramides (Cer), 
as well as a respective depletion of sulfatides (ST), was observed in all deposits 
irrespective of plaque morphology. This observation was also complemented by 
morphology-independent localization of arachidonic acid (AA) conjugated 
phosphatidic acids (PA) and lyso-PA.  
In contrast, a morphology-dependent localization pattern of ceramide matching 
cerebrosides (HexCer) and phospho-ceramides (CerP and PE-Cer) displayed 
significant localization solely to the center of cored Aβ plaques. Moreover, a specific 
localization to the periphery of cored plaques and diffuse deposits was observed not 
only for arachidonic acid (AA) but also for docosahexaenoic acid (DHA) containing 
anionic phosphoinositols (PI), as well as lyso-PI (LPI). Finally, the LMPC-IP-MS, 
suggested that presence of the cores in the plaques was associated with an increased 
Aβ1-40/1-42 ratio.  
Previous studies suggest the involvement of differentially localized phospho-
ceramides as well as omega-3 (DHA) and omega-6 (AA) conjugated fatty acids in 
cellular mechanism. Here, both PE-Cer and Cer1P have been proposed to suppress 
ceramide-induced apoptosis 435-438. On the other hand, DHA and AA are essential 
precursors in eicosanoid synthesis underlying inflammatory response mechanisms 439-
441. Interestingly, while DHA has been suggested to have an anti-inflammatory role 
and prevent cognitive decline at prodrome of AD 439, AA appears to play a crucial role 
in Aβ pathogenesis 295,442. Therefore, while the observed accumulation of phospho-
ceramides could indicate a cellular defense mechanism that prevents apoptosis at the 
site of Aβ core formation, localization of AA and possibly DHA containing 
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phospholipids to the diffuse plaques and periphery of cored Aβ deposits, likely reflects 
their involvement in the immune response at the site of plaque formation. This 
localization appears to also be linked to Aβ peptide truncations (Aβ1-40 in cored-, 
respective Aβ1-42 in diffuse plaque areas).  
Taken together, high resolution MALDI-IMS when combined with complementary 
methods, such as structural amyloid differentiation based on LCOs, offers the 
opportunity to both elucidate chemical differences in plaque populations and enables 
correlation of chemical distribution patterns to morphological features detected 
through hyperspectral analysis.  The multimodal chemical imaging data presented in 
this work suggest differential roles of various lipid species associated with 
polymorphic Aβ aggregation. These results emphasize the need to study morphological 
heterogeneity among Aβ plaques, as further studies might shed light upon the 
mechanisms underlying the diverse aggregation of Aβ peptides into structurally 
distinct deposits.  
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4.5 Paper V: MALDI IMS and structural LCO staining delineate 
Aβ peptide truncations associated with plaque 
polymorphism 
Morphologically heterogeneous amyloid beta (Aβ) plaque pathology have been 
suggested to differ not only in terms of structure, but also in terms of chemical 
composition 431,432. In particular, Aβ1-42, commonly believed to seed the plaque 
pathology, has been suggested to be the main constituent of protofibrils 443, and 
underlie the diffuse deposits 57,58. In contrast, more aggregated cored deposits have 
been suggested to display more Aβ1-40 antibody staining 56,434,444-446.  Further, recent 
study, were antibody detected, LMPC isolated and Lys-C digested cored deposits in 
PS2APP mice were analysed did also show such Aβ1-40 positivity 447In agreement 
with previous studies, the MALDI IMS analysis performed in Paper I revealed brain 
region specific differences in Aβ peptide composition in tgAPPArcSwe mice. Further, 
LMPC-IP-MS, respective IMS analysis in Paper III and Paper IV, of both tgAPPArcSwe 
and tgAPPSwe mice suggested both inter- and intra-plaque heterogeneity in terms of 
both Aβ peptide and lipid composition.  
The Aβ plaque pathology is present not only in Alzheimer’s patients (sporadic (sAD) 
and familial (fAD)), but has also been found for instance in cognitively unaffected 
amyloid positive patients (CU-AP). Aβ plaques present in CU-AP brains are mostly 
diffuse in nature, whereas in sAD brains the Aβ plaques are mostly mature/cored. 
Therefore, we wondered whether the Aβ core identification with subsequent MS 
analysis, as used in Paper III, could also be used to reveal Aβ-peptides truly associated 
with the core formation in sAD, as well as to elucidate potential similarities and 
differences between diffuse plaques in sAD and CU-AP.  
To assess polymorphism associated amyloid peptide signatures, we investigated post- 
mortem brain tissue (temporal cortex) from 8 sAD patients and 4 CU-AP patients. For 
this, the q-FTAA/h-FTAA staining approach described in Paper IV was used for 
hyperspectral imaging guided plaque annotation and subsequent isolation with LMPC 
and IP-MS based Aβ detection. In order to verify the plaque type and specific Aβ 
peptide distributions observed in LCO/LMPC-IP-MS experiments, MALDI IMS was 
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performed on a consecutive tissue section to avoid interference with the hyperspectral 
fluorescent imaging.  
)LJXUH $''RXEOHVWDLQLQJZLWKT-)7$$DQGK-)7$$ZLWKVXEVHTXHQWKHDWPDS 
EDVHGVSHFWUDOGHOLQHDWLRQRIGLIIXVHSODTXHVLQ&8-$3DQGFRUHGDQGGLIIXVHSODTXHV
LQV$'7KHQPHPLVVLRQUDWLR FRUUHVSRQGLQJWRT)7$$DQGK)7$$HPLVVLRQ
PD[LPD UHYHDOHG VWUXFWXUDO KHWHURJHQHLW\ EHWZHHQPRUSKRORJLFDOO\ VLPLODU GLIIXVH
SODTXHV LQ&8-$3DQG V$' %&(0DVV VSHFWURPHWULF DQDO\VLV RI H[WUDFWV IURP
VSHFWUDOO\ GHOLQHDWHG DQG /03& LVRODWHG SODTXH VXESRSXODWLRQV GHPRQVWUDWH
HQULFKPHQWRI$ȕ-LVVSHFLILFDOO\LQFRUHGSODTXHVLQV$')XUWKHUWKHSUHVHQFHRI
S\URJOXWDPDWH-PRGLILHG $ȕ VSHFLHV DSSHDUV WR EH DVVRFLDWHG ZLWK V$' SDWLHQWV
6FDOHEDUȝP$GDSWHGIURP 3DSHU9)LJXUH  
Based on the described hyperspectral paradigm, we identified spectral differences 
between cored and diffuse plaques in sAD (blue shift across the core), and also 
between diffuse plaques in sAD and those present in CU-AP cases (Figure 12A,D). In 
combination with LMPC-IP-MS data, and subsequent MALDI IMS spatial 
verification, this showed that the presence of the core was indeed associated with the 
GHSRVLWLRQ RI $ȕ-40 peptide (Figure 12B,C,E). The generally more blue-shifted 
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homogenous emission of diffuse plaques in sAD, compared to diffuse plaques in CU-
AP, was shown to be associated with an increased amount of N-terminally 
pyroglutamated Aβ3pE-42 (Figure 12B,C,E). Interestingly, the Aβ4-42 peptide 
appeared to be the most prominent peptide in all types of plaques (both sAD and CU-
AP). Further, closer investigation of the general spatial distribution pattern of N-
terminally truncated Aβ peptides showed that they did indeed follow the same 
core/respective periphery localization as the Aβ1-40, respective Aβ1-42. In addition, 
the results show that vascular deposits (CAA) in human sAD consisted mainly of Aβ1-
40 and Aβ4-40 peptides.  
To gain a more mechanistic insight into evolving plaque pathology, the human tissue 
analysis were complemented with LCO-IP analysis 12-, and 18-months old tgAPPSwe 
mice. In tgAPPSwe mice, Aβ1-40 was the most prominent peptide, whose deposition 
mechanism appeared to be age-dependent. Cored plaques in 12-month-old mice 
displayed lower Aβ1-40/Aβ1-42, compared to the 18-month-old mice. This trend was 
even more prominent when investigating the CAA pathology in these mice.  
Together, these results provide further support for the theory that Aβ deposit 
maturation is reflected in an increased content of less hydrophobic C-terminal peptides, 
such as Aβ1-40. Spectrally, this increase is represented by the blue shift corresponding 
to q-FTAA staining, and presence of more mature, dense fibrillary structures, apparent 
particularly in cored plaques and CAA. In line with these observations, a higher risk 
of CAA associated hemorrhage is observed in fAD subjects with mutations leading to 
an increase in total Aβ, rather than those mutations which lead to a relative increase in 
Aβ1-42/Aβ1-40 ratio56,60,174. Therefore, our results strengthen previous suggestions 
that a higher rigidity of Aβ40 fibrils might underlie the CAA occurrence 56,59,60. 
Further, as presented here, differences in individual peptides, such as Aβ3pE-42, might 
underlie morphologically similar plaques, but with actually structurally different 
fibrils. Here, such case is demonstrated between diffuse plaques in sAD and CU-AP.  
Therefore, our data demonstrates that hyperspectral imaging guided - MS based 
workflow is a powerful alternative to conventional IHC assessment of Aβ pathology 
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in AD. When combined with LMPC-IP-MS experiments, the LCO approach allows 
for the analysis of pooled and purified plaque extracts, which yield a higher signal and 
possibility for MS/MS verification. On the other hand, when combined with IMS, 
hyperspectral imaging allows for the spatial analysis of multiple Aβ peptides, and the 
identification of distinct localization patterns, such as similar localizations of N-
terminally truncated forms of the major C-terminal truncations (i.e. Aβx-42 appear to 
have one localization pattern, and Aβx-40, another) at the individual plaque level. 
Further, analysis of intact Aβ species through IP-MS and IMS overcome the limitations 
of proteomic approaches such as incomplete Aβ digestion, which likely influences 
relative levels and diversity of Aβ peptides observed. 
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4.6 Paper VI: Use MALDI IMS to study Aβ processing and 
deposition across regions and ages 
Aβ plaque precipitation is believed to start long before the onset of clinical symptoms. 
The chain of events that lead to Aβ peptide aggregation into plaques, however, remains 
unclear. On top of that, the presence of both diffuse and cored deposits further 
complicates the matter. Still, Aβ plaque maturation has long been proposed as the main 
mechanism underlying the transition of diffuse Aβ plaque pathology into cored 
plaques. Based on the results presented in Paper V, this appears to be associated with 
precipitation of Aβ1-40. There are many other truncated Aβ peptides present in the 
plaques, and their distribution across anatomical regions can differ. Therefore, we 
wondered whether we could employ MALDI IMS to probe the evolution of Aβ plaque 
pathology in AD over time.  
For this purpose, we investigated tissue sections from 6-, 9-, 12-, 18-, and 23-month-
old tgAPPSwe mice using MALDI IMS. TgAPPSwe mice display the first signs of plaque 
pathology typically around 12-months, and exhibit extensive Aβ plaque pathology by 
18-months. Therefore, this cohort represented both animals where Aβ plaque 
pathology was not yet developed, as well as those where the full-blown pathology had 
been present for some time. Following the MALDI IMS analysis, a simple h-FTAA 
staining was performed in order to allow for a visual inspection of any amyloid 
deposits. For the division of Aβ plaques into cored and diffuse subpopulations, we 
employed spatial segmentation. This technique allowed for characterization purely 
based on the chemical signature as revealed by IMS.  
No plaques, or for that matter any Aβ peptide signal, were detected in 6-, and 9-month-
old animals. Further, Aβ plaques present in 12-month-old mice were observed only in 
the somatomotor cortex. Older mice, on the other hand, displayed full-blown 
pathology. Single plaque analysis, based on the Aβ plaque ROIs identified through 
spatial segmentation, revealed a trend similar to that reported in Paper V where cored 
plaques in 18- and 23-month-old mice had a significantly higher Aβ1-40/Aβ1-42 
peptide ratio. Interestingly, the ratio appeared to be consistent across all three analysed 
regions, the somatomotor cortex, hippocampus, and somatosensory cortex, for both the 
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pseudo-clusters corresponding to either diffuse plaques or cored plaques. 7KH$ȕ-
$ȕ-42 ratio in the 12-month old animals was intermediate to that of diffuse and 
cored plaques in older mice.  
)LJXUH  $0$/',,06RILQGLYLGXDOSODTXHVUHYHDOHGVWURQJORFDOL]DWLRQRI$ȕ-
SHSWLGH LQ FRUHGGHSRVLWV %&)XUWKHU$ȕ-DQG$ȕ- GLVSOD\HG VLPLODU
ORFDOL]DWLRQ SDWWHUQV DV $ȕ- SHSWLGH &RUUHODWLRQ DQDO\VLV UHYHDOHG VWURQJ
FRUUHODWLRQ EHWZHHQ $ȕ- DQG $ȕ- LQ ERWK GLIIXVH DQG FRUHG SODTXHV 7KLV
VXJJHVWVFR-SUHFLSLWDWLRQRUFR-SURFHVVLQJRIWKH$ȕ- DQG$ȕ-SHSWLGHVLQWJ6ZH
PLFH $GDSWHGIURP 3DSHU9,)LJXUH 
,06 DQDO\VLV LGHQWLILHG WKUHH RWKHU$ȕ SHSWLGHV LQ WKH SODTXHV 7KHVH LQFOXGHG&-
WHUPLQDOO\ WUXQFDWHG$ȕ-$ȕ-DQG$ȕ-7KH ORFDOL]DWLRQRI$ȕ-37 was 
present in small amounts, with only some plaques displaying the signal. Further, the 
$ȕ-37 did QRWGLIIHUEHWZHHQWKHGLIIXVHDQGFRUHGSODTXHV7KHVLJQDOVRI$ȕ-38 
DQG$ȕ-39 were stronger in the cored plaques compared to the diffuse plaques (Figure 
13 A-&&RUUHODWLRQDQDO\VLVUHYHDOHGDZHDNFRUUHODWLRQRI$ȕ-DQG$ȕ-40 in 
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diffuse plaques (Figure 13D, top). On the other hand, both Aβ1-38 and Aβ1-39 
correlated with the Aβ1-40 signal in cored plaques (Figure 13D, bottom).  
The data presented here is in agreement with previous IHC based results on tgAPPSwe 
where the first plaques were observed in the neocortex of 12-month-old mice. This 
reaffirmation demonstrates that MALDI IMS can be used for early Aβ plaque 
detection. Further, IMS analysis offers the benefit of chemical classification of plaques 
based on their multi peptide pattern, and relative signal ratio, which is not easily 
achievable with IHC. Surprisingly, only two pseudo clusters, corresponding to diffuse 
and cored plaques in 18-, and 23-month-old mice, were observed, which indicates that 
plaque types (cored respective diffuse) remain similar across ages and areas. Still, IMS 
based relative quantification allowed for the identification of an intermediate Aβ1-
40/Aβ1-42 ratio in plaques in 12-month-old mice, compared to diffuse and cored 
plaques in older mice. One could speculate this to be a result of a “sink effect” 299,312. 
In the presence of limited pathology, Aβ1-42 seeded structures quickly drive 
deposition of other peptides into new plaques. In older mice where an extensive 
pathology is present, new Aβ1-42 seeds are formed more frequently, leading to a more 
heterogeneous Aβ plaque subpopulation.  
Besides the clear difference in Aβ1-40/Aβ1-42 ratio across plaque types, MALDI IMS 
data also reveals potential sequential processing patterns responsible for the generation 
of shorter C-terminally truncated peptides. In particular, Aβ1-38, previously shown to 
be generated independently of Aβ1-42 98,449, appears to strongly correlate with the 
precipitation of the dominant Aβ1-40.  
In conclusion, data presented here demonstrates that MALDI IMS can be used for time 
series experiments centered on the Aβ plaque pathology, similar to IHC studies. It does 
however outperform conventional IHC as it offers the advantage of simultaneous 
relative quantification of multiple Aβ peptides at a single plaque level. Still, like other 
post-mortem in situ analyses, MALDI IMS provides only static information and does 
not to resolve the true temporal timeline of Aβ peptide specific accumulation, 
aggregation and deposition in the formation and growth process of single Aβ plaques.    
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4.7 Paper VII: Development of iSILK for spatiotemporal 
analysis of Aβ plaque spread, formation and development 
Evolution of Aβ plaque pathology is not well understood. Furthermore, the study of 
Aβ plaque evolution through conventional IHC based time series experiments, or even 
MALDI IMS, as presented in Paper VI, has its limitations. These analyses allow for 
the identification of changes in Aβ peptide composition within single plaques across 
ages. Further, they enable comparison of Aβ in different regions. With these in situ 
imaging approaches there is, however, no way to actually tell which Aβ peptides were 
deposited first, and which ones were generated and deposited at a later time point as 
these are only static measurements. Neither is it possible to truly delineate the primary 
site of plaque deposition, both in terms of anatomical regions, but also in terms of how 
a plaque physically grows in size. The advent of metabolic labelling with stable 
isotopes together with mass spectrometry analysis greatly increases the resolution of 
dynamic molecular interactions events in vivo.  
Stable isotope labelling kinetics (SILK) has been shown to be a powerful tool to 
measure protein turnover dynamics in cells, tissue and bodily fluids. Recently, it has 
also been demonstrated to be useful for probing Aβ peptide turnover in cerebrospinal 
fluid (CSF) from AD patients450,451. IMS based analysis of metabolically labeled tissue 
has also been demonstrated452-454.  
We were therefore curious as to whether metabolic labeling with stable isotopes 
combined with IMS could be used to visualize true Aβ aggregation dynamics in 
morphologically heterogeneous plaques across different brain regions.  
To help answer this question, we developed a novel multimodal approach to image 
stable isotope labelling kinetics (iSILK) to visualize Aβ aggregation dynamics in vivo. 
For this, we isotopically labeled (15N) recently developed knock in mice with familial 
mutations in Amyloid Precursor Protein (APPNL-G-F)208 using different labeling 
schemes: one labelling starting prior to and one after the reported plaque onset (Figure 
14A). Half of the brain of the labeled mice was frozen, while the other half was 
subjected to chemical processing for EM. Analysis of the heavy nitrogen’s 
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LQFRUSRUDWLRQLQWRWKH$ȕVHTXHQFHSHSWLGHVZDVSHUIRUPHGRQWKHIUR]HQWLVVXHXsing 
MALDI imaging (Figure 14B). Sections adjacent to those analysed through MALDI 
IMS were double stained with q-FTAA and h-FTAA, and delineated in terms of 
amyloid aggregation state following hyperspectral image acquisition (Figure 14C). 
EM prepared tissue obtained from the other hemisphere was analysed through annular 
bright-field STEM analysis using GAIA3, a FIB-SEM workstation. Subsequent super 
high-resolution analysis and quantification of 15N within single plaques was performed 
using NanoSIMS (Figure 14D,E).  
)LJXUH  $ 7ZR IHHGLQJ VFKHPHV ZHUH GRQH LQ RUGHU WR SHUIRUP WKH QRYHO
PXOWLPRGDOLPDJLQJRIVWDEOHLVRWRSHODEHOOLQJNLQHWLFVL6,/.,QWKLVDSSURDFK%
0$/',-,06&K\SHUVSHFWUDO/60DQDO\VLVRI/&2GRXEOHVWDLQHGWLVVXH'67(0
XOWUDVWUXFWXUDODQDO\VLVDQG(1DQR6,06DQDO\VLVZHUHSHUIRUPHGWRVWXG\WKH$ȕ 
SODTXHIRUPDWLRQGHYHORSPHQWDQGVSUHDGLQNQRFN-in $331/-G-F PLFH)%DVHGRQ
WKHN in $ȕ-SHSWLGHV0$/',,06LGHQWLILHG WKH FRUWH[DVSULPDU\VLWHRI$ȕ 
DJJUHJDWLRQDQGGHSRVLWLRQ*7KLVZDVIXUWKHUYHULILHGWKURXJK1DQR6,06DQDO\VLV 
$GDSWHGIURP 3DSHU9,,)LJXUHDQG  
MALDI IMS analysis of the tissue from the APPNL-G-F metabolically labeled prior to 
demonstrating plaque onset revealed the presence of 15N-$ȕ-42 in plaques. The 
STEM, with subsequent NanoSIMS analysis, verified this plaque specific 15N signal 
enrichment (based on the 12C15N-VLJQDO&RPSDULVRQRIWKHSODTXHVLQWKHFRUWH[DQG
hippocampus of the APPNL-G-F using MALDI-IMS further reYHDOHGWKHFRUWH[DVWKH
SULPDU\ VLWH RI DJJUHJDWLRQ DQG GHSRVLWLRQ RI WKH $ȕ SHSWLGHV EDVHG RQ 15N 
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incorporation (Figure 14F). This discovery was verified by the relative quantification 
of the 15N/14N ratio in cortical, respective hippocampal, plaques using NanoSIMS 
(Figure 14G). In addition to 15N-Aβ1-42, 15N-Aβ1-38 was also observed in some of 
the plaques and was found to localize primarily to the core of the deposits. Inspection 
of individual 15N-Aβ1-42 with a different degree of 15N incorporation suggested the 
deposition of “older Aβ” peptides in the center of the plaques. The denser nature of the 
plaque center was confirmed by linear unmixing of hyperspectral data from q-
FTAA/h-FTAA double staining.  
An analysis of the additional feeding scheme, where 15N label was introduced after the 
initial plaque onset at 10 weeks, strengthened this observation. This data showed the 
presence of completely unlabeled 14N-Aβ1-42 predominantly in cortical plaques, 
primarily at the center of these deposits. This data further demonstrates that Aβ1-38 is 
synthesized and deposited at a later time point as no unlabeled 14N-Aβ1-38 was 
detected.  
Overall, the data demonstrated verifies the primary role of Aβ1-42 peptide as seeding 
for Aβ plaque formation in the APPNLGF mouse model. The employed iSILK approach 
delineates spatial plaque growth mechanism, not previously reported for either APPNL-
G-F or any other mouse model. On a large scale, these results demonstrate the iSILK 
chemical imaging paradigm as highly suitable for general studies of Aβ plaque 
formation dynamics over time. The iSILK method allows for the identification of the 
primary regions of Aβ plaque deposition. Further, through close inspection of 15N label 
incorporation, iSILK also offers the possibility to delineate mechanisms responsible 
for Aβ plaque growth, including both the order of generation and deposition of 
different peptides, but also the peptides’ involvement in structural heterogeneity 
associated with plaque growth.  
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5 CONCLUSION AND FUTURE 
PERSPECTIVES 
Over 100 years have passed since Dr. Alois Alzheimer’s initial characterization and 
diagnosis of his patient, Auguste Deter, with Alzheimer’s disease. The initially 
described hallmarks of the disease, the intracellular neurofibrillary tangles (NFT) 
composed of hyperphosphorylated microtubule-associated protein Tau, and the 
extracellular plaques composed of amyloid-β (Aβ) peptides, remain central to the 
definite post-mortem diagnosis of AD. While both tau (total tau and phosphorylated 
tau) and Aβ are monitored in cerebrospinal fluid (CSF) as biomarkers of the disease, 
the relevance of Aβ pathology as such is currently under debate as Aβ plaques (as 
identified with e.g. Congo Red, CR) do not correlate with cognitive decline 64,66,67.  
However, Aβ plaque pathology is morphologically (e.g. diffuse and cored plaques) and 
structurally (polymorphism of underlying fibrils) highly heterogeneous. This 
heterogeneity in amyloid pathology is observed, both in between the different forms 
of fAD with different AD causing mutations, as well as within sAD pathology itself, 
as highlighted by the presence of Aβ plaques with diffuse and cored morphology. 
Moreover, (primarily diffuse) Aβ plaques are also present in cognitively unaffected-
amyloid positive (CU-AP) patients. Along diversified plaque morphology, distinct 
pools of Aβ peptide truncations have been identified both in CSF but also in brain 
homogenates among AD subtypes and CU-AP. Furthermore, distinct Aβ peptide 
truncations have been suggested to underlie structural polymorphism among Aβ fibrils. 
Thus, Aβ plaque pathology as such is likely much more heterogeneous than simply 
categorizing the plaques as either diffuse (CR negative) or cored (CR positive) plaques. 
Instead, Aβ plaque pathology might be reflective of much more complex changes in 
the chemical microenvironment. 
Common approaches to study Aβ plaque pathology and its diversity involve IHC with 
a variety of antibodies targeting the different specific Aβ peptides. This approach 
suffers from limitations associated with both specificity and throughput.  
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The studies presented in this thesis demonstrate the suitability of mass spectrometry-
based chemical imaging, specifically MALDI IMS, in combination with spectroscopic 
approaches, such as LCO based hyperspectral fluorescence microscopy, to study the 
structural and chemical traits of amyloid polymorphism in Aβ plaque pathology in AD. 
The suitability of these techniques is demonstrated in studies of both mouse models of 
AD as well as human post-mortem AD brain tissue.  
A limitation of the work on post-mortem brain tissue is that interpretation of the results 
presented here cannot be directly used for diagnostic purposes due to the post-mortem 
nature of the sample. Furthermore, the tissue is obtained at a point of time when AD 
pathology is full-blown and degenerative, and not during the early stages of AD. 
Similarly, mouse models of AD display accelerated amyloid pathology without well-
defined cognitive deficits limiting the translational potential of the data to biochemical 
aspects of the disease pathology. 
However, there are still some similarities between mice models and human subjects, 
particularly in terms of cerebral Aβ chemistry. It’s widely demonstrated that large 
amounts of biochemical information, particularly mechanistic insight, can be obtained 
from animal studies performed in a controlled environment. Therefore, the high 
resolution multimodal approaches developed offer a great potential for the 
identification of novel biomarkers and, thus, targets for future treatment.  
Importantly, the presented novel insights into Aβ  polymorphism  highlight the need 
to revisit the Aβ plaque pathology, as it is demonstrated to be highly heterogeneous 
both between different plaque subtypes (e.g. diffuse and cored), but also within a single 
Aβ deposit (a single plaque). This in terms of both Aβ peptides, but also lipids. Further, 
as demonstrated by the LCO hyperspectral imaging, this heterogeneity what is 
associated with the distinct aggregation states of Aβ peptides.  
Further work is needed to truly deepen the understanding of the Aβ plaque pathology 
in AD. Besides the analysis of a larger cohort of patients, the expansion of the 
analytical approaches towards other classes of biomolecules, for instance broader 
proteome, glycans or different lipid classes, is necessary to truly deepen the 
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understanding of local microenvironment changes associated with progressing Aβ 
plaque pathology. Here, the IMS based analysis, especially in combination with offline 
LMPC-based approaches, might prove itself indispensable in order to study these on a 
single of Aβ plaque level. However, the incorporation of novel technological 
developments, such as ozone-induced dissociation (to study isomeric lipid molecules) 
or MALDI-2 (aiding ionization of neutral species through post ionization), might be 
needed to truly characterize the complexity of the bimolecular processes underlying 
these deposits366-368.  
On the other hand, the approaches presented in this thesis could potentially be 
expanded to other protein aggregates demonstrated to exhibit structural polymorphism 
(e.g. α-synuclein, or maybe even tau). Given the distinct characteristics of these 
proteins, including their molecular size (tau), application of these approaches might 
require further method optimization.  
Finally, use of here developed the approaches for analysis of various AD causing 
mutations, might be crucial in aiding the delineation of the role distinct Aβ peptide 
truncations play in Aβ fibrillary and plaque polymorphism. Indeed, while the different 
genetic mutations have been shown to alter the Aβ peptide production, the general γ-
secretase processing, and the relative hydrophobicity of the peptides, little is known 
about the actual Aβ peptide truncations generated, their role in amyloid structural 
polymorphism, or their effect on the brain’s microenvironment.  
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